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Introduction and |  
outline of the thesis I
Introduction
Since the first successful renal transplantation in 1953 results have improved substantially 
(1;2). A t this time the first year graft survival is around 90% for recipients of a deceased 
donor and 95% for recipients of a living donor. The first year patient survival is around 95% 
and 98% respectively for recipients of a deceased and a living donor (3). The improvement 
in first year graft survival is mainly due to more potent immunosuppressive therapy and 
a decrease in acute rejection rate from 50-60% in the early eighties to 10-15% in most 
centers nowadays (www.USRDS.org)(4) . Patient survival improved due to the better 
treatment of infectious diseases and improvements in the treatment and prevention of 
cardiovascular disease (5).
In contrast to the clear improvement in first year graft survival, only a modest 
increase in long term graft survival has been observed in recent years (4;6). Late graft loss 
is related to calcineurin toxicity, chronic rejection, recurrence of primary renal disease, and 
graft loss due to patient death (6).
In recent years, the demographics of the end-stage renal disease population 
has changed dramatically (7). Data show that patients are older, are more likely to have 
diabetes, and have an increased number of comorbid conditions (7;8)(USRDS annual data 
report 2009). In 1999 Wolfe et al. showed that survival after renal transplantation is better 
compared to survival in renal transplant candidates on dialysis (9). This survival benefit was 
also found for patients in the higher age groups. Due to the change in the population and 
the improved outcome after transplantation, patients with significant comorbidity and of 
older age are nowadays accepted for renal transplantation in many transplant centers (5;7).
Although survival after renal transplantation is better compared to dialysis, 
patients are exposed to an increased risk of death and complications both perioperatively 
and in the early postoperative period (9). Furthermore, mortality rates after transplantation 
improved over the last decades, but are still markedly higher compared to the general 
population (5;9). Increased comorbidity at the time of transplantation has been associated 
to an increased mortality both at the short- and long-term after transplantation (7). 
Cardiovascular death is still the most important cause of death after transplantation, 
followed by malignancies and infectious diseases (5;8). M ortality due to malignancy even 
increased in the last two decades (5). So, although results after renal transplantation have 
improved over the years, patients are still exposed to several risks and complications both 
on the short and long term after transplantation. Careful consideration of the advantages 
and disadvantages of transplantation is necessary in all potential renal transplant 
candidates, especially in the older patient with increased comorbidity. Renal transplant 
candidates should be informed about the risks and benefits of renal transplantation.
Several international guidelines exist for the evaluation of renal 
transplant candidates, unfortunately many recommendations are opinion based 
or based on evidence from observational studies (10-12). Further research is 
necessary to define risk factors for early and long-term complications, and to 
find out what the consequences of pre-transplant examinations and measures are.
In 2004, a National program to improve the quality of the treatment of 
renal transplant recipients was initiated by the National Kidney Foundation and the 
Nierpatiënten Vereniging. Four Dutch transplant centers actively participated in the 
program and they all analyzed a part of the kidney transplant program. In Nijmegen we 
studied the process of evaluation and preparation of the renal transplant candidate. Part of 
this process was to review the access criteria for the renal transplant waiting list of the seven 
Dutch transplant centers. The goal was to make uniform access criteria for the waiting list,
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to prevent unnecessary investigations and ultimately to improve transplantation outcome. 
During the review of the guidelines for the evaluation of renal transplant candidates of the 
different Dutch transplant centers several differences were found. Controversy existed on 
several subjects. We therefore decided to study the following subjects:
1. The effect of obesity (BMI > 30 kg/m2) on graft and patient survival in renal transplant 
recipients.
2. Pre-transplant risk factors for cardiovascular events after transplantation
3. The effect of cardiac evaluation in renal transplant candidates
4. The effect of pre-transplant blood transfusions in female renal transplant candidates
5. The use of a plain pelvic or abdominal X-ray for the detection of vascular calcifications 
in the iliac arteries
6. Treatment of secondary hyperparathyroidism with cinacalcet in renal transplant 
candidates.
In this thesis we will present the results of these studies and discuss their impact on the 
current guidelines for the evaluation of renal transplant candidates. We will first briefly 
introduce the six studies:
1. O b e s i ty  a n d  re n a l t r a n s p la n ta t io n
Obesity is an emerging problem both in the general population and in the end-stage renal 
disease population (13). The prevalence of obesity in the general population increased 
from 4-6% in 1981 to 10-12% in 2007 (RIVM). In the Netherlands, the prevalence of 
obesity in renal transplant recipients increased from 5.9% in the early nineties to 10.6% 
in 2006 (unpublished data). In several studies, the effect of obesity on graft survival and 
patient survival has been analyzed. In some studies a decreased patient survival, graft 
survival or an increased complication rate was found (14-16). In contrast, some other 
studies did not find a significant difference in transplantation outcome between obese 
and non-obese renal transplant recipients (17-20). Based on this data, no consensus 
could be reached about the treatment of end-stage renal disease patients with obesity. 
M ost transplant centers in 2004 did not accept obese renal transplant candidates 
at that time and recommended weight reduction before renal transplantation. No 
studies at that time had evaluated the effect of weight reduction on transplantation 
outcome. Besides, Glanton et al. showed in a large historical cohort study that obese 
ESRD patients, who received a renal transplant, had a survival advantage compared to 
obese renal transplant candidates on the waiting list (21). Questions could therefore 
be raised by the justification to withhold obese patients a renal transplantation.
We therefore decided to analyze the National Organ Transplant Registry 
(NOTR). All adult renal transplant recipients, with valid data for weight and length who 
received a renal transplantation between 1994 and 2005, were included. We analyzed 
transplantation outcome in patients with and without obesity. The results of this study are 
given in chapter 2. The consequences of the study for the evaluation of renal transplant 
candidates are discussed in chapter 8.
2. C a rd io v a s c u la r  d i s e a s e  a n d  o u tc o m e  a f te r  re n a l t r a n s p la n ta t io n
Cardiovascular disease is the most important cause of death after renal transplantation (22). 
Although the cardiovascular death rate decreased in the last two decades, the cardiovascular
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death rate in renal transplant recipients is still considerably higher compared to the 
general population. The incidence of cardiac events is highest early after transplantation, 
related to the increased perioperative risk (23-25). In several international guidelines 
non-invasive cardiac stress tests or angiography are recommended in asymptomatic renal 
transplant candidates to detect cardiac ischemia or significant coronary artery disease 
(10;11). In case of significant coronary artery disease, pre-operative revascularization is 
recommended. No randomized clinical trials (RCTs) of sufficient size have been done 
to evaluate if this policy decreases the incidence of cardiac events after transplantation. 
Since 2004, two RCTs in patients scheduled for major non-cardiac surgery did not 
find benefit of preoperative revascularization over optimal medical treatment (26;27).
In 2004, we introduced a standardized cardiac assessment program in our 
hospital. In this protocol cardiac risk was assessed based on 6 clinical risk factors. All 
asymptomatic high risk renal transplant candidates had to undergo non-invasive cardiac 
stress testing and if significant cardiac ischemia was found a coronary angiography had to 
be done. Revascularization had to be done in case of significant coronary artery disease.
In chapter 3 we will present our study in which we analyzed risk factors for post­
transplant cardiac events. In chapter 4 we will show the results of our cardiac assessment 
program. In chapter 8 we will discuss the results of these studies and present our future 
policy for the cardiac screening of renal transplant candidates.
3 . P r e - t r a n s p la n t  b lo o d  t r a n s fu s io n s  a n d  re n a l t r a n s p la n ta t io n
Before the introduction of calcineurin inhibitors graft survival was significantly better 
in renal transplant recipients who received one or more blood transfusions (28). Since 
the introduction of calcineurin inhibitors the effect of pre-transplant blood transfusions 
on graft survival is controversial (29-33). Although, an immunological effect of blood 
transfusions is unchallenged, the precise mechanism behind the improved graft survival 
has never been totally clarified (34). Based on the decreased effect of blood transfusions 
on graft survival after the introduction of calcineurin inhibitors, the risk of sensitization 
and the risk of the spread of infectious diseases most transplant centers abandoned pre­
transplant blood transfusions. In the Netherlands pre-transplant blood transfusions were 
still given to female renal transplant candidates in several transplant centers. The rationale 
behind the Dutch transfusion policy was to detect hidden anti-HLA-antibodies in female 
renal transplant candidates. Women with prior pregnancies are prone to be sensitized, but 
the antibodies may have disappeared after several years. A  historical positive crossmatch 
could therefore be missed in female renal transplant candidates. A  positive historical 
crossmatch is associated with an increased risk of acute rejection and a decreased graft 
survival after renal transplantation (35-39). Prior studies and clinical observations have 
shown that historical anti-HLA-antibodies can become apparent after blood transfusions
(40). Avoidance of the related HLA-antigens in the future kidney donor may improve 
transplantation outcome. The results of the blood transfusion study are given in chapter 5 
and the consequences of the study will be discussed in chapter 8.
4 . V a s c u la r  c a lc if ic a tio n s  a n d  re n a l t r a n s p la n ta t io n
The prevalence of vascular calcifications in renal transplant recipients is very high (41-43). 
Several factors may play a role in the increased vascular calcification in chronic kidney 
disease. The first is passive precipitation of calcium and phosphate. Secondly, the presence 
or upregulation of promoters of cellular osteogenic transformation and hydroxyapatite
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formation may play a role and thirdly deficiencies of calcification inhibitors are present in 
ESRD (44). The presence of vascular calcifications in the iliac arteries might complicate or 
preclude the construction of a vascular anastomosis between the renal artery of the donor 
and the iliac artery of the recipient (45;46). Historically, a plain abdominal or pelvic X-ray 
was made before renal transplantation in many Dutch renal transplant centers. Aim of this 
X-ray was to detect vascular calcifications in the iliac arteries of the renal transplant recipient. 
No data exist about the accuracy of a pelvic X-ray in detecting vascular calcifications in the 
iliac arteries of renal transplant recipients. It is also unknown what the predictive value of 
vascular calcifications on a pelvic X-ray is for vascular complications in renal transplant 
recipients (e.g. problems with or impossibility to make a vascular arterial anastomosis). We 
therefore analyzed, in a prospective cohort study, the accuracy and predictive value of a 
plain pelvic X-ray for vascular calcifications in the iliac arteries and vascular complications, 
in renal transplant recipients without clinical evidence of peripheral vascular disease. The 
results of this study are given in chapter 6 and will be discussed in chapter 8.
5 . S e c o n d a r y  h y p e rp a ra th y ro id is m  a n d  re n a l t r a n s p la n ta t io n
Secondary hyperparathyroidism is a frequent complication in chronic kidney disease. 
Several mechanisms play a role in the initiation and maintenance of secondary 
hyperparathyroidism in chronic renal failure (47). Although renal transplantation 
reverses many of the endocrine and metabolic imbalances that cause hyperparathyroidism 
in chronic kidney disease, hyperparathyroidism often persists after renal transplantation
(48). Evenepoel et al. showed that increased iP T H  levels are present in 25% of the renal 
transplant recipients at one year after transplantation (48). Post-transplant hypercalcemia 
may contribute to delayed graft function and nefrocalcinosis which is related to decreased 
allograft survival (47;49;50). Several authors have advocated parathyroidectomy in those 
with severe secondary (or tertiary) hyperparathyroidism before renal transplantation, 
in order to prevent post-transplant complications (11), but recommendations are not 
uniform (49;51). The introduction of the calcimimetic agent cinacalcet has provided an 
alternative to parathyroidectomy in dialysis patients (52-54). Several studies evaluated 
the effect of cinacalcet in stable renal transplant patients and found that it effectively 
corrected hypercalcemia and decreased iP T H  levels (55-58). However, to date no study 
has evaluated the use of cinacalcet in the immediate post-transplant period. In our study 
we prospectively followed all patients who continued cinacalcet after transplantation. We 
aimed to determine whether cinacalcet could be safely used in the immediate postoperative 
phase and whether it could prevent hypercalcemia after transplantation in patients with 
moderate to severe secondary hyperparathyroidism. The results of the study are presented 
in chapter 7 and the implications are discussed in chapter 8.
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Abstract
To determine short- and long-term patient and graft survival in obese [body mass 
index (BMI) > 30 kg/m2] and non-obese (BMI < 30 kg/m2) renal transplant patients 
we retrospectively analyzed our national-database. Patients 18 years or older receiving a 
primary transplant after 1993 were included. A  total of 1871 patients were included in the 
non-obese group and 196 in the obese group. In the obese group there were significantly 
more females (52% vs. 38.6%, P  < 0.01)) and patients were significantly older [52 (43-59) 
years vs. 48 (37-58) years, P  < 0.05]. Patient survival and graft survival were significantly 
decreased in obese renal transplant recipients (1 and 5 year patient survival were respectively 
94% vs. 97% and 81% vs. 89%, P  < 0.01; 1 and 5 year graft survival were respectively 86% 
vs. 92% and 71% vs. 80%, P  < 0.01). Initial BM I was an independent predictor for patient 
death and graft failure. This large retrospective study shows that both graft and patient 
survival are significantly lower in obese renal transplant recipients.
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Introduction
The prevalence of obesity in patients with end-stage renal disease (ESRD) is 
increasing rapidly (1). In 2003, sixty percent of the renal transplant candidates in the 
United States were either obese or overweight (2). In The Netherlands the prevalence 
of obesity at the time of transplantation increased from 5.9% in the early nineties to 
10.6% in the last four years (J. Aalten, M H  Christiaans, JW  de Fijter, unpublished 
data). This increase is most probable because of an increase of the prevalence of obesity 
in ESRD patients, although we cannot exclude that a change in inclusion criteria is in 
part responsible. The increase of obesity at the time of transplantation underlines the 
importance to evaluate the policy regarding obese renal transplant candidates.
In the past in most centres obesity was an exclusion criterion for renal transplantation. 
This policy was based on a worse patient and graft survival and a higher incidence of post­
transplantation complications (3-5). In a review article from Pischon and Sharma (6), the 
authors confirmed this policy. They concluded that obesity [body mass index (BMI) S 30 
kg/m2] in patients undergoing a renal transplantation was associated with a significantly 
higher overall mortality, a reduced allograft survival and a higher incidence of peri- and 
postoperative complications. They advised that before renal transplantation all patients with 
obesity should lose 5-10% of their weight with subsequent weight maintenance.
Since 2001 a few articles are published in which there was no difference 
in short-term graft and patient survival between obese and nonobese patients. The 
authors stated that obesity alone should no longer be a contra-indication for renal 
transplantation (7-10). Moreover, Glanton et al. (11) showed in a large historical 
cohort study that obese ESRD patients who received a renal transplant have a survival 
advantage compared to obese renal transplant candidates still on the waiting list.
In the Netherlands, as in the rest of the world, there is no consensus on the 
management of obese renal transplant candidates. In some transplantation centres obesity 
(BMI > 30 kg/m2) is considered as a relative contra-indication for renal transplantation while 
in other transplant centres in the N etherlands obese patients are accepted for transplantation.
In order to find out what our policy in the future should be, we decided to study 
the patient and graft survival of obese and non-obese renal transplant patients in the 
Netherlands. Follow-up data of all renal transplantations in the Netherlands are stored in 
the Netherlands Organ Transplantation Registry (NOTR). We retrospectively analyzed 
these data. Aim of this study was to investigate if there is a difference in short- and long­
term graft and patient survival between obese and nonobese renal transplant patients.
Patients and Methods
In the N O T R  database, data about all renal transplantations since 1966 are 
stored. Because the BM I from most patients transplanted before 1994 was 
not known, we only included patients transplanted after this date. Other 
exclusion criteria were age below 18 years or a previous transplantation.
In the database information was stored about recipient age and sex, donor age 
and sex, type of donor, cold and warm ischemia times, date of patient death and graft loss, 
cause of death, cause of graft failure, delayed graft function (DGF; defined as the need for 
dialysis in the first week after renal transplantation) and BM I at the time of transplantation 
and at 3 months, 1 year, 5 years, and 10 years after transplantation.
Primary endpoints were the difference in patient survival, graft survival and death-
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censored graft survival between patients with obesity (BMI S 30 kg/m2) and without 
obesity (BMI < 30 kg/m2) at the time of transplantation [BMI= weight (kgVheight2 
(m)]. Because the relation between BM I and transplantation outcome is more complex 
than only the difference between obesity and normal weight, BM I was also analyzed as a 
more granulated category variable. For this analysis patients were divided in 7 categories 
according to their initial BM I (BMI < 19 kg/m2, from 19-34 kg/m2 at 3 unit increments 
and BM I > 34 kg/m2). A  BM I between 22 and 25 kg/m2 was considered as the reference 
group. Secondary endpoints were cause of graft failure, cause of patient death, D G F  and 
change of BM I during follow-up.
S ta tis tic a l  a n a ly s is
Statistical analysis was carried out using SPSS version 12.0.1. Normality of data was 
evaluated with the Kolmogorov-Smirnov test. Results are expressed as median (interquartile 
range) for continuous nonparametric data. Comparisons between groups were made using 
the M ann-W hitney Latest for continuous variables and the chi-square test or Fisher’s exact 
test for categorical variables. Kaplan-Meier curves were constructed for patient survival, 
graft survival and death-censored graft survival. Differences between survival curves were 
calculated with the log-rank test. To evaluate the impact of obesity on short- and long- term 
graft and patient survival we analyzed them separately. For the short-term graft and patient 
survival we analyzed the difference in survival between obese and nonobese patients until 3 
months. For the long-term survival, the conditional long-term survival in both groups was 
analyzed (conditional on being alive after 3 months with a functioning graft).
A  multivariate Cox regression analysis was used to correct for potential 
confounders. All covariates which were significantly related to patient or graft survival in 
the univariate analyses were included in the multivariate analysis. In the Cox regression 
analysis BM I was assessed both as continuous and as categorical variable (seven 
categories). A  backward stepwise method was used to define the final models.
Multivariate analysis of categorical outcome variables was performed using logistic 
regression. The influence of change in BM I on transplantation outcome was analyzed in 
a time-dependent Cox model. Initial BMI, BM I after 3 months, 1 year, and 5 year were 
included. A  P value < 0.05 was considered as significant.
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Results
A total of 4245 patients of 18 years or older received a first renal transplantation since 
1994. From 2067 patients (48.7%) there were enough data to calculate the BM I at the 
time of transplantation. The median follow-up time was 2.0 years (interquartile range 
0.25-5.0 years). Baseline characteristics for obese and non-obese patients at the time of 
transplantation are given in Table 1. Obese patients were significantly older and there 
were significantly more females in the obese group. The second warm ischemia time 
(anastomosis time) was significantly longer in obese patients.
Table 1. Baseline characteristics of the non-obese and obese patients
BMI <30 kg/m 2 BMI > 30  kg/m 2
Recipient 
A ge (yr) 
Male (%) 
W eight (kg) 
BMI (kg/m 2)
“(n=1871)
4 8  (37-58)
61.5
71 (62-80)
2 3 .8  (21.6-26.0)
(n=196)
5 2  (43-59)*
48.0*
94  (85-103)*
3 2 .2  (30.9-34.2)*
Donor
C adaveric  donor (%) 67 .3 68 .4
A ge (yr) 4 8  (37-56) 4 8  (35-57)
Male (%) 47.1 5 2 .0
Cold ischem ia time (min) 1080 (181-1453) 1180 (291-1440)
S e c o n d  w arm  ischem ia time (min) 31 (25-38) 3 4  (28-40)*
*P < 0.05
G ra f t  a n d  p a tie n t  su rv ival
Patient survival was significantly lower in patients with an initial BM I > 30 kg/m2 compared 
to patients with an initial BM I < 30 Kg/m2 (1 and 5 year patient survival were respectively 
94% vs. 97% and 81% vs. 89%, P < 0.01). Graft survival and death-censored graft survival 
were also significantly lower in obese patients compared to nonobese patients (1 and 5 
year graft survival were respectively 86% vs. 92% and 71% vs. 80%, P < 0.01; 1 and 5 year 
death-censored graft survival were respectively 88% vs. 94% and 81% vs. 87%, P < 0.01). 
Patient survival, graft survival and death-censored graft survival were also significantly 
lower in patients with overweight (BMI 25-30 kg/m2) compared to patients with normal 
weight (BMI < 25 kg/m2). In Figs 1 and 2 patient and graft survival in patients with 
normal weight, overweight and obesity are shown. There was no difference in patient 
survival, graft survival and death-censored graft survival between patients with morbid 
obesity (BMI > 35 kg/m2, n = 36) compared to patients with obesity (n = 160).
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Figure 1.
Patient survival in obese patients 
(BMI > 30 kg/m2), patients with 
overweight (BMI 25-30 kg/m2) 
and patients with normal weight 
(BMI < 25 kg/m2).
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Figure 2.
Graft survival in obese patients 
(BMI > 30 kg/m2), patients with 
overweight (BMI 25-30 kg/m2) 
and patients with normal weight 
(BMI < 25 kg/m2).
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Graft loss after 3 months was significantly higher in obese patients than in nonobese 
patients (9.5% vs. 5.5%, P < 0.05). The conditional long-term graft and patient survival 
was also significantly lower in obese compared to nonobese patients ( 5  year graft survival 
was 90.8% vs. 85.7% in nonobese vs. obese patients, P < 0.01; 5 year patient survival was 
85% vs. 78.9%, P < 0.01). In a multivariate Cox regression analysis initial BMI was an 
independent predictor for patient death [hazard ratio (HR) 1.05 (95% CI 1.00-1.09) P
< 0.05]. In the Cox regression model recipient age, donor age, type of donor and initial 
BMI were included. Initial BMI was also an independent predictor for graft failure 
(HR 1.04 (95% CI 1.01-1.07) P < 0.05). In the Cox regression model for graft failure 
recipient and donor age, type of donor, DGF, cold and warm ischemia times, and initial 
BMI were included. In Table 2 the entire Cox regression model for graft failure and 
patient death are shown. After correction for the same variables as in the model for graft 
failure initial BMI was no independent predictor for death-censored graft failure (HR 
1.04 (95% CI 1.00 -1.09) P = 0.06).
Table 2. Unadjusted and adjusted hazard ratios for the risk factors related to graft 
failure and patient death.
Graft survival Patient death
Covarlate Unadjusted Adjusted Unadjusted Adjusted
Recipient age 
Donor age 
C adaveric  
Initial BMI
Delayed g ra ft function 
Second warm  ischemia 
time
Cold ischemia time
Hazard ratio
1.03 (1.02-1.04) 
1.01 (1.00-1.02) 
2.¿7 (1.68-3.01) 
1.07 (1.04-1.10) 
1.51 (1.38-2.01) 
1.01 (1.01-1.02)
1.02 (1.01-1.04)
Hazard ratio
1.03 (1.01-1.04) 
1.01 (1.00-1.02) 
1.96 (1.11-3.46)
1.04 (1.00-1.07) 
0.86 (0.62-1.18)
1.00 (0.99-1.01)
1.00 (0.98-1.02)
Hazard ratio
1.0Z'(1.06-1.09) 
1.02 (1.00-1.03) 
1.-77 (1.22-5.58) 
1.09 (1.05-1.13)
Hazard ratio
1.07 (1.05-1.08) 
1.01 (1.00-1.02) 
1.23 (0.83-1.82) 
1.05 (1.00-1.09):
In a multivariate Cox regression model we also analyzed the influence of BMI as a 
categorical variable (seven categories) on graft and patient survival. In this analysis both a 
high and a low BMI were related to patient death, graft survival and death-censored graft 
survival. In Figs 3 and 4 the adjusted hazard ratios for graft survival and patient death 
categorized for BMI are given. The risk for graft failure was significantly increased for 
patients with a low and a high BMI compared to the reference group, with the highest risk 
for patients with a BMI > 34 kg/m2. For death-censored graft survival a similar pattern 
was found. W hen we removed DG F from the Cox regression model the results were not 
significantly different. The risk for patient death was increased for all patients with a BMI 
> 28 kg/m2 with the highest hazard ratio for patients with a BMI > 34 kg/m2. For patients 
with a BMI under 19 kg/m2 there was a trend to an increased risk for death.
Because data about cardiac risk factors and disease at baseline were missing we did 
a sub-analysis in patients with a lower cardiovascular risk. In this analysis we included all 
patients under 55 years of age. In this sub-analysis obesity was also significantly related to 
a decreased patient and graft survival.
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Figure 3. Hazard ratios for graft survival by categorized BMI group (model is corrected 
for recipient and donor age, donor type, DGF and cold and warm ischemia times)
2,5
2-
O
0 
DC 
■g 1 5
□
N
0
1  1-
0,5- I
<19 19 22 22  25 25 28  2 8  31 31 34  >34 
Body mass index
Patients 113 422 675 461 252 90 54
Events 18 57 71 86 48 15 14
* P < 0.05; # P = 0.07
Figure 4-. Hazard ratios for patient death by categorized BMI group (model is 
corrected for recipient and donor age and donor type)
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C a u s e  o f g ra ft failure a n d  p a tie n t d e a th
In the obese group significantly more patients lost their graft through an infection. 
Permanent non-functioning was also significantly more frequent in obese patients. There 
were no significant differences in cause of patient death, although there was a trend to a 
higher infectious (P = 0.05) and cardiovascular mortality (P = 0.09) in the obese group. 
Causes of graft failure and patient death are given in Table 3 and 4.
C h a n g e  in BMI a f te r  tra n sp la n ta tio n
After transplantation the mean BMI increased from 24.7 ± 4 at baseline to 25.7 ± 4.3 after 
1 year and 26.2 ± 4.6 kg/m2 after 5 years (P < 0.01). During this period the percentage 
of patients with obesity increased from 9.5 to 14.7%. In a time dependent Cox model 
increase in BMI was significantly related to graft loss (HR 1.03 (95% CI 1.00-1.05) P < 
0.05). Increase in BMI was not related to patient death and death-censored graft survival.
D e lay ed  g ra ft function
Delayed graft function was significantly more frequent in obese patients compared to non­
obese patients (respectively 31.1% compared to 21.1%, P < 0 .0 1 ). In a logistic regression 
model initial BMI was an independent predictor for DGF (HR 1.08 (95% CI 1.05-1.11) 
P < 0.01).
Discussion
In this large, retrospective study we found that obesity and overweight are significantly 
related to a decreased short- and long-term patient and graft survival. We also found 
that obesity and overweight had a negative impact on death-censored graft survival. 
Next to that we found that the initial BMI was an independent predictor for patient 
death and graft failure. Both patients with an increased and decreased BMI compared 
to the reference group (BMI 22-25 kg/m2) had a significantly increased risk for graft 
failure and death-censored graft failure. The increase in risk was most pronounced for 
patients in the highest BMI group (BMI > 34 kg/m2). For these patients the risk for 
graft failure increased more than twofold. Risk for patient death also increased more 
than twofold for obese patients. These results are in agreement with the large study 
from Meier-Kriesche et al. (12). W hen the initial BMI was analyzed as a continuous 
variable there also was a significant relation between BMI and graft failure and 
patient death. Because both a high and low BMI are related to a worse transplantation 
outcome this relation was less strong than for BMI as a categorical variable.
A lot of other studies also found a decreased patient and graft survival in obese 
renal transplant patients (3-5;12;13). In contrast, there are some recent studies in which no 
significant differences in graft and patient survival between obese and non-obese patients 
were found (7-10;14). There are a few differences between our study and the recent studies 
that found an equal patient and graft survival. One possibility is the difference in sample 
size. Most of these recent studies are much smaller and differences in graft survival and 
patient survival could have been missed because of a lack of power. In the study from 
Marks et al. (7) for instance there was a trend to a decreased 3 year graft survival in 
morbid obese patients. Another possibility could be a difference in patient selection.
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Table 3. Causes o f graft failure in patients w ith  and w ithout obesity.
BMI <30 kg/mz BMI > 30 kg/m 2
Cause of graft failure (n=1871) (n=196)
Rejection (%) 73 (4.0) 8 (4.1)
Died with functioning graft (%) 95 (5.1) 13 (6.6)
Vascular (%) 10 (0.5) 3 (1.5)
Thrombosis (%) 20 (1.1) 5 (2.6)
Technical problem (%) 7 (0.4) 1 (0.5)
Removal o f functioning graft (%) 4 (0.2) 0 (0)
Recurrence (%) 13 (0.7) 1 (0.5)
Permanent non-functioning (%) 10 (0.5) 4 (2.0)*
Infection (%) 4 (0.2) 3 (1.5)*
Other (%) 28 (1.5) 6 (3.0)
* P <0.05
Table 4. Causes of death in patients with and without obesity.
BMI <30 kg/m2 BMI > 30 kg/m2
Cause of Death (n=1871) (n=196)
Cardiovascular (%) 43 (2.3) 9 (4.6)
Infection (%) 35 (1.9) 8 (4.1)
Malignancy (%) 25 (1.3) 0 (0)
Gastro-intestinal disease (%) 6 (0.3) 2 (1.0)
Pulmonary embolus (%) 4 (0.2) 0 (0)
Renal failure (%) 1 (0.1) 1 (0.5)
Other (%) 6 (0.3) 3 (1.5)
Unknown (%) 27 (1.4) 4 (2.0)
N one o f  the  d iffe rences  w e re  s ta tis tica lly  s ign ifican t
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In the study ofJohnson et al. (8 ) and Massarweh et al. (14) all obese patients underwent a 
rigorous cardiac screening before inclusion and patients were excluded when significant 
abnormalities were found. Although most transplantation centers in the Netherlands are 
reluctant in accepting obese renal transplant candidates, we do not know the exact 
screening policy of all transplantation centers. Besides Johnson et al. (8 ) included diabetes, 
cardiovascular disease and smoking in their multivariate analysis. Unfortunately these data 
were lacking in our database. As a surrogate analysis for the correction of possible 
differences in cardiovascular risk factors and disease at baseline we repeated our analysis in 
patients with a lower cardiovascular risk. In this analysis we only included patients under 
55 years of age. In this subgroup obesity was also significantly related to a decreased patient 
and graft survival. Although these results do not exclude that the difference in patient and 
graft survival is in part due to a difference in cardiovascular disease at baseline, it supports 
the finding that obesity is an independent risk factor for patient death and graft failure. 
Because diabetes mellitus and an increased BMI are strongly associated, data still could be 
biased by a higher incidence of DM in obese patients.
In most of the studies, that found a decreased patient survival in obese patients, 
this was the result of a higher cardiovascular or infectious mortality (3;4;12). Although the 
difference in cardiovascular mortality in our study was not statistically significant, there 
was a trend to a higher cardiovascular mortality in the obese group (P = 0.09). This 
observation is not surprising as obesity is an independent risk factor for cardiovascular 
disease (15). Moreover, other important risk factors for cardiovascular disease like diabetes 
mellitus, hypertension and hyperlipidemia are increased in obese patients (12). W ith this 
data and the results from Johnson et al. (8 ) in mind it is possible that a more rigorous 
cardiac screening of obese patients could improve patient and graft survival in obese 
patients.
There also was a trend to a higher infectious mortality in obese patients (P = 0.05). 
In many studies obesity was related to a higher frequency of wound complications or 
infections (3;5;8). It is conceivable that an increased frequency of wound complications in 
patients treated with immunosuppressive medication could lead to a higher infectious 
mortality.
As we stated before many studies reported a decreased graft survival or death- 
censored graft survival in obese patients (3-5;12;16). In our study obese patients had a 
significantly decreased graft survival and death-censored graft survival. Significantly more 
obese patients lost their graft as the result of an infection or primary non-function. Next 
to that significantly more obese patients lost their graft within 3 months after 
transplantation. A higher incidence of early graft loss has been described in a few other 
studies (6 ). This higher incidence of early graft loss has been related to an increased 
frequency of post-operative complications in obese patients (5).
Besides the increased early graft loss there also was an increased late graft loss. 
This is in agreement with some previous studies. In these studies obesity was significantly 
related to chronic allograft nephropathy (12;17;18). In our database we had no information 
about the frequency of chronic allograft nephropathy. One of the theories for the increased 
prevalence of chronic allograft nephropathy in obese patients is a disparity between donor 
and recipient weight which could lead to hyperfiltration in the donated kidney (1 2 ). 
Unfortunately donor weight is not included in our database. There was no significant 
difference in graft loss caused by rejection between the non-obese and obese group. Earlier 
studies also did not find a difference in the frequency of rejections between obese and non­
obese patients (5;8;12;13;18).
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Delayed graft function was also significantly more frequent in obese patients. This is in 
agreement with some former studies (5;12;19). In contrast there are other studies that did 
not find a difference in DGF between obese and non-obese patients (3;4;8;9;18). In our 
study initial BMI was an independent predictor for DGF. Although the second warm 
ischemia time was significantly longer in obese patients in the multivariate analysis second 
warm ischemia time was no independent predictor for DGF or graft failure.
We further observed that an increase of BMI after transplantation is related to a 
decreased graft survival. In the study of El-Agroudy et al. (20) an increase of the BMI 
after transplantation was related to a higher incidence of hypertension, diabetes mellitus 
and ischemic heart disease. This underscores that it is not only important to start with a 
BMI under 30 kg/m2, but that it is also very important to prevent obesity after 
transplantation.
Although our study has many limitations, for several reasons we still think that we 
can draw some hard conclusions. The first limitation of our study is that BMI was missing 
in half of the patients. This might have influenced our results. Although we cannot exclude 
bias there were no baseline differences between patients with known BMI and unknown 
BMI. Next to that we still had information about 196 obese renal transplant patients, 
which is, apart from the study of Meier-Kriesche et al. (12) the largest published cohort of 
obese renal transplant patients in the literature.
The second limitation is the lack of data on patient history, cardiac risk factors, 
and HLA matching. For this reason we do not know whether there were besides the 
difference in age and sex other significant baseline differences between obese and non­
obese patients which could be responsible for the difference in transplantation outcome. 
In a low risk group for cardiovascular disease (patients under 55 years) obesity was also 
related to a decreased patient and graft survival.
W hat are the implications of our results for daily practice? The study from Glanton 
et al. (1 1 ) gave fair evidence that obese patients have a better outcome after transplantation 
compared to staying on dialysis. From this point of view it would not be fair to exclude all 
obese patients from renal transplantation. Additionally, renal transplantation is accepted 
in other groups of patients with a decreased patient and graft survival, for example diabetes 
mellitus or elderly. Some authors state that it is not ethical to make a difference between 
these groups (7).
In our opinion there is a difference between these groups of patients. In contrast 
to age and diabetes mellitus, obesity is a preventable and fundamentally curable situation. 
Therefore it would be fair to motivate patients to lose weight before they get on the 
transplantation list. Losing weight is not only beneficial to the patient, but it is also 
important to give scarce organs to patients with the lowest risk. Unfortunately the 
experience is that it is very difficult for obese ESRD patients to lose weight.
In conclusion we can state that obesity is related to a decreased patient and graft 
survival. Nevertheless obese patients still do better after transplantation than on dialysis. 
W ith this data in mind we suggest that it is not fair to withhold obese patients a 
transplantation. On the other hand we should not disregard the increased risk for obese 
patients after transplantation. Patients with obesity have to be fully informed about their 
increased risk and should be motivated to lose weight. If weight loss is impossible (for 
instance through immobility) or does not succeed the transplant surgeon should judge if 
a transplantation is technically possible. If a transplantation is technically possible and 
cardiac screening is negative obese patients have to be accepted for transplantation.
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Because the prevalence of obesity is increasing rapidly we should focus on the prevention 
and treatment of obesity in ESRD patients. Next to that the effects of weight loss in obese 
patients before transplantation has to be analyzed further.
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Abstract
The prevalence of cardiovascular risk factors in renal transplant candidates is high. A better 
understanding of the relation between these risk factors and cardiovascular morbidity and 
mortality is mandatory to improve transplantation outcome. In this retrospective cohort 
study 2187 adult patients who received a first kidney transplant between 1984 and 1997 
were included. We analyzed the incidence of post-transplant cardiovascular events and 
tried to identify independent pre-transplant risk factors for post-transplant cardiovascular 
events and all-cause mortality. The cumulative incidence of post-transplant cardiovascular 
events was 40%. The incidence was highest in the first three months after transplantation. 
Independent pre-transplant risk factors for a post-transplant cardiovascular event were 
diabetic nephropathy [Hazard ratio (HR) 3.02; 95% CI 2.85-3.98], claudication [HR 
2.17 (1.42-3.31)], cardiac event [HR 1.76 (1.32-2.33)], CVA [HR 1.53 (1.03-2.28)], 
time on dialysis [HR 1.06 (1 .0 2 - 1 .1 1 )], recipient age [Hr 1.04 (1.04-1.05)], and body 
mass index [HR 1.03 (1.00-1.05)]. Diabetic nephropathy and cardiovascular disease were 
also important predictors for all cause mortality. Diabetic nephropathy and cardiovascular 
disease were the most important predictors for cardiovascular events and all-cause 
mortality after renal transplantation. Early treatment of cardiovascular risk factors and 
pre-transplant cardiovascular evaluation might improve transplantation outcome.
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Introduction
Cardiovascular disease is the major cause of death after renal transplantation and the 
incidence is considerably higher than in the general population (1 ;2 ). The incidence of 
cardiovascular events and death is highest in the first three months after transplantation 
(2;3). Several factors seem to play a role in the high incidence of early cardiovascular 
events in renal transplant recipients. First of all chronic kidney disease is a major 
risk factor for cardiovascular disease. Patients with a moderate renal insufficiency 
already have a markedly increased cardiovascular risk (4). Additionally traditional risk 
factors are more prevalent in patients with chronic kidney disease (5). For this reason 
the prevalence of cardiac disease at the time of transplantation is already high (6 ).
The high incidence of cardiovascular events late after transplantation also has a 
multi-factorial origin. Although there is an improved renal function after transplantation 
many patients still have a chronic renal insufficiency after transplantation (7). Besides 
immunosuppressive medication (e.g. calcineurin inhibitors, corticosteroids) are related to an 
increased cardiovascular risk (8 ). Other non-traditional risk factors such as inflammation and 
CMV infections also have been related to an increased cardiovascular risk (3;8).
Although previous studies have evaluated risk factors for cardiovascular disease and 
the incidence of cardiovascular events after transplantation, further study on this subject is 
still necessary (3;9;10). The first reason is that most previous studies are based on registry 
(Medicare) data, which probably underestimate the true incidence of cardiovascular events. 
Besides these studies have a relative short follow-up and are performed in populations that 
differ in risk and ethnicity from our western European population (3;9;10). Apart from that, 
there still is no consensus about which patients should undergo further cardiac evaluation 
before transplantation and what the consequences of further evaluation are (1 1 ).
The aim of our study was to determine the association between pre-transplant 
risk factors and cardiovascular comorbidity and post-transplant cardiovascular events and 
patient death. Secondly, we wanted to study the incidence of post-transplant cardiovascular 
events early and late after renal transplantation. We also tried to find an algorithm that 
could predict which patients are at high risk for an early post-transplant cardiovascular 
event and should undergo extensive cardiac evaluation before renal transplantation. In 
order to answer these questions we collected data from all patients transplanted in three 
transplantation centers in the Netherlands between 1984 and 1997.
Subjects and Methods
For this retrospective study, data from patients who received a first renal transplantation 
in any of the three transplantation centers in the Netherlands were collected. In all 
three centres, baseline and follow-up data were stored in the Netherlands Organ 
Transplantation Registration (NOTR). If data were missing, the medical file was 
claimed for and extensive research was done to complete the data. All adult patients 
who received a primary renal transplantation between 1-1-1984 and 31-12-1997 
were eligible. Neither the patients who had undergone simultaneous kidney pancreas 
transplantations nor those patients who were rejected for pancreas transplantation were 
included in this study. Before transplantation routine, cardiac examination was performed 
in all patients (medical history, physical exam, ECG, blood pressure). Additional cardiac 
examination was only done in patients with diabetic nephropathy, a positive cardiac 
history or abnormal routine evaluation and comprised a stress echocardiography or 
a cardiac scintigraphy. In addition, in patients with an abnormal stress test, coronary
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angiography was performed. Because we were primarily interested in cardiovascular 
events and mortality, patients with graft loss within three months after transplantation 
were excluded (except when graft loss and patient death occurred on the same day).
The primary endpoints of the study were the occurrence of the first post­
transplant cardiovascular event and all-cause mortality. A post-transplant cardiovascular 
event was defined as a myocardial infarction or revascularization procedure [Percutaneous 
coronary intervention (PCI) or coronary bypass grafting (CABG)], cerebrovascular 
accident (CVA), or death with a cardiovascular cause after transplantation. An 
early post-transplant cardiovascular event was defined as the occurrence of an event 
within three months after the transplantation. Patient survival was defined as the 
time between the date of transplantation and death attributable to any cause. Patient 
survival was censored at the date of graft failure if the patient was still alive at that time.
To determine independent predictors for a post-transplant cardiovascular event 
and all-cause mortality the following parameters were collected at baseline: recipient age, 
recipient gender, type of donor (deceased versus living), date of transplantation, history of 
a cardiac event [myocardial infarction or revascularization procedure (PCI or CABG)], 
CVA, claudication, or angina pectoris before transplantation, diabetic nephropathy as 
primary cause of renal failure (DN), body mass index (BMI), cold ischemia time, dialysis 
prior to transplantation, and duration of dialysis. Pre-transplant systolic and diastolic 
blood pressure (n=1201), smoking history (n=1115), and the total cholesterol level (n=796) 
were only collected in one or two centres and were therefore incomplete. To analyze 
the incidence of post-transplant cardiovascular events we determined the incidence 
in the first three months after transplantation and in each year after transplantation.
Nowadays additional cardiovascular evaluation (dobutamine stress echocardio­
graphy or myocardial scintigraphy) is advised for high risk patients (patients over 50 years 
of age, patients with diabetes mellitus or a cardiovascular history or complaints) (11). It is 
generally accepted that additional cardiac evaluation is not necessary in low risk patients. 
In addition to the overall analysis we divided our patients into a low- and high-risk group. 
Patients over 50 years of age, with DN or a cardiovascular history were considered to be at 
high risk and the other patients were considered low risk. The incidence of cardiovascular 
events in the low and high-risk group was analyzed. Sensitivity, specificity and the 
negative and positive predictive value were calculated for this policy. The prevalence of 
cardiovascular events in our study cohort was used to calculate the predictive values.
Initial immunosuppressive therapy consisted of corticosteroids and a calcineurin 
inhibitor in all three transplantation centers. From 1990, most patients received 
azathioprine or mycophenolate mofetil in addition.
Statistical evaluation
In a multivariate Cox proportional hazard model adjusted and unadjusted hazard ratios 
for a post-transplant cardiovascular event and all cause mortality were calculated. First, 
univariate analyses were done to explore the relation between post-transplant cardiovascular 
events and all-cause mortality and all baseline parameters. In order to investigate which of 
these parameters were independent predictors for a post-transplant cardiovascular event 
and all-cause mortality the stepwise selection procedure as suggested by Collet was used
(12). The fit of the models was evaluated by inspection of the Schoenfeld residuals. All 
baseline parameters were included in the primary analysis, except pre-transplant diastolic 
and systolic blood pressure, total cholesterol, and smoking because these parameters 
were systematically missing in some centers. However, these variables were included in
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secondary analyses restricted to the centers they were measured in. In this secondary 
analysis we only included the patients in which all four parameters were present.
In an additional analysis we tried to find a predictive algorithm for the occurrence of 
a post-transplant cardiovascular event and all-cause mortality within three months after the 
transplantation. For this analysis, occurrences of a post-transplant cardiovascular event and 
all-cause mortality within three months after the transplantation were analyzed using logistic 
regression. A multivariate analysis was done following the previous mentioned method. On 
basis of the multivariate logistic regression analysis, a predictive formula was sought. A ROC- 
curve was used to detect the cut-off point with the optimal sensitivity and specificity and 
the area under the curve (AUC) to evaluate the overall usefulness of the predictive formula.
A P-value of< 5% was considered as significant (two-sided). Statistical analyses were 
carried outwith SAS version 9.2 on the AIX 5.2 platform. (SAS Institute Inc. Cary,N C,USA)
Results
Between 1984 and 1997, 2187 patients received a first renal transplant. Seven hundred 
and five patients received their transplant between 1984 and 1988, 785 between 1989 and 
1993, and 697 between 1993 and 1997. At baseline 7% of the patients had a history of a 
cardiac event, 6.3% of angina pectoris, 2.2% of claudication, and 3.1% of a CVA. Diabetic 
nephropathy was the primary kidney disease in 6.9% of the patients. The majority of the 
patients received a kidney from a deceased donor and 92% of the patients were treated with 
dialysis before the transplantation. All baseline characteristics are given in Table 1 . In the 
latest time period, more patients received a kidney from a living donor and more patients were 
transplanted pre-emptively. There was no difference in recipient age, DN and cardiovascular 
morbidity between the three time periods. The median follow-up of the patients was 8 .0  
years (interquartile range 4.5-11.4). Mean patient survival after transplantation was 14.8 
years (95% CI 14.0-16.1), and mean graft survival was 10.3 years (95% CI 9.7-10.9).
Table 1. Baseline characteristics of all patients
All patients (n-2187)
Recipient ag e  (yrs) 45.9  ± 13.1
Male (%) 1337 (61.1)
BMI (kg/m2) 23.5  ± 3.7
Dialysis before transplantation (%) 1990 (92.8)
Time on dialysis (yrs) 2.3 ± 1.9
History of a card iac  event (%) 151 (7.0)
History of a CVA (%) 6 8  (3.1)
History of claudication (%) 47  (2.2)
History of angina pectoris (%) 134 (6.3)
Diabetic nephropathy a s  primary kidney d isea se  (%) 149 (6.9)
D eceased  donor (%) 1815 (83.0)
Cold ischemia time (hours) 23 .8  ± 12.0
A total of 713 patients (32.6%) experienced a fatal or non-fatal post-transplant 
cardiovascular event, 115 patients experienced two post-transplant cardiovascular events
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and 73 patients experienced three or more post-transplant cardiovascular events. The 
incidence of post-transplant cardiovascular events was highest in the first three months after 
transplantation. Eighty-nine patients (4.1%) experienced a post-transplant cardiovascular 
event in the first three months after transplantation. One-hundred and sixty-seven (7.6%) 
patients had a post-transplant cardiovascular event in the first year after transplantation. 
After the first transplant year the incidence of cardiovascular events declined from 4% 
in the second year to 3% in the tenth year. The post-transplant cardiovascular event free 
survival is given in Figure 1.
Time to first cardiovascular event (yrs)
Number o f patients a t risk
2186 1760 1463 1232 969 659 412 255 148 77
Figure 1. Post-transplant cardiovascular event free survival
In univariate analyses a previous cardiac event, angina pectoris, CVA, claudication, DN, 
duration of dialysis, year of transplantation, BMI, living donor and cold ischemia time 
were significantly associated with the occurrence of a post-transplant cardiovascular 
event. In the multivariate Cox regression model DN, claudication, history of a cardiac 
event, history of a CVA, duration of dialysis, recipient age, and BMI were independent 
predictors for a post-transplant cardiovascular event. The unadjusted and adjusted 
hazard ratios and 95% confidence intervals are given in Table 2 . The model complied 
with the proportional hazard assumption because the correlations between the 
Schoenfeld residuals and the survival times were less than 0.1 for all predictors.
The results of the subgroup analyses restricted to the centers that had recorded 
blood pressure, cholesterol and smoking data were similar to the results shown in Table 
2. None of the additional factors were a significant predictor for a post-transplant 
cardiovascular event. In the multivariate logistic regression analysis a previous cardiac 
event (cardiac event and angina pectoris were combined for this analysis), claudication, 
DN and recipient age were independent predictors for the occurrence of a post-transplant
C hapter 3
32
Tobie 2. Unadjusted and adjusted hazard ratios (HR) for predictors of a first 
cardiovascular event after renal transplantation (Cox regression)
Unadjusted hazard ratio Adjusted hazard ratio
n HR (95% CI) P value HR (95% CI) P value
Diabetic nephropa thy 2173 3 .22  (2.86 4.01) <0.0001 3.02  (2.85 3.98) <0.0001
as p rim ary k idney
d isease (yes/no)
C laudication (yes/no) 2154 4 .04  (2.86 5.71) <0.0001 2.17 (1.42 3.31) <0.001
C ard iac  event (yes/no) 2172 2 .47  (1.96 3.11) <0.0001 1.76 (1.32 2.33) <0.0001
CVA (yes/no) 2175 2 .05  (1.46 2.88) <0.0001 1.53 (1.03 2.28) <0.05
Time on dialysis (yrs) 1990 1.07 (1.03 1.10) <0.001 1.06 (1.02 1.11) <0.01
Recipient age  (yrs) 2187 1.05 (1.04 1.05) <0.0001 1.04 (1.04 1.05) <0.0001
BMI (kg /m 2) 1836 1.05 (1.03 1.08) <0.0001 1.03 (1.00 1.05) <0.05
Angina pectoris (yes/no) 2173 1.97 (1.52 2.54) <0.0001
Living donor (yes/no) 2164 0 .60  (0.48 0.75) <0.001
Cold ischem ia time 2184 0.79  (0.68 0.92) <0.01
<24h (yes/no)
Year o f  transp lanta tion 2187 0 .98  (0.96 1.00) <0.05
(yrs)
Recipient gender 2187 1.10 (0.95 1.28) NS
(male/female)
CI, confidence interval; NS, not significant; HR, Hazard ratios; CVA, cerebrovascular accident
Tobie 3. Adjusted hazard ratios (HR) for predictors of a first cardiovascular event 
within 3 months of transplantation (multivariate logistic regression)
C ardiac event (yes/no) 2.71 1.62-4.54 <0.001
Claudication (yes/no) 2.50 1.02-6.08 <0.05
Diabetic nephropathy 2.14 1.10-4.17 <0.05
as prim ary kidney
disease (yes/no)
Recipient age (yrs) 1.03 1.01-1.05 <0.001
CI, confidence interval;HR, Hazard ratio
cardiovascular event within three months after transplantation (Table 3). On basis of the 
logistic regression analysis a predictive formula for the risk of occurrence ofa post-transplant 
cardiovascular event within three months after transplantation was sought. However, the 
formula found,did not show an adequate sensitivityand specificity(AUC=0.72) .We also could 
not find a satisfactory formula for the risk of death early after transplantation (AUC = 0.67).
One-thousand and sixty-four patients belonged to the predefined low-risk 
group and 1016 to the predefined high-risk group (age > 50 years, diabetes mellitus or a 
cardiovascular history or complaints). Fourteen patients (1.3%) in the low risk group and 
75 patients (6 .8 %) in the high-risk group had a post-transplant cardiovascular event within 
three months after the transplantation. Sensitivity and specificity of this algorithm were 84% 
and 51.2%. The negative predictive value of this policy was 98.7%. The positive predictive 
value of this policy was 7.3%. At 1 year, 35 patients (3.2%) in the low risk group and 140 
patients (1 2 .8 ) in the high risk group had a post-transplant cardiovascular event.
In Table 4 the unadjusted and adjusted hazard ratios for pre-transplant risk factors 
for all-cause mortality are given. Independent pre-transplant risk factors for all-cause
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mortality were DN, history of a cardiovascular event, a CVA, or claudication, recipient age 
and year of transplantation. Fifty- three percent of the all-cause mortality had a cardiovascular 
origin. The correlations between the Schoenfeld residuals and the survival times were
< 0.1 for all predictors apart from age. For the latter variable, the correlation was 0.14. 
The results of the subgroup analyses restricted to the centers that had blood pressure, 
cholesterol and smoking data were similar to the results shown in Table 4. Smoking was 
a significant predictor for all-cause mortality in the univariate and multivariate analyses. 
In the univariate analysis, the hazard ratio was 1.82 (95% CI 1.28-2.59) and in the 
multivariate analysis the hazard ratio was 2.34 (95% CI 1.61-3.41).
Tobie 4. Unadjusted and adjusted hazard ratios (HR) for predictors of all­
cause mortality after renal transplantation (Cox regression)
Unadjusted hazard ratio Adjusted hazard ratio
n HR (95% CI) P value HR (95% CI) P value
Diabetic nephropa thy 2173 2 .49  (1.99 3.12) <0.0001 2 .74  (2.17 3.46) <0.0001
(yes/no)
CVA (yes/no) 2175 2.21 (1.60 3.05) <0.0001 1.88 (1.36 2.60) <0.0001
C laud ication  (yes/no) 2154 2 .65  (1.82 3.87) <0.0001 1.55 (1.05 2.29) <0 .05
C ard iac  event (yes/no) 2172 2.46  (1.96 3.08) <0.0001 1.55 (1.24 1.95) <0.001
Recipient age (yrs) 2187 1.07 (1.06 1.08) <0.0001 1.07 (1.07 1.08) <0.0001
Y ear o f 2187 0 .9 8  (0.95 0.99) <0.01 0 .97  (0.95 0.99) <0.001
transp lan ta tion  (yrs)
Time on d ia lysis (yrs) 1990 1.05 (1.02 1.09) <0.01
BMI (kg/m 2) 1836 1.045 (1.02 1.07) <0.001
Angina pectoris  (yes/no) 2137 2 .03  (1.59 2.60) <0.0001
Living donor (yes/no) 2164 0 .54  (0.43 0.68) <0.0001
Cold ischem ia time 2184 0 .70  (0.60 0.82) <0.0001
<24h (yes/no)
Recipient gender 2187 0 .90  (0.78 1.04) NS
(m ale/female)
CI, con fidence  interval; NS, not significant; HR, H azard  ratios; CVA, ce reb rovascu la r acc iden t
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Discussion
This large retrospective cohort study shows that the incidence of post-transplant 
cardiovascular events is very high. Ten years after the transplantation 40% of the patients 
had experienced at least one post-transplant cardiovascular event. Although our patient 
cohort had a relatively low cardiovascular risk at baseline compared to other studies, almost 
half of the patients experienced a post-transplant cardiovascular event within 1 0  years 
after transplantation (3;10). The incidence of cardiovascular events was the highest in the 
first three months after transplantation (4.1%). This is comparable to the results of many 
other studies (3;10;13). After the first transplant year, the incidence of post-transplant 
cardiovascular events slowly declined from 4% in the second year to 3% in tenth year. The 
decline in the incidence of post-transplant cardiovascular events late after transplantation 
probably reflects the fact that in patients without cardiovascular risk factors it takes more 
time before they reach a post-transplant cardiovascular event.
Diabetic nephropathy as primary kidney disease was the strongest predictor for a 
post-transplant cardiovascular event. Other independent risk factors for a post-transplant 
cardiovascular event were cardiovascular co-morbidity, time on dialysis, recipient age, and 
BMI. In the study from Kasiske et al. (10) the same independent risk factors, except for 
BMI, for an acute myocardial infarction after transplantation were found . In contrast to 
our results Kasiske et al. found that patients who were transplanted in the latest part of 
their study (between 1999-2002) had an increased risk for an acute myocardial infarction 
compared to patients transplanted between 1995 and 1998. This is probably related to the 
increase of co-morbidity and age of renal transplant candidates in the last decade (6 ). In 
our patient cohort there was no increase of mean age, DN and cardiovascular disease at 
baseline between 1984 and 1998. Not surprisingly year of transplantation was not an 
independent risk factor for a post-transplant cardiovascular event in our study. In the 
study from Lentine et al. (3) older age, DN and cardiovascular co-morbidity also were the 
most important predictors for a myocardial infarction after transplantation. In contrast to 
their study, deceased donor kidney transplantation was not an independent predictive risk 
factor in our study. This can be explained by the relatively low number of living donor 
kidney transplantations.
Patients with a previous cardiac event had a more than twofold increased risk for 
an early post-transplant cardiovascular event. Increased age, DN and claudication were 
also independently predictive for an early post-transplant cardiovascular event. In the 
study from Humar et al. (13) the same risk factors were independently predictive for a 
peri-operative myocardial infarction. The relevancy of these risk factors was also illustrated 
by the high incidence of early post-transplant cardiovascular events in the high-risk group. 
The very low incidence of early post-transplant cardiovascular events in the low risk group 
confirms the previous findings that extensive cardiac evaluation is unnecessary in low risk 
patients (14).
In our study risk factors for patient death were almost identical to risk factors for 
a cardiac event. This is not surprising since more than 50% of the all cause mortality had a 
cardiovascular origin. Year of transplantation was an independent risk factor for patient 
death, with a higher risk for patients transplanted earlier.This might reflect the improvement 
in the prognosis after a cardiovascular event and the improvement in the treatment of 
infectious diseases. Since we did not collect these data, this remains speculative.
Although our study is limited by its retrospective design, the routine gathering of 
data and yearly follow-up made our database very complete. Data about smoking habits,
Associations between pre-kidney-transplant risk factors and post-transplant cardiovascular events and death.
35
cholesterol, and blood pressure were not complete because some centers did not routinely 
collect these data. In the centers that collected these items, data was almost complete. 
Reporting bias is therefore likely to be minimal. Although inclusion of the missing risk 
factors could have changed our final results the subgroup analysis in the centers who 
reported all parameters does not support this. Another limitation of our study is that all 
our patients were transplanted before 1998 and that cardiovascular treatment and 
preoperative evaluation have changed considerably since then. It is not unreasonable to 
think that standard preoperative treatment with beta-blockers and extensive cardiovascular 
screening in high risk patients would have decreased the incidence of early cardiovascular 
events (15;16). On the other hand incidences in more recent analysis are not lower than in 
our cohort (3;10). Advantage of our inclusion period is that our study had a very long and 
complete follow-up, which gave us the opportunity to give reliable information about the 
incidence of cardiovascular events till more than ten years after transplantation. As far as 
we know, no study of this size with such a long follow-up has been published before. In 
our study we focussed on pre-transplant cardiovascular risk factors and we did not analyse 
the influence of post-transplant risk factors. It is well known that post-transplant risk 
factors like renal function and new-onset DM  play a role in the occurrence of late 
cardiovascular events after renal transplantation (7; 17). A last limitation of the study 
might be the combined endpoint for a post-transplant cardiovascular event. In most recent 
studies, only cardiac events or myocardial infarction were used as primary endpoint 
(3;10;18). Incidences of the events in those studies are not fully comparable to incidences 
in our study for this reason. On the basis of previous studies, it is expected that the majority 
of the cardiovascular events in our study had a cardiac origin. Besides, risk factors for 
stroke are generally the same as for cardiac events (18;19). This explains the fact that we 
predominantly found the same independent risk factors in our study compared to other 
studies (3;10).
In international guidelines cardiovascular evaluation, including nuclear imaging 
or angiography, has been advised for high risk patients (11;20). Unfortunately there is no 
consensus about which cardiovascular screening test should be done. Sensitivity and 
specificity of nuclear imagine tests and dobutamine stress echocardiography differ widely 
between several studies (21). In the study from Lima et al. (22) angiography had the best 
sensitivity for the occurrence of cardiac events after transplantation. There is also no 
evidence that cardiac screening followed by revascularization is beneficial for asymptomatic 
high-risk renal transplant candidates. Manske et al. (23) showed in a small randomized 
clinical trial that pre-operative revascularization in asymptomatic diabetic renal transplant 
candidates with significant coronary disease was superior to conservative therapy. 
Limitation of this study is that the conservative therapy was not adequate compared to 
recent standards. In a recent study from McFalls et al. (24) in high risk patients with 
asymptomatic significant coronary disease revascularization before a major vascular 
operation had no benefit compared to conservative therapy. These results show that further 
prospective research in renal transplant candidates is necessary to elucidate how we can 
decrease the high incidence of post-transplant cardiovascular events.
The main conclusion of our study is that even in our relatively low risk, western 
European population the incidence of post-transplant cardiovascular events is high and is 
responsible for more than 50% of the mortality after transplantation. Traditional risk 
factors like diabetic nephropathy, older age and previous cardiovascular events are the 
most important pre-transplant predictors for post-transplant cardiovascular events. 
Unfortunately we could not find a reliable algorithm to predict which patients would
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experience an early post-transplant cardiovascular event. We propose to do a prospective, 
randomized-controlled trial in high-risk renal transplant candidates to determine if 
cardiac screening followed by coronary revascularisation is better than medical treatment 
alone.
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Abstract
Background. Perioperative cardiovascular events in renal transplantation are 
common and noninvasive cardiac stress tests are recommended in high-risk renal 
transplant candidates. In 2004 we introduced a standardized preoperative cardiac 
risk assessment program with the aim of reducing perioperative cardiac event
M ethods. Since 2004 all asymptomatic high-risk renal transplant candidates 
had to undergo noninvasive cardiac stress testing. Patients with a positive stress 
test went for a coronary angiography and if indicated for revascularization. The 
incidence of perioperative cardiac events (<30 days of transplantation) was analyzed 
in all high-risk patients who received a transplantation (screening group) and 
compared with high-risk renal transplant recipients evaluated in the 4 years before 
the introduction of the cardiac assessment program (historical control group).
Results. Since 2004, 227 of 349 asymptomatic high-risk renal transplant candidates 
underwent noninvasive cardiac stress testing. In 15 patients (6 .6 %) significant 
ischemia was found. Ten of these 15 patients underwent coronary angiography (eight 
patients had significant coronary artery disease and in five patients percutaneous 
coronary intervention was performed). One hundred and sixty of 349 renal 
transplant candidates underwent renal transplantation so far (screening group). In 
the screening group 6 perioperative cardiac events (3.8%) occurred compared to 13 
perioperative events (7.6%) in the historical control group (n = 172) (P = 0.136).
Conclusions. The incidence of significant cardiac ischemia in high-risk renal transplant
patients was low and was followed by revascularization in a small percentage of patients. 
No significant decrease in perioperative cardiac events was observed after the introduction 
of the standardized cardiac assessment program.
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Introduction
Renal transplantation is the preferred treatment option for most patients with end-stage 
renal disease (ESRD). Since the first transplantation, results have improved substantially 
(1;2). In most transplant centers graft survival in the first year is between 90 and 95%
(3). W ith this high success rate, the acceptance rate for renal transplantation has been 
extended. Patients with obesity, older age and a history of cardiovascular events are 
nowadays accepted for renal transplantation (4). This extension of acceptance may lead 
to an increase of perioperative cardiac events and death after transplantation. Humar et 
al. (5) found an incidence of cardiac complications (including arrhythmia and congestive 
heart failure) of 6.1% in the first 30 days after transplantation. In recent studies the 
incidence of myocardial infarction in the first year after transplantation was ~3.5 to 
5%, with the highest incidence in the first three months after transplantation (6 - 8 ).
Although the prevalence of coronary artery disease at the time of renal 
transplantation is high, many renal transplant candidates are asymptomatic (6;9-11). 
Several international guidelines therefore recommend evaluation of asymptomatic 
high-risk renal transplant candidates with stress perfusion (myocardial scintigraphy) 
or dobutamine stress echocardiogram or coronary angiography and to perform an 
intervention in case of significant coronary artery disease (12;13). There is no evidence that 
this policy reduces the incidence of perioperative cardiac events in renal transplantation. 
Recent publications even doubt the benefit of preoperative revascularization (14-17).
In the beginning of 2004 we introduced a protocol for the preoperative cardiac 
assessment of all asymptomatic high-risk renal transplant candidates in our hospital to 
assess significant cardiac ischemia with noninvasive cardiac stress testing. The protocol 
was based on international guidelines (12;13;18). The aim of this study is to evaluate 
the effect of standardized cardiac assessment on the incidence of perioperative cardiac 
events wherefore, we compared the incidence of perioperative cardiac events in high-risk 
renal transplant recipients evaluated before and after the introduction of the standardized 
protocol.
Subjects and methods
In our region all renal transplant candidates, without a clear contra-indication, are referred 
for evaluation to the outpatient clinic of the University Medical Center by their treating 
nephrologist. In January 2004 we introduced a standardized protocol for preoperative 
cardiac risk assessment of renal transplant candidates. In this protocol all asymptomatic 
renal transplant candidates were screened for six clinical risk factors: age (> 45 years for 
men and > 55 years for women), diabetes, current smoker, cardiovascular history [acute 
coronary syndrome (ACS), percutaneous coronary intervention (PCI), coronary artery 
bypass grafting (CABG), cerebrovascular accident (CVA), transient ischemic attack 
(TIA), heart valve operation, heart failure, peripheral arterial disease], an abnormal 
electrocardiography (ECG) (except left ventricular hypertrophy) and obesity (body mass 
index (BMI) > 30 kg/m2) (7;8;18-20) . Patients with > one risk factors were classified 
as high-risk patients. All other patients (with no risk factor) were classified as low-risk 
patients. In all high risk patients non-invasive cardiac stress testing had to be performed 
for further risk stratification [physiologically or pharmacologically (adenosine or 
dobutamine) induced stress perfusion with myocardial scintigraphy or dobutamine stress 
echocardiography]. In most patients, the noninvasive cardiac stress test was performed in 
the general hospital. The type of stress test was dependent on the experience in the general
Is standardized cardiac assessment of asymptomatic high risk renal transplant candidates beneficial?
43
hospital. Dobutamine stress echocardiography was only performed in the University 
Medical Hospital. A noninvasive cardiac stress test was considered positive if two or more 
myocardial segments (17-segment scheme) showed stress-induced ischemia. Patients 
with a positive noninvasive cardiac stress test went for coronary angiography. Significant 
coronary artery disease was defined as a coronary artery stenosis of >70%. All patients 
with significant coronary artery disease were referred for intervention. The final decision 
for intervention (PCI or CABG) was left to the treating cardiologist. All interventions 
were done in the University Medical Center. The final decision whether patients were 
accepted for renal transplantation was made by the transplant team.
Before 2004, noninvasive cardiac stress testing was not performed on a routine 
basis, but driven by the treating physician (cardiologist or nephrologist). These noninvasive 
cardiac stress tests were not often performed at that time, only in patients with diabetic 
nephropathy or with a history of cardiovascular disease.
P a tie n ts  a n d  s tu d y  g ro u p s
We retrospectively collected the data from all adult renal transplant candidates 
who were evaluated in our outpatient clinic for kidney transplantation between 1 
January 2004 and 19 May 2008 (screening group). Patients with angina [NYHA 
functional class > 1 (n = 2 1 )] were excluded from this data analysis.
For all asymptomatic transplant candidates we assessed the clinical risk 
score. All asymptomatic patients were included in this study and all data concerning 
noninvasive cardiac stress testing, coronary angiographies, revascularization, 
waitlisting, renal transplantation and perioperative cardiac events were collected 
from the medical file. In our study we did not collect data about preoperative cardiac 
events (cardiac events between noninvasive cardiac stress testing and transplantation).
H istorical con tro l g ro u p
To analyze if the incidence of perioperative cardiac events decreased after the introduction 
of our standardized cardiac assessment protocol we made a comparison with a historical 
control group. For the historical control group we collected data from all adult 
asymptomatic renal transplant candidates that were evaluated at our outpatient clinic 
during the four years before the introduction of our cardiac assessment program (from
2000 to 2004) and received a renal transplantation. These patients were retrospectively 
divided into a low-and high-risk group, based on the previously given definition.
Definition o f  p e rio p e ra tiv e  c a rd ia c  e v e n ts
A perioperative event was defined as the composite end point of any cardiac event within 
30 days after transplantation including cardiac death, ACS [ST-elevation myocardial 
infarction (STEMI); non-ST-elevation myocardial infarction (non-STEMI)) or unstable 
angina], pC i and cA bG . A STEMI was defined as at least 1 mm (0.1 mV) of ST-segment 
elevation in two limb leads and at least 2 mm ST elevation in two consecutive precordial 
leads. Non-STEMI was defined as an ECG without ST elevation, but with elevated 
troponins (> 0.2|ig/L) >6 h after cardiac complaints. For further analysis, we grouped the 
cardiac events in major (cardiac death, STEMI, non-STEMI with peak troponin > 3 |ig/L 
or intervention) and minor cardiac events (non-STEMI with peak troponin < 3 |ig/L).
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Cardiac evaluation in high-risk renal transplant candidates:
■ The incidence of significant cardiac ischemia
■ The incidence of significant coronary artery disease
■ The incidence of coronary interventions (PCI/CABG)
■ The influence of screening on evaluation time and waitlisting
Perioperative cardiac events after renal transplantation:
■ The incidence of perioperative cardiac events in high-risk 
renal transplant candidates
■ The incidence of perioperative cardiac events before and after 
the introduction of the cardiac evaluation program
S ta tis tica l a n a ly s e s
Statistical analysis was performed with SPSS 16.0. Patient characteristics of the different 
groups were compared using the Pearson’s chi-square test or the Fisher’s exact test for 
categorical data and the Student’s t-test or the Mann-Whitney U-test for continuous 
data. We compared the incidence of perioperative cardiac events between the screening 
and the historical control group. A P-value of <0.05 (two sided) was considered significant.
Results
Cardiac evaluation
Between 2004 and 2008 we evaluated 466 asymptomatic renal transplant candidates prior 
to inclusion on the renal transplant waiting list. Based on clinical risk factors 349 patients 
(74.9%) were defined as high-risk patients. In 227 of these patients (64.9%) noninvasive 
cardiacstress testingwasperformed[203 patients (89.4%)underwentmyocardialscintigraphy 
and 24 patients (10.6%) underwent dobutamin stress echocardiography].
In 122 high-risk patients (35.1%) no noninvasive cardiac stress test was performed. 
In 25 of these patients (20.5%) screening was not finished at 19 May 2008 (end of the study). 
In 11 patients (9.0%) a coronary angiography was performed without prior noninvasive 
cardiac stress testing and 13 patients (10.7%) were excluded from transplantation due 
to non-cardiac reasons. In the remaining 73 high-risk patients (59.8%) the nephrologist 
decided not to do a noninvasive cardiac stress test, although the patients belonged to the 
high risk group. These patients had significantly less cardiovascular risk factors compared 
to the high-risk patients with cardiac stress testing (Table 1 ). In 46 of the 73 patients 
(63%) age and/or smoking were the only clinical risk factor.
R esu lts  o f non in v asiv e  c a rd ia c  s t r e s s  te s ts
In 15 of the 227 (6 .6 %) noninvasive cardiac stress tests significant ischemia was found 
(reversible defect in two or more segments). All 15 patients with significant ischemia on 
noninvasive cardiac stress testing were male. No other significant baseline differences were 
found between patients with cardiac ischemia versus without ischemia. The incidence of 
significant cardiac ischemia in patients with the highest risk [diabetes or a history of 
cardiovascular disease (n=117)] was 8.5%. In 48 of the patients (21.1%) one or more fixed 
defects were found.
E nd p o in ts  o f  th e  s tu d y
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C o ro n a ry  a n g io g ra p h y  a n d  rev ascu la riza tio n
In 10 of the 15 patients with significant cardiac ischemia, a coronary angiography 
was performed. In eight patients significant coronary artery disease in one or more 
vessels was found (none of the patients had three vessel disease). In Figure 1 a flow 
diagram of the cardiac evaluation process is given.
In five patients with significant coronary artery disease a PCI was performed before 
waitlisting (none underwent CABG). No complications were observed in these patients.
In 19 patients with fixed defects in one or more segments a coronary angiography 
was performed. Ten of these patients had significant coronary artery disease and four 
patients underwent revascularization before waitlisting (three PCI and one CABG).
A c c e p ta n c e  for th e  w aiting list
Of the 349 high-risk renal transplant candidates 275 patients (78.9.2%) were accepted for 
the waiting list for renal transplantation [195 of the 227 patients (85.9%) who underwent 
noninvasive cardiac stress testing and 80 of the 122 patients (65.6%) without stress testing]. 
Twelve patients (3.4%) were excluded due to a cardiac cause. The median time between the 
start of the evaluation and the decision about waitlisting was 5 (1-44) months. The mean 
time between noninvasive cardiac testing and renal transplantation was 14 ± 11 months.
R enal tra n sp la n ta tio n
In total 160 of the 349 high-risk patients received a renal transplantation (screening group) 
(Figure 1). The baseline characteristics are given in Table 2. Noninvasive cardiac stress testing 
was performed in 110 patients. Six patients underwent preoperative revascularization. Four of 
the 15 patients with significant ischemia on noninvasive cardiac stress testing received a renal 
transplantation (all had significant coronary artery disease and three patients were treated 
with PCI before transplantation). The other three patients that underwent preoperative 
revascularization (two PCI and one CABG) had one or more fixed defects on noninvasive 
cardiac stress testing (data about cardiac evaluation and revascularization are given in Table 3).
P e rio p e ra tiv e  c a rd ia c  e v e n ts  a f te r  tra n sp la n ta tio n
In the first 30 days after transplantation, six perioperative cardiac events (3.8%) were 
observed (all non-STEMI). All events occurred in patients with negative noninvasive 
cardiac stress testing (none of these patients underwent CAG or revascularization).
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Table 1. Cardiovascular risk factors in asymptomatic, high risk renal transplant 
candidates with (n=227) and without non-invasive cardiac stress testing (n=73).
Non-invasive cardiac 
stress testing (n -227)
No non-invasive cardiac 
stress testing (n-73)
Cardiovascular risk factors
Diabetes (%)
C a rd iovascu la r d isease  (%) 
A cu te  co ro n a ry  synd rom e  (%) 
PC I/C A BG  (%)
Periphera l vessel d isease  (%) 
T IA /s troke  (%)
C urren t sm oking  (%)
M ale /fem a le
A ge
> 4 5  ye a rs  (male) (%)
> 55  ye a rs  (female) (%) 
O bes ity  (%)
A bnorm a l ECG (%)
N um ber o f C a rd iova s ­
cu la r risk fa c to rs
1 risk fa c to r (%)
> 2 risk fa c to rs  (%)
4 3  (18.9) 
90  (39.6) 
24  (10.6) 
26  (11.5) 
29  (11.8) 
36  (15.9) 
70  (30.8) 
1 6 3 /6 4
148 (65.2) 
41 (18.1) 
29  (12.8) 
50  (22.0)
78  (34.4) 
149 (65.6)
2 (2.7)
13 (17.8)
3 (4.1)
7 (9.5)
2 (2.7)
8  (10.9) 
37  (50.8) 
4 1 /32
21 (28.8) 
8  (11.0)
11 (15.1)
9 (12.3)
50  (68.5) 
23  (21.5)
P < 0.0001 
P < 0.01 
ns 
ns
P < 0 .05  
ns
P < 0.01
P < 0.0001
ns
ns
P = 0 .07
P < 0.0001 
P < 0.0001
NS = Not significant
Figure 1. Cardiac evaluation and perioperative cardiac events in renal transplant 
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H istorical con tro l g ro u p
Between 2000 and 2004, we evaluated 375 asymptomatic renal transplant candidates in 
our outpatient clinic. Based on clinical risk factors 298 were retrospectively defined as 
high-risk patients. In 95 patients (31.9%) noninvasive cardiac stress testing was performed 
(six patients had significant cardiac ischemia). The clinical consequences of noninvasive 
cardiac stress testing were low (only one patient with ischemia was excluded from 
transplantation and only one patient underwent pre-operative revascularization). Two 
hundred and thirty-two high-risk patients (77.8%) were accepted for the waiting list [10 
patients (3.4%) were rejected due to a cardiac cause]. There was no significant difference 
in the percentage of patients that were accepted for the waiting list before and after the 
introduction of the standard cardiac workup. The time between the start of the evaluation 
and the decision about waitlisting was significantly longer in the control group [6  (1 -6 6 ) 
months in the control group versus 5 (1-44) in the study group (P < 0.01)]. There was no 
significant difference in the time between waitlisting and transplantation between both 
groups. One hundred and seventy-two of the 298 high-risk patients (57.7%) received a 
renal transplantation.
C o m p a riso n  with historical con tro l g ro u p
In Table 2 the baseline characteristics of the screening and control group are given. 
Significantly more patients in the screening group received a preemptive transplantation, 
received a kidney from a living donor and received a previous renal transplantation and 
significantly more patients in the screening group were treated with a beta-blocker. There 
were no significant differences in cardiovascular risk factors between the screening and 
the control group. Six patients in the screening group versus two in the control group 
underwent preoperative revascularization (Table 3).
C a rd ia c  e v e n ts  in s tu d y  a n d  historical con tro l g ro u p
The incidence of perioperative cardiac events was 6  (3.8%) in the screening group 
compared to 13 (7.6%) in the historical control group (P = 0.136). Although there 
was no significant difference in the total number of events, the severity of the 
events differed: three cardiac deaths, five STEMI, and five non-STEMI [three 
patients had a peak troponin > 3 |ig/L (range 5.2-10.40 |ig/l)] in the control group 
compared to six non-STEMI [one patient had a peak tropinin > 3 |ig/l (54.10 
|ig/L)] in the screening group. Significantly more major perioperative cardiac events 
occurred in the control group compared to the screening group (1 1  major events 
in the control group versus 1 major event in the screening group, P < 0.05).
Patients with a perioperative cardiac event had significantly more cardiac 
risk factors compared to patients without a perioperative cardiac event [respectively 
73.7% versus 49.2% had two or more cardiac risk factors (P < 0.05)]. The number 
of events was too small to perform a multivariate analysis.
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Table 2. Baseline characteristics of all asymptomatic high-risk renal transplant 
candidates that received a renal transplantation (screening and historical control group).
Screening group Control group
(n=160) (n=172)
Recipient age (yr) 50.8 ± 12.1 51.1 ± 12.1 ns
Male (%) 106 (66.2) 109 (63.4) ns
BMI (kg/m 2) 25.2 ± 3.9 25.4 ± 4.4 ns
Dialysis (%) 124 (77.5) 160 (93.0) P < 0.001
Diabetic nephropathy (%) 14 (8.8) 19 (11.0) ns
Previous renal transplantation (%) 19 (11.9) 11 (6.4) P < 0.08
Living donor (%) 94 (58.8) 61 (35.5) P < 0.001
Cardiovascular risk factors
Diabetes (%) 20 (12.5) 27 (15.7) ns
Cardiovascular disease 47 (29.4) 50 (29.1) ns
Acute coronary syndrom e (%) 9 (5.6) 12 (7.5) ns
PCI/CABG (%) 9 (5.6) 6 (3.5) ns
Peripheral vessel disease (%) 14 (8.8) 20 (11.6) ns
TIA/stroke (%) 21 (13.1) 13 (7.6) ns
Current smoking (%) 59 (36.9) 56 (32.6) ns
Age
> 45 years (male) (%) 79 (49.4) 94 (54.7) P < 0.05
> 55 years (female) (%) 26 (16.2) 23 (13.4) ns
Obesity (%) 21 (13.1) 27 (15.7) ns
Abnormal ECG (%) 25 (15.6) 28 (16.3) ns
Number o f cardiovascular
risk factors
1 risk factor (%) 80 (50.0) 84 (48.8) ns
2 risk factors (%) 50 (31.2) 55 (32.0) ns
3 risk factors (%) 22 (13.8) 23 (13.4) ns
> 4 risk factors (%) 8 (5.0) 10 (5.9) ns
Medication
Beta-blocker (%) 143 (89.4) 130 (75.6) P < 0.01
Aspirin (%) 37 (23.1) 28 (16.3) ns
Statin (%) 77 (48.1) 64 (37.2) ns
NS = not sign ificant
Table 3. Cardiac evaluation and outcome in the screening and historical
control group.
Screening group 
(n=160)
Control group 
(n=172)
Non-invasive stress test (%) 110 (68.8) 53 (30.8) P < 0.001
Significant ischemia (%) 4 (3.6) 3 (5.7) ns
C oronary angiography (%) 20 (12.5) 13 (7.6) ns
Significant coronary 11 (55) 4 (30.7) ns
arte ry disease (%)
Revascularization (%) 6 (3.8) 2 (1.2) ns
PCI (%) 5 (83.3) 2 (100) ns
CABG (%) 1 (16.7) 0 (0) ns
Cardiac event < 30 days (%) 6 (3.8) 13 (7.5) P = 0.136
Non-STEMI (%) 6 (100) 5 (38.4) ns
STEMI (%) 0 5 (38.4) P = 0.061
Cardiac death (%) 0 3 (23.1) ns
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Discussion
In 2004, we introduced a standardized cardiac risk assessment program for asymptomatic 
high- risk renal transplant candidates in our center. Based on our retrospective analysis two 
important conclusions can be drawn. First, the incidence of significant cardiac ischemia in 
asymptomatic high-risk renal transplant candidates was low and as a consequence only a 
few patients underwent preoperative revascularization. Secondly, there was no significant 
decrease in the overall incidence of perioperative cardiac events after the introduction of 
the standardized protocol.
Incidence of significant card iac  ischemia
The incidence of cardiac ischemia in our study was lower compared to previous studies. In 
previous studies the incidence of cardiac ischemia was between 14 and 40% (11;18;21).In most 
of these studies, noninvasive cardiac stress tests with reversible defects in only one segment 
were also defined as positive. In our study, as also in daily clinical practice, only noninvasive 
cardiac stress tests with reversible defects in at least two or more segments were defined as 
positive. In the meta-analysis ofEtchells et al. (22) there was no increased risk of perioperative 
cardiac events if reversible ischemia is present in <2 0 % of the left ventricle.
In our study population the incidence of diabetes mellitus was lower compared to 
other studies (17;23). This is caused by the lower incidence of diabetes in The Netherlands 
compared to the United States. The relatively low risk of our study population could 
be the reason for the low incidence of significant cardiac ischemia. The low incidence 
of significant cardiac ischemia in patients with the highest risk (patients with 
diabetes and a history of cardiovascular disease) argues against this theory.
Furthermore, the low incidence of significant ischemia might reflect a 
decrease in significant coronary artery disease due to an increase in preemptive 
transplantations and improved treatment of cardiovascular risk factors after 2004.
In the literature, there is no consensus about the true value of noninvasive cardiac 
stress testing in ESRD. In some studies a low sensitivity of non-invasive cardiac evaluation 
is found, but other studies found a high sensitivity and high negative predictive value 
(9;17;18;24). In our study six patients with a negative noninvasive cardiac stress test had 
a perioperative cardiac event. We cannot exclude that the low incidence of positive non­
invasive cardiac stress testing in our study is related to a low sensitivity of the test in 
patients with end-stage renal disease (ESRD). Although there is doubt about the value 
of noninvasive cardiac stress testing in ESRD patients, Patel et al. (17) it showed that 
exercise tolerance testing can give important prognostic information .
C o ro n a ry  in terven tions
As a consequence of the low incidence of cardiac ischemia the incidence of preoperative 
revascularization in our study was low. Despite the fact that the number of noninvasive 
cardiac stress test doubled after the introduction of our standardized screening program, 
there was no significant increase in the number of preoperative revascularizations. 
Several other studies also found a low incidence of revascularization after pretransplant 
cardiac stress testing (17;25;26). Due to this finding, we cannot make any statement 
if pretransplant revascularization is beneficial. In observational studies no benefit of 
pretransplant revascularization was found (17;27). Unfortunately, no large randomized 
controlled clinical trials (RCT) have been performed in renal transplant candidates (27).
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Yet, in two RCTs no benefit of preoperative revascularization was found in patients 
undergoing major vascular surgery (14;28).
P e rio p e ra tiv e  c a rd ia c  e v e n ts
In accordance with the low incidence of cardiac ischemia no significant decrease in the 
incidence of perioperative cardiac events was observed after the introduction of our 
standardized cardiac risk assessment protocol. However, there was a trend to a decrease in 
perioperative cardiac events and significantly less major perioperative cardiac events were 
observed after the introduction of the screening program. First, we cannot exclude that 
these differences are related to the implementation of the screening program. Secondly, 
this finding could also be due to improved perioperative medical treatment. Significantly 
more patients were treated with beta-blockers. Most studies in patients undergoing major 
noncardiac surgery found a decrease in perioperative cardiac events in patients treated 
with beta-blockers (29). Furthermore, an increased number of patients were treated with 
aspirin and statins. During the last few years we continued aspirin perioperatively. First, we 
discontinued aspirin a few days before transplantation to minimize bleeding complications 
and to do a renal biopsy postopera tively when indicated. Both the use of statins and 
aspirin are associated with less perioperative cardiac events (30-32). Thirdly, in 11 of the 
15 patients with significant cardiac ischemia no renal transplantation was performed yet 
due to the long waiting time of 4-5 years in The Netherlands. Earlier studies showed that 
patients with significant cardiac ischemia on noninvasive cardiac stress testing have an 
increased risk for perioperative myocardial infarction (24). On the contrary, there is no 
evidence that revascularization is better than best medical treatment alone in reducing the 
perioperative risk in patients with inducible ischemia (14;15;17). Although, noninvasive 
cardiac stress testing might be helpful in identifying high-risk patients, there is no evidence 
of improved clinical outcome after revascularization compared to best medical treatment. 
Finally, the decrease we found in major cardiac events could be explained by differences in 
baseline characteristics between the two groups before and after standardized cardiac risk 
assessment. More patients in the screening group received a preemptive transplantation 
and therefore were not exposed to the harmful effects of dialysis. However, no differences 
in cardiovascular risk factors were found.
Lim itations o f th e  s tu d y
Our study has several limitations. First, our study is limited by its retrospective design. 
Secondly, the protocol was violated by the treating physician in 20% of the high-risk patients 
and no a noninvasive cardiac stress test was performed. The reason of nonadherence might 
be our broad definition of high risk. Patients without cardiac stress testing had significantly 
less risk factors (>50% had only smoking or increased age as risk factor). It is likely that 
clinicians did not perform cardiac stress tests in young patients in good clinical condition 
with only one risk factor. In these patients, no perioperative cardiac events were observed. 
Furthermore, violation of the protocol could be due to the growing evidence during the 
study that preoperative revascularization is not superior to optimal medical treatment 
(14;15). Thirdly, comparison with a historical control group can be criticized. Firstly, there 
was a difference in the treatment of cardiac risk factors between the study and control group. 
Secondly, 32% of the high-risk patients in the control group underwent noninvasive cardiac 
stress testing and some underwent revascularization. Despite its limitations comparison 
with a historical control group gives valuable information about the effect of introducing
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a standard cardiac evaluation program. Fourthly, we did not collect data about cardiac 
events in the time between evaluation and transplantation. Data about the occurrence of 
cardiac events in this time period could have given more information about the value of 
noninvasive cardiac stress testing. Fifthly, we did not have complete information about the 
left ventricle ejection fraction in our study. Previous studies showed that the left ventricle 
ejection fraction is a strong prognostic marker for cardiac events in ESRD patients 
awaiting renal transplantation (1 0 ). At last, the mean delay between noninvasive cardiac 
stress testing and transplantation was 14 months. It is possible that a stress test closer to the 
transplantation might have a better prognostic value. Despite its limitations, information 
from observational studies like ours is necessary as long as no randomized controlled 
clinical trials compared preoperative revascularization to optimal medical treatment alone 
in renal transplant candidates. Unfortunately, it is not very likely that such a randomized 
controlled clinical trial will be set up in renal transplant candidates (17).
In conclusion, noninvasive cardiac stress testing in high-risk renal transplant 
candidates had little clinical consequences and no significant decrease in perioperative 
cardiac events was observed after the introduction of a standard cardiac evaluation 
program. Our study suggests that noninvasive cardiac stress testing in all high­
risk renal transplant candidates is unnecessary. Because of the small sample size, 
the relatively low-risk profile of our study group and the significant difference in 
major perioperative cardiac events between the screening and control group a final 
conclusion about the necessity of noninvasive cardiac stress testing in all high-risk renal 
transplant candidates cannot be drawn solely on our study. Prospective, randomized 
studies will be necessary to draw a final conclusion about the effect of noninvasive 
cardiac evaluation and intervention in high-risk renal transplant candidates.
Based on our results and the fact that there is no evidence that preoperative 
revascularization is better than medical treatment alone we believe that noninvasive 
cardiac stress testing in all high- risk renal transplant candidates should not be 
recommended. Revascularization should be restricted to those patients with an indication 
for revascularization regardless of the transplantation. Although the guidelines for 
preoperative cardiac risk assessment and perioperative cardiac management of the 
European Society of Cardiology are not directly applicable to chronic renal failure 
patients, we propose to follow these guidelines in renal transplant candidates as long as 
evidence from randomized clinical trials in renal transplant recipients is lacking (33). 
These guidelines recommend restricting noninvasive cardiac stress testing to patients 
with a low functional capacity (inability to climb two flights of stairs) and three or more 
cardiovascular risk factors undergoing high risk surgery. All other patients should only 
receive maximal medical treatment (low-dose titrated beta-blocker, statins and an ACE 
inhibitor in case of systolic left ventricle dysfunction). Thus, noninvasive cardiac stress 
testing in all high-risk asymptomatic renal transplant candidates did not significantly 
decrease the incidence of perioperative cardiac events and is therefore not recommended.
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Abstract
Background. Female renal transplant candidates are prone to be sensitised 
by prior pregnancies, and undetected historical sensitization might decrease 
transplantation outcome. Hypothesis of our study was that pre-transplant 
blood transfusions (PTFs) can elucidate historical sensitization and that the 
avoidance of the associated antigens can improve transplantation outcome.
M ethods. Data from all female non-immunized renal transplant candidates who received 
a random PTF (rPTF) (n = 620), matched PTF (mPTF) (1 HLA-A and B and 1 HLA-DR 
match)(n = 8 6 ) or donor specific blood transfusion (DST) (n = 100) between 1996 and 2006 
were collected. Complement dependent cytoxicity was used to detect anti-HLA-antibodies. 
Sensitization and transplantation outcome after a PT F were analyzed. Non-immunized 
female renal transplant recipients who did not receive a PTF were used as control group.
Results. In 165 patients, anti-HLA-antibodies (IgG) were detected after the 
PTF. Both historical as well as primary sensitizations were found. A DST induced 
donor specific anti-HLA antibodies in 25% of the DST recipients. Our policy did 
not improve transplantation outcome in recipients of a kidney from a deceased 
donor (n=368) or in recipients of a living donor [DST (n=49) and mPTF (n=6 6 )].
Conclusions. A PT F did elucidate historical sensitization, but induces primary 
sensitization as well. No beneficial effect from pre-transplant blood transfusions 
on transplant outcome was found, and pre-transplant blood transfusions with 
the intention to detect historical sensitization are therefore not suggested.
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Introduction
A positive historical crossmatch is associated with an increased risk of acute rejection and 
a decreased graft survival in renal transplantation (1-5). All sexual active women are prone 
to be sensitized due to prior pregnancies or miscarriages, but the antibodies may have 
disappeared after several years. A historical positive crossmatch could therefore be missed 
in female renal transplant candidates. In a study by Mahanty et al., non-immunized 
women with more than two prior pregnancies who received a kidney from their 
offspring had a decreased graft survival (6 ). Several case reports suggest that undetected 
sensitization plays a role in the decreased allograft survival in these patients (7;8).
Prior studies and clinical observations have shown that historical anti-HLA- 
antibodies can become apparent after blood transfusions (9). This was the rationale behind 
the practice in several Dutch transplant centres to pretreat potentially sensitized female 
renal transplant candidates with a pre-kidney transplant blood transfusion (PTF). Our 
hypothesis is that a PT F improves the detection of historical anti-HLA-antibodies and that 
avoidance of the associated antigens on a future donor kidney will improve graft survival.
The aim of the present study was to investigate how often historical sensitization 
is detected after a PTF and to find out if the avoidance of the associated antigens has a 
beneficial effect on transplantation outcome. To analyse the effect of a PTF on sensitization 
and transplantation outcome we conducted a retrospective, multi-centre study in all seven 
Dutch transplantation centres.
Materials and Methods
In the Dutch transplantation centres, three PT F protocols are used. One protocol for 
recipients planned to get a kidney from a deceased donor and two protocols for recipients 
planned to get a kidney from a living donor. A PTF was only administered to patients 
with a current negative complement dependent cytotoxicity (CDC) screening, defined as 
the absence of relevant IgG anti-HLA-antibodies.
Protocol 1: Random PTF (rPTF)
One rPTF was given to all female recipients before they were entered on the waiting list 
for a kidney from a deceased donor in four centres. The rPTF consisted of one unit of non­
leukocyte-depleted packed cells, without buffy-coat and less than 72 hours old.
Protocol 2: donor specific blood transfusion (DST)
One DST was given to all female recipients planned to get a kidney from a living donor. 
In two centres the DST consisted of one unit of non-leukocyte-depleted packed cells, 
without buffy-coat and less than 72 hours old and in one centre it was an erythrocyte 
transfusion with buffy-coat.
Protocol 3: matched PTF (mPTF)
One mPTF was given to all female recipients planned to get a kidney from a living donor. 
The mPTF consisted of one unit of non-leukocyte-depleted packed cells, without buffy- 
coat and less than 72 hours old. The aim was 1 HLA-A and 1 HLA-B and 1 HLA-DR 
match (broad) between the transfusion-donor and the recipient. The HLA-antigens of the 
intended organ donor were avoided in the transfusion donor.
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Antibody screening
In all centres pre-transplant screening was performed with the CDC for antibodies against 
HLA classes I and II. Specificity of anti-HLA-antibodies was determined with the CDC. 
In all centres, specificity of anti HLA class I antibodies was determined, and in all except 
one the specificity of anti HLA class II antibodies was determined as well. Dithiothreitol 
(DTT) was added to exclude IgM anti-HLA-antibodies and/or auto-antibodies.
Standard antibody screening was performed 2 and 4 weeks and three months 
after the PTF. Sensitization after a PTF was defined as the presence of IgG anti-HLA- 
antibodies in the CDC. Screening was also done after all potentially sensitizing events 
according to the standards of the European Federation for Immunogenetics (EFI).
Transplantation criteria
A negative B and T-cell crossmatch with all historic and the current serum was mandatory 
for transplantation. Transplantations with kidneys from deceased donors fulfilled the 
matching criteria of at least 1DR match (HLA-DR matching on split level).
P a ra m e te r s  a n d  definitions
Inclusion criteria
■ One rPTF after 1January 1996 or one mPTF or DST after 1 January 1998
■ Age > 18 years
■ Female sex
■ No previous renal transplantation
■ No anti-HLA-antibodies in the CDC before the pre-TX transfusion 
Baseline and follow-up data
All centres identified patients who received a PTF in the defined time-period and fulfilled 
the inclusion criteria. Histocompatibility data were collected at the local HLA laboratories. 
From the Netherlands Organ Transplantation Registry (NOTR), we collected baseline 
and transplantation data. If data were incomplete, we contacted the transplant centre and 
searched for the data in regional databases or the medical file.
Sensitization after a PTF
Historical sensitization was defined as the appearance of anti-HLA-antibodies 
against antigens of the male partner or children of the recipient, in the absence 
of anti-HLA-antibodies against HLA-antigens of the PTF donor.
Primary sensitization was defined as the appearance of anti-HLA-antibodies 
against antigens of the PTF donor in the absence of antibodies against HLA- 
antigens of the partner or children. A judgement about the kind of sensitization 
was only possible when the HLA-type of the PTF donor and the HLA-type of the 
partner or children were known. In recipients of a DST differentiation between 
historical or primary sensitization was impossible when the partner or a child
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was the donor. W hen a recipient had anti-HLA-antibodies after a PTF these 
HLA-antigens were unacceptable for a future kidney-donor combination.
To analyse the influence of HLA-matches and mismatches between the recipient 
and the transfusion donor on sensitization, we counted the number of matches and 
mismatches on split-level. For statistical analysis, we created the parameters HLA- 
ABDR-matching (> 3 HLA-ABDR matches versus 0-2 HLA-ABDR-matches) and 
HLA-DR-matching (> 1 HLA-DR matches versus 0 HLA-DR matches).
Transplantation outcome 
Control group
To evaluate the effect of the transfusion policies on transplantation outcome, we 
collected data from all adult female transplant recipients who did not receive a PTF. 
From these patients, all women without a previous transplantation, with a peak PRA
< 10%, who received a kidney from a deceased donor after 1 January 1996 or a kidney 
from a living donor after 1 January 1998 were included in the control groups. Data were 
collected from the NOTR.
Clinical outcome
Graft loss was defined as loss of kidney function including death with a functioning 
graft. In death-censored graft survival, recipients who died with a functioning graft were 
censored at the time of death. Acute rejection was defined as any rejection treatment 
within the first three months after transplantation. In general, a transplant biopsy is done 
in all transplantation centres when an acute rejection is suspected.
Primary end-point
■ The primary end-point was the appearance of IgG anti-HLA-antibodies 
(CDC) after a PTF (historical and primary anti-HLA-antibodies)
Secondary end-points
■ Difference in graft survival and death-censored graft survival between the trans­
fusion groups and the control group.
■ Difference in the rate and severity of acute rejections between the transfusion 
groups and the control group.
■ Difference in renal function at 3 months and 1 year after transplantation be­
tween the transfusion groups and the control groups.
Statistical analysis
Results are expressed as the mean ± standard deviation for parametric data and as 
mean (range) for non-parametric data. Comparisons between groups were made
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with the independent t-test or one-way ANOVA when appropriate for continuous, 
parametric data. For non-parametric data the Mann-Whitney Latest was used. 
For categorical variables the chi-square test or Fisher’s exact test was used.
Kaplan-Meier curves were constructed for graft survival and death-censored 
graft survival. Differences between survival curves were calculated with the log-rank 
test. Multivariate Cox-proportional hazard analysis was used to correct for baseline 
differences between groups and identify independent predictors for graft failure. First 
univariate analyses were done for all relevant parameters. All parameters with a P < 0 .0 1  
in the univariate analyses were included in the multivariate analysis. A backward stepwise 
method was used to define the final model. Logistic regression was used to identify 
predictors for sensitization after a PTF and for acute rejection. A multivariate analysis 
was done following the previous mentioned method. A P-value < 0.05 was considered 
as significant. Statistical analyses were carried out with SPSS version 12.01.
Results
Anti-HLA-antibodies after a PTF
Eight hundred and six recipients of a PTF fulfilled the inclusion criteria. Six hundred and 
twenty received an rPTF, 100 received a DST and 8 6  an mPTF. From the DST recipients, 
24 patients received erythrocytes with buffy-coat and 76 patients received a non-leukocyte 
reduced packed cell without buffy-coat. Sixty patients received a DST from their spouse 
or offspring. The baseline characteristics of the three groups are given in Table 1 .
In 165 (20.1%) patients, anti-HLA-antibodies (IgG) were detectable after the 
PTF. Anti-HLA-antibodies were detectable in 131 of the rPTF recipients (21.1%), in 27 
of the DST recipients (27%) and in 7 of the mPTF recipients (8.1%). In the multivariate 
logistic regression analysis prior pregnancy and an mPTF were the only factors that 
were significantly related to the formation of anti-HLA-antibodies. Prior pregnancy 
was associated with a more than threefold increased risk of sensitization. The risk of 
sensitization was almost 3-fold lower in recipients of an mPTF compared to recipients of 
a DST or rPTF. The complete logistic regression model is given in Table 2.
Type o f sensitization after a PTF
In 103 of the 165 patients with anti-HLA-antibodies, both HLA-types of the PT F donor 
and the partner and/or children were known. In 21 of these patients (20.3%) antibodies 
against the transfusion donor were detectable (primary sensitization), and in 15 patients 
(14.6%), the antibodies were directed against the partner and/or children (historical 
sensitization). In 67 patients (65.0%), the antibodies were directed against the PT F donor 
and the partner or children.
T ra n sp la n ta tio n  o u tc o m e
Transplantation outcome in recipients o f a kidney from a deceased 
donor (rPTF versus no rPTF) From the 620 patients who received an rPTF, 368 
patients were transplanted with a kidney from a deceased donor. Two hundred and 
four female recipients fulfilled the inclusion criteria for the control group. The baseline 
characteristics of the treatment and control group are given in Table 3. Patients in the 
treatment group were significantly younger, had a longer cold ischemia and anastomosis
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Table 1. Baseline characteristics o f the recipients o f an rPTF, DST and mPTF
rPTF DST mPTF
(n=620) (n=100) (n=86)
Recipient age (years) 49.9 ± 13.1 48.0 ± 11.3 43.8 ± 13.2
Prior pregnancy (%) 425 (69.2) 79 (79.0) 57 (68.7)
Previous non-pre-TX blood transfusions
No (%) 317 (51.1) 53 (53.0) 22 (25.6)
Yes (%) 136 (21.9) 21 (21.0) 13 (15.1)
Unknown (%) 167 (26.9) 26 (26.0) 51 (59.3)
HLA-AB sharing (pre-TX transfusion 0.81 ± 0.81a 1.15 ± 0.93 1.5 ± 0.8
donor-recipient) (mean ± SD)
HLA-DR sharing (pre-TX transfusion 0.38 ± 0.52 b 0.56 ± 0.52 0.86 ± 0.44
donor-recipient) (mean ± SD)
an = 417; b n=416
Table 2. Unadjusted and adjusted predictors for immunization after a pre-TX blood 
transfusion
Unadjusted hazard ratio Adjusted hazard ratio
------------------------B S M n HR (95% CI) P-value HR (95% CI)* P-value
Prior pregnancy (yes/no) 798 3.15 (1.97-5.05) < 0.001 3.04 (1.89-4.89) < 0.001
mPTF (yes/no) 806 0.32 (0.14-0.70) < 0.01 0.34 (0.15-0.76) < 0.01
DST (yes/no) 806 1.52 (0.94-2.46) 0.09 - ns
DST with buffy 2.40 (1.03-5.60) < 0.05 - ns
coat (yes/no)
DST-donor spouse 2.25 (1.29-3.94) < 0.01 1.72 (0.98-3.06) 0.06
or child (yes/no)
Recipient age (yrs) 806 1.01 (1.00-1.03) 0.058 - ns
HLA-ABDR-matching 596 0.57 (0.33-0.98) < 0.05 not included -
(yes/no) #
HLA-DR matching 586 0.65 (0.44-0.97) < 0.05 Not included -
(yes/no) #
rPTF (yes/no) 806 1.20 (0.79-1.82) ns Not included -
Prior non pre-TX blood 562 0.79 (0.50-1.24) ns Not included -
transfusions (yes/no)
* Prior pregnancy, recipient age, mPTF, DST, pre-TX-transfusions with buffy coat and pre-TX-transfusion from spouse or 
child were included in the multivariate analysis (backward selection method)
# The parameters HLA-ABDR-matching (3-6 HLA-matches versus 0-2 matches and HLA-DR-matching (1-2 HLA-DR 
matches versus 0 HLA-DR matches) were not included in the multivariate analysis because too many data were missing 
(inclusion of the parameters HLA-ABDR matching an HLA-DR matching did not significantly change the model)
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time and more often received two instead of three immunosuppressive medicaments as 
initial immunosuppressive therapy. Delayed graft function occurred significantly more 
often in the control group. In one centre, data about prior pregnancies was not collected. 
In the control group, pregnancy status was therefore unknown in 54 patients.
Comparing the rPTF group with the control group, no significant differences 
were observed in graft survival, death censored graft survival (Figure 1), cause of graft 
failure, and serum creatinine levels at 3 months and 1 year after transplantation. Twenty- 
five patients (6 .8 %) in the rPTF group and 8 patients (3.9%) in the control group lost 
their graft by rejection. No patients lost their graft by hyperacute rejection.
Donor age, DGF, and time on dialysis appeared to be independent 
predictors for graft failure. A random PTF was no independent predictor for 
graft failure. The entire Cox regression model for graft survival is given in Table 4.
Significantly more patients in the rPTF group experienced an acute rejection 
within three months after the transplantation [98 patients (27.0%) versus 24 
patients (12.2%), P < 0.001] (Figure 2). An rPTF [HR 1.76 (95% CI 1.03-3.00)], 
immunosuppressive therapy (two medicaments versus 3 or more) [HR 2.05 (95% 
CI 1.31-3.22)] and recipient age (HR 0.98 (95% CI 0.96-0.98) were independently 
related to an acute rejection in the first three months after renal transplantation.
To evaluate differences in the severity of acute rejections, we analyzed how many 
patients were additionally treated with OKT-3 or ATG. In the rPTF group, 38% of the 
patients with an acute rejection received OKT-3 or ATG versus 41% in the control group 
(not significant). No significant differences in renal function at 3 months and 1 year after 
transplantation were observed between patients with an acute rejection in the rPTF and 
in the control group. Comparing patients with (n = 75) and without (n = 293) anti-HLA 
antibodies after the rPTF no significant difference were observed in waiting time and 
graft survival.
Transplantation outcome in recipients o f a kidney from a living donor 
(mPTF/DST versus no PTF) Among the 1 0 0  patients who received a DST, 49 
patients received a transplant from the intended kidney donor. In 25 patients, the 
transplantation with the intended living donor was cancelled because the recipient 
had donor specific anti-HLA-antibodies after the DST. In the other 26 patients, 
the transplantation was cancelled for non-immunological reasons. Among the 8 6  
patients who received an mPTF, 6 6  patients were transplanted with a kidney from 
the intended living donor. In this group, in only one patient the transplantation with 
the intended kidney donor was cancelled because of donor specific anti-HLA- 
antibodies. One hundred and seventy-two patients fulfilled the inclusion criteria for 
the control group. The baseline characteristics of the three groups are given in Table 5.
No significant differences were observed in graft survival, death-censored graft 
survival (Figure 3), and acute rejection rate within 3 months after transplantation, cause 
of graft failure and serum creatinine at 3 months and 1 year after transplantation between 
the three groups. In univariate analyses, none of the factors, including mPTF or DST, 
were significantly related to graft failure. No differences in acute rejection episodes within 
in three months after the transplantation were observed between the three groups (2 1 % 
in the DST group, 23% in the mPTF group and 14% in the control group, P > 0.05). 
In univariate analyses, an mPTF and a DST were not significantly related to acute 
rejectionepisodes within three months after the transplantation. Recipient age was the 
only factor that was significantly related to acute rejection [HR 0.98 (0.95-0.99), p < 
0.05].
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rPTF (n-368) No rPTF (n-204) P value
Table 3. Baseline characteristics o f recipients o f a kidney from a deceased donor:
rPTF versus no rPTF
Recipient age (yrs) 51.4 (18.3-79.1) 54.3 (18.7-76.2) < 0.05
Prior pregnancy (%) 257 (70) 119 (58)* < 0.05
Donor age (yrs) 45 .5  (5.9-74.2) 48.6  (3.6-71.9) ns
Male donor (%) 197 (53.7) 100 (49) ns
Dialysis (yrs) 3.3 (0-13.2) 3.4 (0-12.1) ns
Non-heartbeating donor (%) 109 (29.6) 74 (36.3) ns
Cold ischemia time (hours) 21.0(0-48) 18.0 (0-53.7) < 0.001
Anastom osis time (min) 35 (10-95) 30 (10-103) < 0.001
HLA-m atch (A-B-DR) 3.5 ± 1.1 3.1 ± 1.3 ns
Immunosuppressive medication
Triple therapy (%) # 139 (37.8) 121 (59.3) < 0.05
2 m edicam ents (%) 129 (35.1) 24 (11.8) < 0.001
Induction therapy (%) 79 (21.5) 40  (19.6) ns
Other (%) 21 (5.7) 19 (9.3) ns
Delayed g ra ft function (%) 87 (23.7) 66 (32.4) < 0.01
* Unknown in 54  cases of the no rPTF group, $  Only patients in whom the pregnancy status was known were included 
in the statistical analysis. # Triple therapy = calcineurin inhibitor, mycophenolic acid and corticosteroids
Figure 1. Death-censored graft 
survival in recipients of a kidney 
from a deceased donor: rPTF 
versus no rPTF
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Table 4. Cox-regression model for graft failure in recipients of a kidney from a 
deceased donor (adjusted and unadjusted hazard ratios)
Unadjusted hazard Adjusted
ratios P-value hazard ratios* P-value
Donor age (yrs) 1.02 (1.01-1.04) < 0.001 1.01 (1.001-1.03) < 0.05
DGF (yes/no) (n=537) 1.96 (1.33-2.88) < 0.001 1.72 (1.15-2.57) <.0.01
Time on dialysis (yrs) 1.10 (1.02-1.22) < 0.01 1.13 (1.03-1.24) < 0.05
Recipient age (yrs) 1.02 (1.00-1.03) < 0.05 - ns
HLA-match (0-6) 0.84 (0.73-0.96) < 0.01 - ns
rPTF (yes/no) 0.80 (0.57-1.14) 0.22 - ns
Immunosuppressive medication 
- 2 medicaments (versus 3 or more) 0.72 (0.49-1.06) 0.09 ns
- Induction therapy (yes/no) 1.02 (0.64-1.61) ns Not included
Anastomosis time (min) 1.00 (0.99-1.02) ns Not included
Cold ischemia time (hrs) 1.00 (0.98-1.03) ns Not included
Pregnancy before NTX 1.40 (0.92-2.13) ns Not included
(yes/no) (n=518) 
Male donor (yes/no) 1.11 (0.79-1.55) ns Not included
Heartbeating donor (yes/no) 0.94 (0.65-1.37) ns Not included
*Donor age, DGF, time on dialysis, recipient age, HLA-match, two immunosuppressives vs other and rPTF were included in 
the multivariate analysis (backward selection method) (n=515)
Figure 2. Acute rejection rate within 3 months of transplantation in recipients of an 
rPTF compared to the control group (p < 0.05)
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Table 5. Baseline characteristics o f recipients o f a kidney from a living donor: mPTF
versus DST versus no pre-TX-blood transfusion (control group)
mPTF (n—66) DST (n=49)
Control group 
(n=172)
Recipient age (yrs) 41.5 (18.3-66.6) 49 .4  (18.8-71.8) 44 .7  (18.1-71.7)
Prior pregnancy (%) 45 (68.2) 41 (83.7) 90 (52.3)*
Donor age (yrs) 52.2  ± 9.5 48 .5  ± 13.0 50.2  ± 13.1
Male donor (%) 24 (36.4) 14 (28.6) 78 (45.3)
Pre-em ptive transplantation (%) 25 (37.9) 17 (34.7) 43  (25.0)
Time on dialysis (yrs) 0.55 (0-3.5) 0 .94  (0-3.9) 0 .95 (0-6.3)
Immunosuppressive medication
- Triple therapy (%) # 57 (86.4) 12 (24.5) 114 (66.3)
- Induction therapy (%) 7 (10.0) 24 (49.0) 19 (11.0)
- Tw o m edicam ents (%) 2 (3) 12 (24.5) 14 (8.1)
- other (%) 0 1 (2) 25 (14.5)
Related donor (%) 39 (59.1) 24 (49.0) 122 (70.9)
- Child (%) 0 (0) 3 (6.1) 12 (7.0)
Unrelated donor (%) 27 (40.9) 25 (51) 50 (29.1)
Spouse (%) 23 (34.8) 24 (49.0) 35 (20.3)
* Pregnancy status unknown in 61 patients, # Triple therapy = calcineurin inhibitor, mycophenolic acid and corticosteroids
Figure 3. Death-censored graft survival in recipients of a kidney from a living donor: 
mPTF versus DST versus no PTF.
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Discussion
The hypothesis of our study was that a PTF would improve graft survival by identifying 
historical sensitization in female renal transplant candidates. Although a PT F was helpful 
in identifying historical sensitization, most of the patients also had anti-HLA-antibodies 
against antigens of the PT F donor, suggesting that a PT F was also associated with primary 
sensitization.
Discrimination between primary and historical sensitization was based on the 
concept of antigen mismatches. Duquesnoy et al. showed that antibody-antigen recognition 
is based on epitope recognition and immunogenic epitope mismatches (10). Different 
HLA antigens share the same epitopes, and the appearance of antibodies against a new 
antigen might as well be the recognition of the same epitope on a different antigen. The 
molecular based algorithm by Duquesnoy et al. might be a better way to analyze the kind 
of sensitization and should probably be used in future analysis. The conclusions on the 
incidence of primary and historical sensitization in the current study are therefore of 
limited value.
In our study, recipients of an mPTF had a significantly lower risk of sensitization 
compared to recipients from an rPTF or DST. Compared to recipients of an rPTF or a 
DST, recipients of an mPTF were much less exposed to HLA-mismatches, meaning less 
epitope (triplet) mismatches. It is well known that sensitization increases with increasing 
triplet mismatches (1 1 ). The results of our study are in agreement with the study from 
Lagaaij et al. in which it was clearly shown that sensitization occurs significantly less often 
in recipients of a one HLA-DR matched blood transfusion (12). Recipients of an mPTF 
all had one HLA-DR match with their pre-transplant blood transfusion donor.After a 
DST transplantation with the intended kidney donor was cancelled because of donor 
specific HLA-antibodies in 25% of the patients. In the literature immunization levels 
after a DST differ widely (13-15). This can be explained by the differences in populations 
that are investigated and the number of transfusions given in these studies.
In many countries, cell based flow-cytometry or solid phase based techniques, 
such as ELISA or Luminex are used additionally for the detection of anti-HLA-antibodies. 
It is possible that with these more sensitive techniques some of the anti-HLA-antibodies 
that were detected after a PT F could have been detected before the PTF was given. In the 
Netherlands flow-cytometry, ELISA and Luminex techniques are being used but the 
CDC is considered as the golden standard because no firm evidence is available that anti- 
HLA-antibodies only found by flow-cytometry, ELISA or Luminex (and not in the 
CDC) do have a negative effect on transplantation outcome (16-18).
Although anti-HLA-antibodies were detected after a PTF, our policy did not 
lead to an improvement of the graft survival in any of the groups. To our surprise, even 
more acute rejection episodes appeared in the transfusion groups. The question is why our 
policy did not improve transplantation outcome. Several factors might explain our 
findings.
Firstly, the PTFs did not only identify historical sensitization, but also seem to 
induce primary sensitization. Opelz showed that an increased PRA is related to a lower 
graft survival (19). This is most probably due to antibody reactivity against unrecognized 
mismatched HLA antigens or non HLA antigens. Claas et al. showed that highly 
sensitized patients have comparable graft survival compared to unsensitized patients (2 0 ). 
So the presence of anti HLA-antibodies as such does not have a negative impact on 
transplantation outcome. And indeed in our study no difference is seen in graft survival
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between sensitized and non-sensitized patients, most probably related to a well functioning 
screening and crossmatching programme.
Secondly, historical antibodies are only relevant when the recipient is re-exposed 
to the related HLA-antigens (21). However female recipients who received a kidney from 
their spouse or offspring are always re-exposed and this finding seems somewhat 
contradictory because no significant difference in graft survival in this group between 
recipients of a DST or mPTF compared to non-transfused recipients was demonstrated. 
Assuming that 25% of the recipients of a kidney from their spouse or child in the control 
group (n = 47) would have been transplanted across a positive historical cross match, ~50% 
of those patients should have lost their graft by rejection within one year of transplantation
(5). It would be expected that at least six patients in the control group would have lost 
their graft by rejection in the first year. In fact 94% of the patients in the control group had 
a functioning graft after one year and none of the failures were due to rejection. Our 
results suggest that historical antibodies identified after the administration of a PTF have 
no or little impact on graft survival.
Thirdly, acute rejections and the reaction on treatment have been related to a 
decreased graft survival (22). In contrast, Starzl et al. postulated that some immune 
activation might be necessary to induce tolerance and that histopathological immune 
activation (low grade rejection) could theoretically represent the evolution ofimmunological 
tolerance rather than predicting graft loss (23). Burlingham et al. showed that in 
transplantation with a one HLA haplotype mismatched kidney from a sibling donor, graft 
survival is higher when the donor has non-inherited maternal HLA-antigens compared 
to non-inherited paternal HLA-antigens. Paradoxically the incidence of early acute 
rejections was higher in these patients, suggesting that fetal and neonatal exposure results 
in immunologic priming (24). Our data do not support these findings. As we mentioned 
before, an rPTF was an independent predictor for acute rejection but no differences were 
found in the relative number of severe acute rejections in the rPTF group as compared to 
the control group, whereas in both groups the graft survival was the same. Prior studies 
showed that acute rejection rates were lower after PTFs (9;25).
Fourthly, the retrospective character and differences in baseline characteristics 
were a possible bias and a difference in transplantation outcome was therefore not found. 
In the recipients of a deceased donor, there were some baseline differences between the 
recipients of an rPTF and the control group. In recipients of an rPTF, the cold ischemia 
time and anastomosis time were longer, less immunosuppression was given and as far as 
we know more patients had a prior pregnancy. In spite of these differences, no difference 
in graft survival was found. We cannot fully exclude that an rPTF was just able to 
compensate for the higher risk profile in the rPTF group. The results of the multivariate 
analysis in which an rPTF was not significantly related to graft failure do not support this 
theory. Besides, we do not think that the high risk of sensitization outweigh a possible 
small advantage in graft survival. In the recipients of a living donor, groups were too small 
for a multivariate analysis. Although a difference in transplant outcome could have been 
missed here due to baseline differences or small numbers, we think the high incidence of 
donor specific anti-HLA-antibodies in DST recipients gives enough evidence to abandon 
DSTs.
A fifth reason why we found no difference in graft survival could be that our 
follow-up was too short. Although we cannot fully exclude this, we think that it is unlikely 
that a significant difference will evolve in the long term, because most studies that found 
a difference in graft survival found a difference early after transplantation (12;14;26).
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In the past, several studies evaluated the effect of blood transfusions on graft 
survival and acute rejection rate. Before the introduction of calcineurin inhibitors, a major 
improvement in graft survival was seen in recipients of one or more PTFs (27-29) In 
several animal studies, it is shown that blood transfusions can induce regulatory T-cells 
and improve graft survival (30;31) Since the introduction of calcineurin inhibitors the 
effect of pre-transplant blood transfusions is controversial. Some studies could not find a 
significant advantage from PTFs (32;33), while others did find a significant difference 
(14;26). In the study from Marti et al. for instance, a significant better graft survival was 
found after the administration of two DSTs (14). Major differences between this study 
and ours were that more than sixty percent of the patients were men and that two instead 
of one DST was given. Although there is substantial evidence that an immunological 
effect of blood transfusions exists, our study clearly shows the disadvantages of PTF in 
female renal transplant candidates. Our study further shows that a substantial effect on 
graft survival is very unlikely.
In conclusion, PTFs do not elucidate unambiguously hidden or historic 
sensitization against HLA in female renal transplant recipients prone to be sensitized by 
pregnancy and primary sensitization occur as well. A clear answer to whether a PTF 
results in de novo sensitization is hampered by the antigen approach instead of epitope 
(triplet) approach. An important finding was that a DST in female renal transplant 
recipients led to donor specific sensitization in 25% of the patients. The findings within all 
other recipient groups do not justify the use of a DST moreover a DST should not be 
given anymore to avoid unnecessary sensitization against the intended donor.
The administration of one PTF (rPTF, mPTF, or DST) with the intention to 
detect historical sensitization and the avoidance of the associated antigens did not 
significantly influence transplantation outcome. Our policy even increased the number of 
acute rejections. PTFs are therefore not suggested in female renal transplant recipients 
and on basis of our results PTFs have now been abandoned by all renal transplant centres 
in the Netherlands.
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Abstract
Background. It is unknown whether a plain x-ray of the iliac arteries (pelvic 
X-ray) is a reliable tool to detect calcifications and predict vascular complications.
M ethods. In a prospective study, a pelvic X-ray was performed before transplantation 
in patients without evidence of peripheral vascular disease (n=109) and vascular 
calcifications were scored. Vascular calcifications in the iliac arteries and complications 
were scored by the transplant surgeon during the operation (gold standard).
Results. Vascular calcifications were found on the pelvic X-ray in 33 patients (30.2%). The 
transplant surgeon identified vascular calcifications in 35%. Sensitivity and specificity of the 
pelvic X-ray for vascular calcifications in the iliac arteries was 48% and 82%, respectively. 
Technical problems with the arterial anastomosis due to vascular calcifications were 
observed in five patients. The negative predictive value and positive predictive value of a 
pelvic X-ray for complications with the arterial anastomosis was 99% and 14%, respectively.
Conclusions. A pelvic X-ray is not a reliable tool to detect vascular calcifications. Technical 
problems with the arterial anastomosis due to calcifications are infrequent in the absence 
of vascular calcifications on the pelvic X-ray.
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Introduction
The prevalence of vascular calcifications in patients with end-stage renal disease is very 
high. In a study from Blacher et al., 6 6 % of the hemodialysis patients had vascular 
calcifications in the common carotid artery, abdominal aorta or in the iliofemoral vessels 
(1). Goldsmith et al. found that the prevalence of vascular calcifications increased from 
39% at the start of dialysis to 92% after 16 years of hemodialysis (2). In a study from 
Hernandez et al., in 273 (24.4%) of1117 renal transplant candidates vascular calcifications 
were present on a plain abdominal or pelvic X-ray before renal transplantation (3).
The presence of vascular calcifications in the iliac arteries might complicate or 
preclude the construction of a vascular anastomosis between the renal artery of the donor 
and the iliac artery of the recipient (4;5). In the study from Droupy et al., moderate to 
severe atherosclerosis of the iliac arteries was detected by the vascular surgeon in ~108 
renal transplant recipients (10%). In 38 of these patients, an additional endarterectomy 
was necessary to make the vascular anastomosis (4). W hen vascular disease of the aorta, 
the iliac or femoral arteries is suspected further evaluation by ultrasound and/or CT or 
angiography is recommended (5-8). It is known from clinical observations and previous 
studies that severe vascular calcifications in the iliac arteries can also be present in patients 
with normal physical examination (4;7). A plain pelvic or abdominal X-ray is therefore 
used to detect vascular calcifications in the iliac arteries in many transplant centres in 
the Netherlands. No data exist about the accuracy of pelvic X-ray in detecting vascular 
calcifications in the iliac arteries of renal transplant recipients. It is also unknown what the 
predictive value of vascular calcifications on a pelvic X-ray is for vascular complications 
in renal transplant recipients (e.g. problems with or impossibility to make a vascular 
arterial anastomosis). We therefore analysed in a prospective cohort study the accuracy 
and predictive value of a plain pelvic x-ray for vascular calcifications in the iliac arteries 
(detected by the vascular surgeon) and vascular complications in asymptomatic renal 
transplant recipients without clinical evidence for peripheral vascular disease. Patients 
with symptomatic peripheral vascular disease were excluded from the study because 
further evaluation by echo-Doppler or CT is always done in these patients.
Materials and Methods
Patients
All adult renal transplant recipients transplanted between January 2006 and October
2007 were asked to participate in the study. All patients underwent complete clinical 
examination by both the nephrologist and the transplant surgeon. Exclusion criteria 
for the study were clinical evidence for peripheral vascular disease (claudication, 
absence of femoral artery pulsations, an abdominal aortic aneurysm or major vascular 
surgery in the history). These patients were excluded from the study because extensive 
vascular evaluation is always done in these patients. The study was approved by the 
medical ethical committee of the University Medical Centre Radboud Nijmegen. 
Before inclusion in the study, written informed consent was given by all patients.
In all patients, a supine view of the pelvis in anteroposterior direction 
(pelvic X-ray) was performed within two weeks for the renal transplantation. These 
conventional radiographies were executed on an Axiom Aristos FX system (Siemens 
Medical Solutions, Forcheim, Germany). The pelvic X-rays were judged by three 
independent researchers (HD, AH and JA) by a standardized scoring system.
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Scoring o f vascular calcifications on plain pelvic X-ray
All linear (media) vascular calcifications in the region of the iliac arteries were scored (no 
calcifications -  moderate calcifications -  severe calcifications). Isolated patchy calcifications 
were excluded because they could be confounded with extravascular calcifications like 
pheboliths. The left and right side were scored separately. The researchers further scored 
the quality of the x-ray based on complete image, sharpness, contrast (good-moderate-bad) 
and whether coprostasis was present or not (yes or no). The researchers were blinded for 
the clinical data of the patients. The final score was based on the mean of the three scores. 
Vascular calcifications were only considered when at least two of the three researchers 
described vascular calcifications.
Scoring o f vascular calcifications and complications with the arterial 
anastomosis by the vascular surgeon
During the operation the transplant surgeon scored the calcifications in the iliac arteries 
on the side of the implantation of the kidney (no calcifications -  moderate calcifications -  
severe calcifications). The severity of the calcifications was defined as follows:
(i) severe calcifications: problems with clamping of the artery or making of 
the anastomosis due to vascular calcifications
(ii) moderate calcifications: calcifications visible/palpable in artery but no 
consequences for procedure
To make clear that we only counted vascular calcifications that were visible or palpable for 
the vascular surgeon we will use the term “palpable vascular calcifications” to the describe 
vascular calcifications detected by the vascular surgeon. The transplant surgeon further 
noted all technical problems with the arterial anastomosis and clamping of the arteries, 
vascularisation of the kidney and all other perioperative vascular complications. The results 
from the plain pelvic x-ray were blinded for the transplant surgeon.
Follow-up after transplantation
After the transplantation, the following data were collected to detect complications 
that could be related to the operative procedure: delayed graft function (defined as the 
use of dialysis in the first week after transplantation), haemorrhage within 5 days of 
transplantation (defined as the necessity of the transfusion of two or more packed cells), 
transplantectomy within 5 days of transplantation and arterial or venous thrombosis of 
the renal arteries. We further collected data about renal function (creatinine at 3 months, 
1 year and 2  years after transplantation) and data about graft failure and patient death.
Risk factors for vascular calcifications and complications
We compared patients with and without vascular calcifications and analysed if there were 
differences in baseline characteristics and in the incidence of vascular complications. We 
further divided the patients in a high-risk and low-risk group and analysed the incidence 
of calcifications and complications in both groups. All patients with 1 of the following 
risk factors were defined as high-risk patients: age > 55 years, diabetes or history of 
cardiovascular disease. All other patients were defined as low-risk patients.
Chapter 6
78
Statistical analysis
Differences between groups were analysed with Pearson’s chi-square test or Fisher’s 
exact test for categorical data and the Student’s t-test or the Mann-Whitney Latest for 
continuous data. The inter-observer variability for the detection of vascular calcifications 
on a pelvic X-ray was analysed. We further calculated the sensitivity, specificity, and the 
positive and negative predictive value of vascular calcifications on a pelvic X-ray for the 
presence of palpable vascular calcifications (the calcification score of the surgeon was used 
as the gold standard) and the occurrence of complications with the arterial anastomosis 
due to calcifications. Statistical analysis was performed with SPPS 16.0. A P-value of < 
0.05 (two-sided) was considered significant.
Results
In the study period, 135 patients underwent a renal transplantation. One-hundred and 
nine patients were included in the study. Twenty-six were not included in the study (four 
patients were excluded because of clinical evidence for peripheral vascular disease and 
in 2 2  patients no informed consent was given or data was incomplete). The baseline 
characteristics of the patients are given in Table 1 .
Table 1. Baseline characteristics of all patients in the study (n=109)
All patients (n-109)
Age (years) 49 ± 12
Male (%) 74 (67.9)
BMI (kg/m2) 24.6 ± 3.9
D iabetes mellitus (%) 8  (7.3)
Smoking (%) 42 (48.5)
Myocardial infarction (%) 3 (2.8%)
PCI/CABG (%) 5 (4.6)
Stroke/TIA (%) 10 (9.2)
Hypertension (%) 91 (83.5)
Parathyroidectom y (%) 18 (16.5)
Dialysis (%) 8 6  (78.9)
Time on dialysis (months) 34  (1 206)
D iabetes a s  primary kidney d isea se  (%) 6  (5.5)
Living donor (%) 61 (56)
Previous transplantation (%) 10 (9.2)
PCI, percutaneous co ronary  intervention
Vascular calcifications on pelvic X-ray
The quality of the pelvic X-ray was defined as good in 90 cases (83%) and moderate in 19 
cases (17%). In patients with overweight [BMI > 25 kg/m2 (n=41)] the quality of the X-ray 
was significantly more often defined as moderate compared to patients with normal weight 
[BMI < 25 kg/m2 (n=6 8 )] (moderate quality in 26.8% versus 11.8%, respectively, in patients
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with overweight and normal weight, P < 0.05). Coprostasis was found in 19 cases (17%).
In 33 patients (30.2 %) vascular calcifications in the iliac arteries were found on 
pelvic X-ray in one or both sides. Twenty-six patients (23.8%) had vascular calcifications 
in both iliac artery regions. Nine patients (8.3%) had severe vascular calcifications in the 
region of the left iliac arteries and 8 patients (7.3%) had severe vascular calcifications 
in the region of the right iliac arteries. Moderate calcifications were present on the left 
side in 20 patients (18.3%) and on the right side in 22 patients (20.2%). The baseline 
characteristics of patients with and without vascular calcifications on the pelvic X-ray are 
given in Table 2 .
Inter-observer variability
Agreement between the different researchers was: 90.5% between JA and AH, 78.5% 
between researcher JA and HD and 85% between researcher AH and HD. W hen only the 
presence or absence of vascular calcifications was scored (yes/no), agreement between the 
three researchers was 93.6% between JA and AH, 86.7% between JA and HD and 87.2% 
between AH and HD.
Vascular calcifications (during operation)
The operations in the study were performed by six different vascular surgeons 
[median number of operations 16 (range 6-37)]. They all used the previous 
mentioned scoring system and the surgical technique was the same for all surgeons. 
One surgeon significantly more often scored moderate palpable vascular 
calcifications compared to the other five surgeons. Between the other five surgeons 
no significant differences in calcification score were present. No significant 
differences in outcome were found between the six vascular surgeons.
In 35 patients (32.1%) the transplant surgeon detected palpable vascular 
calcifications in the iliac arteries during the operation. Fifty patients received a kidney 
on the left side (in 43 patients an end-to-side anastomosis with the external iliac artery 
and in 7 patients an end-to-side anastomosis with the common iliac artery was made). 
Sixteen patients had palpable vascular calcifications in the left external iliac artery and/or 
in the left common iliac artery. Fifty-nine patients received a kidney on the right side (in 
51 patients an end-to-side anastomosis with the external iliac artery and in 8 patients an 
end-to-side anastomosis with the common iliac artery was made). Nineteen patients had 
palpable vascular calcifications in the right external iliac artery (severe calcifications in two 
patients) and/or in the right common iliac artery.
Sensitivity and specificity o f a pelvic X-ray for the detection o f vascular 
calcifications in the iliac arteries
Agreement between the pelvic X-ray and the findings of the surgeon was 70% 
[presence of calcifications (yes/no)]. Sensitivity and specificity of a pelvic X-ray for 
the detection of palpable vascular calcifications was 48% and 82%, respectively. The 
positive and negative predictive value of a pelvic X-ray for the detection of palpable 
vascular calcifications in the iliac arteries was 55% and 76%, respectively (Table 3). 
The positive predictive value of severe calcifications on the plain pelvic x-ray was 78%.
In patients with overweight, sensitivity of the pelvic x-ray was only 21% with a 
positive predictive value of 33%.
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Table 2. Baseline characteristics of patients with (n=33) and patients without
(n=76) vascular calcifications in the iliac arteries on the pelvic X-ray.
Vascular Calcifications No vascular
on x-ray (n=33) calcifications on x-ray  (n=76) P-value
A ge (years)
M ale (%)
BMI (kg /m 2)
D iabetes mellitus (%) 
C urren t sm oking (%) 
M yocard ia l in farction (%) 
PCIVCABG  (%)
S troke /T IA  (%)
H ypertension (%) 
P a ra thyro idec tom y (%) 
D ialysis (%)
Time on dialysis (months) 
Living donor (%)
Previous transp lan ta tion  (%)
56  ± 8 
27  (81.8)
23 .9  (17.7-33.1)
4 (12.1)
3 (9.1)
3 (9.1)
5 (15.2)
7 (21.2)
31 (93.9)
8 (24.2)
30  (0.9)
41 (5-214)
12 (36.4)
3 (9.1)
PCI, percutaneous coronary intervention
45  ± 12 
47  (61.8)
23 .8  (18.1-36.5)
5 (5.3)
9 (12.3)
0 (0)
0 (0)
3 (3.9)
60  (78.9)
10 (13.2)
56  (73.7)
30  (1-268)
49  (64.5)
7 (9.2)
< 0.0001
< 0 .05  
ns
ns
ns
< 0 .05
< 0.01 
< 0.01 
0 .0 53  
0.152 
< 0 .05  
0 .056  
0 .05  
ns
Table 3. Negative and positive predictive value and sensitivity and specificity of a 
pelvic X-ray for the detection of palpable vascular calcifications in the iliac arteries
Palpable
vascular
calcifications
(surgeon)
16
Vascular 
calcifications 
(pelvic X-ray)
19
No vascular 
calcifications 
(pelvic X-ray)
35
Sensitivity 48%
No palpable 
vascular 
calcifications 
(surgeon)
13 29
Positive 
Predictive 
value 55%
61 80
Negative 
Predictive 
value 76%
74 109
Specificity 82%
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Vascular complications
In all patients it was possible to make an arterial anastomosis with the external iliac artery or 
the common iliac artery. In nine patients (8.2%) the transplant surgeon had problems with 
the construction of the arterial anastomosis. In five of these patients (4.6%), the difficulties 
were due to significant vascular calcifications in the iliac arteries. Two patients had a rupture 
of the iliac artery after clamping because of severe calcifications. In one of these patients, an 
endarterectomy had to be performed and a new arterial anastomosis had to be made. This 
kidney never functioned and had to be removed due to arterial thrombosis. In two patients, 
it was difficult to clamp the iliac artery because of calcifications, but there were no further 
complications. In one patient, clamping of the iliac artery was difficult because of vascular 
calcifications, and a new arterial anastomosis had to be made because of ongoing bleeding. 
Four of the five patients had a functioning kidney transplant 2 years after the transplantation.
All perioperative and post-operative complications in patients with calcifications 
and without calcifications on the pelvic X-ray are given in Table 4. Significantly more 
technical problems with the arterial anastomosis due to calcifications occurred in patients 
with calcifications on the pelvic X-ray. Differences in the other complications were not 
statistically significant. Two patients with a thrombosis of the renal artery and one with 
thrombosis of the renal vein lost their kidney. In one patient with a thrombosis of the renal 
artery, a new anastomosis was made after thrombectomy and vascularisation of the kidney 
was restored.
Predictive value o f vascular calcifications on the pelvic X-ray for technical 
problems with the arterial anastomosis due to calcifications
Twenty-nine patients had calcifications on the pelvic X-ray on the side of the kidney 
transplantation (in nine patients severe calcifications were found). In four patients with 
vascular calcifications on the pelvic X-ray, the surgeon had problems with the arterial 
anastomosis due to vascular calcifications. In one patient without vascular calcifications 
on the pelvic X-ray, a technical problem with the arterial anastomosis related to vascular 
calcifications was observed. The sensitivity and specificity of vascular calcifications on a 
pelvic X-ray for complications with the arterial anastomosis due to vascular calcifications 
was 80% and 76%, respectively. The negative predictive and positive predictive value 
of vascular calcifications on a pelvic X-ray for vascular complications due to vascular 
calcifications was 98.8% and 13.8%, respectively (Table 5).
Characteristics o f  patients with palpable vascular calcifications in the iliac arteries
The baseline characteristics of patients with and without vascular calcifications detected 
by the vascular surgeon are given in Table 6 . Patients with palpable vascular calcifications 
in the iliac arteries significantly more often had diabetes, a history of TIA or stroke, and 
a prior parathyroidectomy. There was a trend to a higher age and more hypertension in 
patients with palpable vascular calcifications.
Vascular calcifications and complications in high risk patients
Fifty patients (45.8%) were defined as high-risk patients (age > 55 years, diabetes or 
history of cardiovascular disease). The incidence of vascular calcifications on the pelvic 
X-ray was significantly higher in high-risk patients compared to low-risk patients (50% 
in high risk patients compared to 13.6% in low risk patients, P < 0.001). The incidence
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Table 4. Vascular complications after transplantation in patients with and
without calcifications in the iliac arteries on the pelvic X-ray
Vascular Calcifications No vascular
on x-ray (n=33) calcifications on x-ray (n=76) P-value
Problems with arterial 4 (12.1)
anastomosis due to 
calcifications (%)
Problems with clamping o f 4 (12.1) 
iliac artery (%)
Direct vascularisation after 28 (84.8) 
releasing of arterial clamp (%)
Bleeding < 5 days (%) 5 (15.2)
Arterial thrombosis (%) 1 (3.0)
Venous thrombosis (%) 0 (0)
Transplantectomy < 5 days (%) 1 (1.3) 
Delayed graft function (%) 10 (30.3) 
Anastomosis time (artery and 30.5 (11-85) 
vein) (min)
1 (1.3)
2 (2.6)
72 (94.7)
4 (5.3)
2 (2.6)
1 (1.3)
0 (0)
15 (19.7) 
29 (15-113)
< 0.05
0.067
0.126
0.126
ns
ns
ns
ns
0.061
Table 5.
Negative and positive 
predictive value and sensitivity 
and specificity of a pelvic 
X-ray for the prediction of 
complications with the arterial 
anastomosis due to vascular 
calcifications.
Vascular
complications
Vascular 
calcifications 
(pelvic X-ray)
No vascular 
calcifications 
(pelvic X-ray)
No vascular 
complications
25
5 104
Sensitivity 80% Specificity 76%
29
Positive 
Predictive 
value 13.8%
Negative 
Predictive 
value 98.8%
109
Table 6. Baseline characteristics of patients with vascular calcifications in the
iliac arteries detected by the vascular surgeon.
Palpable vascular 
calcifications (surgeon) 
(n—35)
No palpable vascular 
calcifications (surgeon) 
(n=74) P-value
Age (years) 52 ± 11 47 ± 13 0.058
Male (%) 23 (65.7) 51 (69.9) ns
BMI (kg/m2) 23.3 (17.7-31.1) 23.8 (18.1-36.5) ns
Diabetes mellitus (%) 6 (17.1) 2 (2.7) < 0.05
Current smoking (%) 5 (14.7) 7 (9.9) ns
Myocardial infarction (%) 2 (5.7) 1 (1.4) ns
PCI/CABG (%) 2 (5.7) 3 (4.1) ns
Stroke/TIA (%) 7 (20) 3 (4.1) < 0.05
Hypertension (%) 33 (94.3) 57 (78.1) 0.095
Parathyroidectomy (%) 12 (34.3) 6 (8.2) 0.05
Dialysis (%) 28 (80) 57 (78.1) ns
Time on dialysis (months) 36 (1-214) 31 (2-268) ns
Living donor (%) 20 (57.1) 41 (56.2) ns
Previous transplantation (%) 2 (5.7) 8 (11) ns
PCI, percutaneous coronary intervention
Does a plain x-ray of the pelvis predict arterial complications in renal transplantation: a prospective study
79 80
83
of palpable vascular calcifications found by the surgeon was also significantly higher in 
high-risk patients compared to low-risk patients (respectively 42% compared to 24%, P <
0.05). Agreement between the pelvic X-ray and the findings of the surgeon in high-risk 
patients was 6 6 %. All technical problems due to vascular calcifications (n = 5) occurred 
in high-risk patients.
Renal function and graft and patient survival
There was no difference in graft and patient survival between patients with and without 
palpable vascular calcifications in the iliac arteries (1 -year graft and patient survival, 
respectively, for patients with and without vascular calcifications was 94% versus 97% 
and 97% versus 98%). There also was no significant difference in renal function after 
transplantation between patients with and without palpable vascular calcifications (serum 
creatinine at 1 and 2 years after transplantation was respectively 130 ± 38 |imol/l versus 
136 ± 49 |imol/l and 131 ± 41 |imol/l versus 146 ± 56 |imol/l).
Discussion
In a prospective cohort study, we analysed the predictive value of a pelvic X-ray in 
renal transplant candidates for palpable vascular calcifications and complications. In 
this study, the incidence of palpable vascular calcifications in patients without clinical 
evidence for peripheral vascular disease was high. In a subgroup of high-risk patients 
palpable vascular calcifications were detected during operation in more than 40% of the 
patients. This is in agreement with previous studies (3;9;10). In the study from Andres 
et al., 33 out of 114 high- risk patients had severe vascular calcifications in the iliac 
arteries on CT angiography. These 33 patients were excluded from transplantation (1 0 ). 
In contrast with the conclusions from Andres et al., technical problems with the arterial 
anastomosis due to vascular calcifications were only found in a minority of the patients in 
our study. We found no other studies that specifically analysed the incidence of technical 
problems with the arterial anastomosis due to calcifications, but the incidence of major 
vascular complications leading to early graft loss is between 1 and 3% in most studies 
(11;12). Although we performed no computed tomography (CT) in our patients, our 
results challenge the conclusion that diffuse calcifications on CT justify exclusion from 
transplantation. On the other hand one patient in our study without obvious peripheral 
vascular disease lost his kidney due to technical problems with the arterial anastomosis 
due to vascular calcifications. It is therefore important to know whether screening with a 
simple pelvic X-ray could be helpful in preventing these severe complications.
It was demonstrated that a pelvic X-ray is not a reliable tool to detect palpable 
vascular calcifications in the iliac arteries. Both the sensitivity and positive predictive value 
are around 50%. As far as we know, no other studies analysed the predictive value of a 
plain pelvic x-ray for the detection of palpable vascular calcifications in the iliac arteries. 
The low sensitivity and positive predictive value might be related to misclassification due 
to over-projection of other structures and overweight. The quality of the pictures was 
defined lower in patients with overweight, and in accordance with this finding, sensitivity 
and the positive predictive value of a pelvic X-ray was lower in patients with overweight. 
The inter-observer variability also shows that it is sometimes difficult to detect vascular 
calcifications. It can also be related to our gold standard (detection of vascular calcifications 
by the transplant surgeon during the operation). Detection of vascular calcifications by the 
transplant surgeon might not be the most precise method to detect calcifications and some
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calcifications could have been missed. Although high resolution helical CT is probably the 
most sensitive method to detect vascular calcifications, it does not give direct information 
about the relevance of the calcifications for the operative procedure. In our study, we were 
interested in the detection of vascular calcifications that might cause problems during the 
operation (e.g. problems with clamping of the artery or making of the arterial anastomosis). 
Although we have to admit that our gold standard is not perfect, we think it is the best way 
to answer our study question. We therefore think it is justified to use this gold standard. In 
the literature, CT or Doppler ultrasound is recommended to detect vascular calcifications 
(3;7). As far as we know, no studies evaluated the sensitivity and positive predictive 
value of CT or Doppler ultrasound for the detection of vascular calcifications in the iliac 
arteries and the occurrence of complications with the arterial anastomosis.
Not surprisingly, calcifications on a pelvic X-ray were also no reliable predictor 
for complications with the arterial anastomosis due to vascular calcifications. The 
positive predictive value for complications of vascular calcifications on an iliac x-ray 
was only 13.8%. On the other hand, the negative predictive value of a pelvic X-ray 
for technical problems with the arterial anastomosis was very high (99%).
Patients with palpable vascular calcifications were significantly older, had 
significantly more often diabetes, had more often undergone a parathyroidectomy and had 
more cardiovascular risk factors. This is in accordance with the previous study of Hernández 
et al (3). Another important finding was that all technical problems with the arterial 
anastomosis occurred in high-risk patients (age > 55 years, DM  or history with cardiovascular 
disease). We therefore conclude that additional studies are not necessary in low-risk patients, 
but might be useful in high-risk patients. In high-risk patients with vascular calcifications 
on a pelvic X-ray, a tailored low dose non-enhanced CT of the pelvis might be helpful to 
identify zones of the iliac arteries without calcifications. Further research will be necessary 
to study if this approach will decrease the incidence of vascular complications.
In contrast to several other studies, no difference in patient survival between 
patients with and without palpable vascular calcifications was found (3;13). This is 
probably due to the relatively short follow-up of two years and to the exclusion of patients 
with peripheral vascular disease. In the KDIGO CKD-MBD guideline, it is suggested 
that a lateral abdominal radiograph can be used to detect vascular calcifications and 
that patients with CKD stages 3-5D with vascular calcifications should be considered 
to be at highest cardiovascular risk (14). Although we did not find a difference in 
survival between patients with and without palpable vascular calcifications, our study 
did clearly show that a plain pelvic X-ray in asymptomatic renal transplant candidates is 
not a reliable tool to detect palpable vascular calcifications in the iliac arteries.
In conclusion, a pelvic X-ray is not a reliable tool to detect palpable vascular 
calcifications in the iliac arteries of renal transplant candidates and does not reliably 
predict the occurrence of technical problems with the arterial anastomosis due to vascular 
calcifications. Despite the high incidence ofvascular calcifications, the incidence oftechnical 
problems due to calcifications was low and was restricted to high-risk patients. The use 
of a pelvic X-ray to detect palpable vascular calcifications is therefore not recommended 
as screening tool in all renal transplant candidates, but can probably be helpful in high­
risk patients. Based on our results we no longer make a pre-operative pelvic X-ray in 
asymptomatic renal transplant candidates with normal arterial femoral pulses.
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Abstract
Background. Cinacalcet is used for treating secondary hyperparathyroidism in dialysis 
patients,but it is currently unknown whether it can safely be continued immediately after renal 
transplantation.
M ethods. We prospectively studied renal transplant recipients with severe secondary 
hyperparathyroidism who were receiving cinacalcet before transplantation and continued 
treatment afterwards (n = 29) at a dose of 30 mg/day. Cinacalcet dose was titrated to 
serum calcium. Patients were followed for six months. Incidence of hypercalcemia, 
serum calcium and intact PTH  (iPTH) were analyzed. Tacrolimus levels, acute rejection 
rate and renal function were compared with an age and sex matched control group.
Results. In 16 patients hypercalcemia was observed after transplantation. Severe 
hypercalcemia (> 2.87 mmol/L) (n = 4) and hypocalcemia (n = 2) were infrequent. No 
difference in acute rejection rate or renal function between the cinacalcet and the control group 
was found. There also was no clinically relevant influence of cinacalcet on tacrolimus levels.
Conclusions. Our study shows that cinacalcet can safely be continued immediately 
after renal transplantation. Studies are needed to determine if continuation of 
cinacalcet is better than early withdrawal. Also, the optimum dose of cinacalcet 
and the long-term effects of cinacalcet after renal transplantation must be defined.
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Introduction
Persisting hyperparathyroidism is a frequent problem in renal transplant candidates
(1 ). The resulting post-transplant hypercalcemia may contribute to delayed or 
impaired graft function and interstitial calcification (2-4). Several authors have 
advocated parathyroidectomy in those with severe secondary hyperparathyroidism 
before renal transplantation, in order to prevent post-transplant complications (5), but 
recommendations are not uniform (4;6). The introduction of the calcimimetic agent 
cinacalcet has provided an alternative to parathyroidectomy in dialysis patients (7-9). 
Several studies evaluated the effect of cinacalcet in stable renal transplant patients and 
found that it effectively corrected hypercalcemia and decreased iPTH  levels (10-13). 
However, to date no study has evaluated the use of cinacalcet in the immediate post­
transplant period. Continuation of treatment might increase the risk of hypocalcemia 
and interactions of cinacalcet with high doses of immunosuppressive agents cannot be 
excluded (14). On the other hand, discontinuing the drug at the time of transplantation 
might lead to rebound hyperparathyroidism and severe hypercalcaemia (15).
Since 2005 the use of cinacalcet in patients with stage 5 kidney disease increased 
and the positive results made it no longer justifiable to withhold cinacalcet from patients on 
the waiting list for renal transplantation. Based on the available data we decided to continue 
cinacalcet after transplantation. To collect data about the safety and efficacy of cinacalcet 
in the early post-transplant period, we prospectively followed all patients who continued 
cinacalcet after transplantation. We aimed to determine whether cinacalcet could be safely 
used in the immediate postoperative phase and whether it could prevent hypercalcemia 
after transplantation in patients with moderate to severe secondary hyperparathyroidism.
Subjects and Methods
Patients
The decision to initiate cinacalcet in patients on the waiting list for renal transplantation 
was left to the nephrologist in charge. We aimed for an iPTH  < 454 pg/ml at the time 
of transplantation. All adult renal transplant recipients who were treated with cinacalcet 
at the time of transplantation continued treatment with the drug in a dose of 30 mg/day 
after transplantation and were prospectively followed for six months (the use of cinacalcet 
after transplantation is off label).
Cinacalcet treatment after transplantation
Cinacalcet was restarted after transplantation, as soon as the patient resumed eating. 
The initial dosage of 30 mg/day was subsequently titrated according to serum calcium 
levels. Target levels for serum calcium (corrected for albumin) were 2.1-2.4 mmol/L. All 
patients received calcium carbonate 500 mg/day and 1-alpha cholecalciferol 0.25 |ig/ 
day as osteoporosis prophylaxis (unless serum calcium was > 2.6 mmol/L). These drugs 
were withheld if calcium levels exceeded 2.6 mmol/L. If hypercalcemia persisted, the 
daily cinacalcet dose was increased by 30 mg (maximum 180 mg/day). If serum calcium 
decreased below 2.1 mmol/L cinacalcet was decreased by 30 mg. If calcium decreased 
below 2.0 mmol/L cinacalcet was temporarily stopped and restarted at the lowest dose 
when serum calcium was > 2.1 mmol/L again.
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Laboratory measurements
Intact PT H  was measured with the Abbott Architect assay (Abbott Laboratories, Abbott 
Park, IL, USA), a two-step immunoluminometric assay (ILMA). All blood samples were 
drawn in the morning. Calcium levels were corrected for albumin as follows: serum calcium 
+ [(40 -  serum albumin) * 0.02] mmol/L. All calcium levels mentioned in this article are 
corrected for albumin. Whole blood tacrolimus concentrations were measured by the IMx 
analyzer (Abbott Laboratories, Abbott Park, IL, USA). Target levels for tacrolimus were 
15-20 |ig/L for the first two weeks, 10-15 |ig/L during week 3-6, and 5-10 |ig/L thereafter.
Follow-up after transplantation
All patients were monitored according to our regular post-transplantation protocol. 
After hospitalization, they were seen in our outpatient clinic (weekly during the first two 
months, and at least every 2-3 weeks thereafter). Serum calcium and phosphate levels 
were measured 3 times per week during hospitalization and at regular intervals thereafter. 
Intact PTH  was measured at weeks 4, 12 and 24 after transplantation. Hypercalcemia 
and hypocalcemia were defined as serum calcium > 2.6 mmol/L or < 2.1 mmol/L, 
respectively. Severe hypercalcemia was defined as serum calcium > 2.87 mmol/l and/or 
additional treatment for hypercalcemia (hospitalization, parathyroidectomy or treatment 
with bisphosphonates). Drug levels of calcineurin inhibitors were measured twice weekly 
during hospitalization and at every visit thereafter. Symptoms of hyper- and hypocalcemia 
and potential side effects of cinacalcet were recorded. The estimated glomerular filtration 
rate (eGFR) was calculated using the Cockcroft-Gault equation at week 4, 12 and 24. All 
acute rejection episodes were recorded. Delayed graft function (DGF) was defined as the 
necessity for dialysis in the first week after transplantation. Differences in serum calcium 
and cinacalcet dose after transplantation between patients with or without D G F were 
analyzed.
Immunosuppressive treatment after transplantation
Our standard immunosuppressive regimen consisted of a combination of tacrolimus, 
mycophenolic acid and prednisolone. No standard induction treatment was given.
Historical matched control group
To evaluate the effect of cinacalcet on calcineurin inhibitors, renal function and acute 
rejection rate, we compared the cinacalcet patients with a historical control group matched 
for sex and age (n = 29). We also compared the acute rejection rate and renal function at 
3 months with all renal transplant recipients treated at our center since 2001 (n = 644).
Statistical analysis
Parametric and nonparametric data are expressed as mean ± standard deviation and median 
(range), respectively. Comparison between groups was made using the chi-square test for 
categorical data and with the Student’s t-test or Mann-Whitney Latest for continuous 
data. The serial change of serum calcium after transplantation was analyzed with the use of 
a general linear method for repeated measurements. SPSS 16.0 was used for the statistical 
analysis. A P value < 0.05 (two-sided) was considered statistically significant.
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Results
Thirty renal transplant recipients used cinacalcet at the time of transplantation and all 
continued treatment with the drug after transplantation. One patient was transferred to 
another center and lost to follow-up.
Baseline characteristics
Twenty-nine renal transplant recipients who continued treatment with cinacalcet 
immediately after renal transplantation were prospectively followed for six months. The 
baseline characteristics are given in Table 1 . Fifteen patients received a kidney from a 
living donor. Serum calcium at baseline was significantly lower in recipients of a living 
donor compared to recipients of deceased donor [2.35 ± 0.20 versus 2.50 ± 0.16 mmol/l 
(P < 0.05)]. Intact PTH  and cinacalcet dose at the time of transplantation, and the time 
on cinacalcet before transplantation were not significantly different between recipients of 
a living donor or a deceased donor.
Incidence of hypercalcemia
The incidence of severe hypercalcemia (> 2.87 mmol/L) was 4 (13.8%). In two of these 
patients the hypercalcemia was complicated by an increase of serum creatinine. Both 
patients were treated with forced diuresis with sodium chloride and furosemide, with one 
patient also receiving intravenous pamidronate. In both patients serum creatinine returned 
to previous levels with good allograft function at 6  months after transplantation. Both 
patients received a high dose of cinacalcet before transplantation (90 mg/day and 180 mg/ 
day respectively). Sixteen patients (55.2%) had one or more episodes of hypercalcemia 
(> 2.6 mmol/L) in the first 6 months after transplantation. Fifty-three percent of the 
hypercalcemic episodes were observed in the first two weeks after transplantation. 
Hypercalcemia was present in 24.1% of the patients at six months after transplantation.
Serum calcium after transplantation
The time course of mean serum calcium is given in Figure 1. Serum calcium significantly 
increased in week one (P < 0.05) and slowly decreased afterwards. Serum calcium at 
week 4 and month 3 and 6  did not significantly differ compared to baseline. Median 
time between transplantation and restarting cinacalcet was 2 (1- 7) days. Mean 
cinacalcet dose increased from 39 ± 17 mg/day after the first week to 49 ± 43 mg/day 
at 6 months after transplantation. In 21 patients 28 dose adjustments were required, 
mostly because of hypercalcemia. In two patients cinacalcet was temporarily interrupted 
because of hypocalcemia (lowest value 2.05 mmol/l). Both patients were receiving 
a dose of 30 mg before transplantation and had a relatively low PT H  at the time of 
transplantation. In one patient cinacalcet was stopped 3 months after TX because of 
hypoparathyroidism and one patient stopped cinacalcet 2  months after transplantation 
for unclear reasons. No hypercalcemia was observed in these patients. The use of 
osteoporosis prophylaxis increased from 34% in week 1 to 69% in month 6 .
Serum calcium after transplantation was significantly lower in patients receiving 
a low dose of cinacalcet (< 30 mg, n = 16) before transplantation, compared to patients 
on a high dose of cinacalcet before transplantation (> 30 mg, n = 13) (Figure 2). The 
latter group was receiving a significantly higher median cinacalcet dose at 3 months 
and 6 months after transplantation [60 (30-180) mg/day in the high dose group versus
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30 (0-90) mg in the low dose group at 6  months after transplantation (P < 0.05)]. 
In both recipients of a living donor and a deceased donor there was an increase of 
serum calcium in the first week after transplantation, although the rise in recipients 
of a deceased donor was not statistically significant. No significant differences in 
serum calcium, incidence of hypercalcemia or cinacalcet dose after transplantation 
were found between recipients of a living donor or a deceased donor.
Delayed graft function (DGF) was present in 8 patients. No significant differences 
in serum calcium or cinacalcet dose after transplantation were found between patients 
with or without DGF:
Effect of cinacalcet on iPTH and  p h o sp h a te  levels after transplantation
Intact PTH  levels decreased significantly after transplantation [317 (90-1096) pg/ml 
before transplantation compared to 107 (20-636) pg/ml 6  months after transplantation].
Serum phosphate levels decreased significantly in the first week after 
transplantation. Hypophosphatemia developed in 20 patients (69.0%) and nine patients 
(31.0%) received oral phosphate supplementation.
Renal function after renal transplantation
All patients had a functioning renal transplant at the end of follow-up. There was no 
difference in eGFR at 3 months and 6  months after transplantation, between the cinacalcet 
and the matched control group (6 6  ± 24 mL/min versus 6 8  ± 22 mL/min at 3 months 
and 6 6  ± 24 mL/min versus 6 8  ± 25 mL/min at 6 months, respectively in the cinacalcet 
and the control group). No difference in renal function at 3 months after transplantation 
was observed between the cinacalcet group and the cohort of all renal transplant patients.
Immunosuppressive treatment and acute rejection rate
In the cinacalcet group 25 patients received tacrolimus as calcineurin inhibitor (3 patients 
received cyclosporine and one patient was not treated with a calcineurin inhibitor 
because of hemolytic uremic syndrome as primary disease) compared to the matched 
control group. The mean dose of tacrolimus did not differ between the two groups at 
two weeks, four weeks and three months after transplantation. There also was no 
difference in the number of patients who had tacrolimus levels within the target range.
Eight patients (27.5%) were treated with methylprednisolone for suspected acute 
rejection, compared to 7 patients (24.1%) in the control group. Six patients (20.6%) in the 
cinacalcet group and 6  patients (2 0 .6 %) in the control group had biopsy-confirmed acute 
rejection within 3 months after transplantation. The incidence of acute rejection treatment 
within 3 months of transplantation in all renal transplant recipients in our transplant 
clinic since 2 0 0 1  was comparable (2 2 %).
Side effects o f cinacalcet
In several patients mild gastrointestinal complaints were observed, but it was unclear 
whether cinacalcet was the cause. In none of the patients cinacalcet therapy was stopped 
because of side effects.
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Table 1. Baseline characteristics of all patients continuing cinacalcet after
transplantation (n = 29)
Cinacalcet (n -29)
Age (years)
Male (%)
Dialysis (%)
Time on d ia lysis (months)
Previous renal transp lan ta tion  (%) 
P a ra thyro idec tom y be fo re  TX (%)
Living donor (%)
PTH be fore  TX (pg/mL)
PTH be fore  starting C inaca lce t (pg/mL) 
Calcium  (mmol/L) be fo re  TX# 
H yperca lcem ia  (%)
Alkaline p hospha tase  (U/L)
Phosphorus (mmol/L)
C inaca lce t dose  be fore  TX (m g/day)
4 5 .7  ± 3.4 
17 (58.6)
2 7  (93.1)
4 3  (0-183)
9 (31.0)
4  (13.8)
15 (51.7) 
4 6 3  ± 309  
77 3  ± 34 5  
2 .43  ± 0.2 
4  (13.8)
8 8  (46-236) 
1.56 ± 0 .55  
3 0  (15-180)
# co rrec ted  fo r serum  album in; TX =  renal transp lanta tion;
Figure 1. Time course of serum calcium (corrected for serum albumin) after renal 
transplantation in patients treated with cinacalcet (n=29).
Calcium
(mmol/L)
TX
T------ 1------ 1------ 1----------r
Week 1 Week 4 Month S Month 6
Figure 2. Time course of serum calcium (corrected for serum albumin) after renal 
transplantation in patients on a low dose (< 30 mg/day) [n=16] or a high dose (> 30 mg/ 
day) [n=13] of cinacalcet before transplantation (p < 0.05).
Calcium
(mmoI/L)
Cinacalcet 
s SG mg
Cinacalcet 
> SG mg
t------- 1------- 1------- 1------- r
TX Week 1 Week 4 Month S Month 6
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Discussion
Ourstudyis the firstthatanalyzed the use ofcinacalcet in the immediate post-kidney-transplant 
period. Although our study has several limitations, it gives important information about 
the safety and efficacy of cinacalcet in the immediate post-transplant period.
Firstly, we found that continuation of cinacalcet after transplantation did not 
induce severe hypocalcemia: only two patients had to temporarily stop treatment because 
of (mild) hypocalcemia. This is in agreement with previous studies (12-14). It is further 
likely that the regular use of osteoporosis prophylaxis (calcium 500mg and 1-alpha 
cholecalciferol 0.25 |ig) has prevented hypocalcemia in some patients. Secondly, there 
was no evidence of clinically relevant drug interactions with tacrolimus. There were 
no clinical relevant differences in tacrolimus trough levels and no differences in the 
number of patients with a tacrolimus level within the target range. Falck et al. found 
a moderate but significant decrease in the AUC of tacrolimus when cinacalcet was co 
administered, although this effect did not appear to be clinically relevant (16). In two 
other studies there was no evidence of clinically relevant interactions between tacrolimus 
and cinacalcet (13;17). Moreover, we did not observe an increased acute rejection rate 
in patients treated with cinacalcet. Thirdly, none of the patients had to stop cinacalcet 
treatment because of side effects. This is in agreement with several other studies (1 0 ;1 2 ). 
However, Szwarc et al. found that three out of nine patients had to stop cinacalcet 
because of gastrointestinal adverse effects (13). Fourthly, no negative effect of cinacalcet 
on renal function was found. The results of previous studies on the effect of cinacalcet 
on renal function are conflicting. Some studies did not find any effect of cinacalcet on 
renal function (12;17), while Kruse et al. found a small reduction in renal function (11).
Another important question is whether continuing with cinacalcet effectively 
prevents hypercalcemia after renal transplantation. In a study by Gwinner et al. it was 
shown that hypercalcemia after transplantation can lead to renal calcifications and loss of 
transplant function (4). In a large observational study from Evenepoel et al. approximately 
50% of the patients with moderate to severe secondary hyperparathyroidism had 
hypercalcemia at 6 months after transplantation. Although fifty percent of the patients in 
our study had a episode with hypercalcemia, the incidence of hypercalcemia at six months 
after transplantation was much lower compared to the study from Evenepoel et al (2). 
Besides, the incidence of severe hypercalcemia after transplantation in our study was very 
low. The reason that many patients had a hypercalcemic episode in the first two weeks after 
transplantation might reflect our policy of starting with a dose of 30 mg in all patients, 
irrespective of their dose before transplantation. Patients who were receiving > 30 mg of 
cinacalcet before transplantation had a significantly higher mean serum calcium level after 
transplantation and a higher median dose of cinacalcet at 6  months after transplantation. It 
is important to state that osteoporosis prophylaxis was given to all renal transplant recipients 
in our clinic, unless hypercalcemia was present. The incidence of hypercalcemia will probably 
be lower when no regular osteoporosis is given. Torregrosa et al. showed that withdrawl of 
cinacalcet at the time of transplantation led to post-transplant hypercalcemia in patients 
receiving more than 30 mg cinacalcet per day (15). We therefore propose that if cinacalcet is 
continued after transplantation in further studies, the same dose as before transplantation 
should be given. While it is possible that starting with a higher dose might have led to more 
hypocalcemic episodes, the low incidence of hypocalcemic episodes does not support this.
As we said before our study has several limitations. First, as we let the initiation
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of cinacalcet to the physician in charge, the study group was quite inhomogeneous and 
not all patients had severe hyperparathyroidism before the start with cinacalcet. On the 
other hand 83% of the patients had an iPTH  > 454 pg/ml before start with cinacalcet. 
Secondly, we did not have a control group with the same degree of hyperparathyroidism 
and we therefore do not know if continuation of cinacalcet is better than withdrawal 
at the time of transplantation. Thirdly, longer follow-up will be necessary to find 
out whether cinacalcet treatment is able to reverse secondary hyperparathyroidism 
or whether it merely postpones the need for parathyroidectomy. In a small study by 
Kruse et al. it was shown that PT H  and calcium levels remained stable in the majority 
of patients after stopping cinacalcet (18), whereas Leca et al. found that iPTH levels 
recurred to pretreatment levels immediately after cessation of cinacalcet in two of 1 0  
patients (1 0 ). An interesting finding of Meola et al. was that parathyroid gland size can 
decrease after treatment with cinacalcet in some patients (19). We will further follow 
our patients and will attempt to stop cinacalcet within one year of transplantation and 
study the effects of cinacalcet treatment on parathyroid function and bone metabolism.
In conclusion, our data shows that treatment with cinacalcet early after 
transplantation is safe and feasible. Our data suggest that if cinacalcet is continued 
after transplantation a higher starting dose is necessary in patients with a high dose of 
cinacalcet before transplantation. Further studies are needed to determine if continuation 
of cinacalcet is better than early withdrawal. Also, the optimum dose of cinacalcet and the 
long-term effects of cinacalcet after renal transplantation must be defined.
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General discussion and Recommendations
The evaluation of the renal transplant candidate is very complex due to the differences 
in primary renal disease and the extensive comorbidity in many of the patients with 
end-stage renal disease. The comorbidity can be related to the cause of the renal 
disease, the duration of the renal insufficiency, prior renal transplantations and/ 
or other unrelated diseases. Due to all these factors, the number of subjects that 
are relevant in the evaluation procedure is enormous. It was therefore impossible 
to study all the subjects that are relevant for the evaluation process.
As shown in the introduction, several international guidelines for the evaluation 
of the renal transplant candidate exist, but for many recommendations firm evidence is 
lacking. In 2004 we started with the evaluation of the guidelines for the evaluation of renal 
transplant candidates in the Dutch renal transplant centers. Several differences between the 
centers were found and we decided to initiate several studies to evaluate these subjects. In 
this thesis we presented the six studies in which we analyzed these subjects. In this chapter 
we will summarize the results of these studies, discuss the impact of the studies and give 
recommendations for the evaluation of the renal transplant candidate for these subjects. The 
level ofevidence and the strength ofthese recommendations areweighted and graded according 
to previously published scales, which are given in Table 1 and Table 2 (1).
In the study presented in chapter 2 we evaluated the relation between the body 
mass index (BMI) and transplantation outcome. In our study it was shown that both graft 
and patient survival are decreased in patients with overweight and obesity. The risk for graft 
survival was increased for both patients with a low and high BMI, with the highest risk for 
patients with a BMI > 34 kg/m2. Obese patients significantly more often lost their graft 
because of an infectious cause. Next to that early graft loss (< 3 months after transplantation) 
was increased in obese renal transplant recipients. The risk for patient death was significantly 
increased for all patients with a BMI > 28 kg/m2. There was a trend to an increased mortality 
due to cardiovascular and infectious causes in obese renal transplant recipients. Limitation 
of our study was the lack of information about diabetes and cardiovascular risk factors.
As we discussed in our article there was no consensus in the literature about the 
effect of obesity on graft and patient survival. Differences between studies were related to 
methodology, time of follow-up and study size (2-10). Since our study in 2006, several 
other studies analyzed the effects of BMI on transplant outcome (11-15). Gore et al. found 
in a large retrospective study (n=27,377) that graft survival was significantly decreased in 
obese and morbid obese (BMI > 35 kg/m2) renal transplant recipients (11). Morbid obesity 
was significantly associated with delayed graft function (DGF), prolonged hospitalization 
and acute rejection. After correction for cardiovascular risk factors morbid obesity was not 
significantly associated with death with a functioning graft. In the single centre study from 
Chang et al. (n=5684) no difference in 1 and 5 year graft survival was found between patients 
with obesity and normal weight after correction for cardiovascular risk factors, but obesity 
was significantly associated with DGF and acute rejection. In this study morbid obesity 
was not treated as separate category (12). Cacciola et al. showed in a small single centre 
study that 1 and 5 year patient and graft survival was significantly lower in morbid obesity 
compared to obesity (13). In a single centre study Lynch et al. found an increased incidence 
of surgical site infections in obese renal transplant recipients (14). Although obesity had no 
independent effect on graft and patient survival, surgical site infections were significantly 
associated with a decreased allograft survival. Bennet et al. found an increased incidence of 
DGF, and wound infections in morbid obese renal transplant recipients, but no significant
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Table 1. Classes of recommendations
Classes of recommendations Definition
Class 1 Evidence and/or general agreement 
that a given treatment or procedure 
is beneficial, useful, and effective
Class 2 Conflicting evidence and/or a 
divergence o f opinion about the 
usefulness/efficacy o f the given 
treatm ent or procedure
Class 2a Weight o f evidence/opinion is in 
favour o f usefulness/efficacy
Class 2b Usefulness/efficacy is less well 
established by evidence/opinion
Class 3 Evidence or general agreement that 
the given treatm ent or procedure is 
not useful/effective, and in some 
cases may be harmful
Table 2. Levels of evidence
Level of evidence A Data derived from multiple randomized 
clinical trials or meta analyses
Level of evidence B Data derived from single randomized 
clinical trials or large non randomized 
studies
Level of evidence C Consensus or opinion o f the experts 
and/or small studies, retrospective 
studies, registries
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difference in graft and patient survival (15). Lentine et al. found an increased risk for cardiac 
events in obese renal transplant recipients (especially congestive heart failure and atrial 
fibrillation). An increased risk of ischemic cardiac events was not found (16).
Based on our study and the literature, we conclude that morbid obesity 
(BMI > 35 kg/m2) is related to a decreased transplantation outcome. Although 
not all studies found a decreased graft and patient survival, the large studies from 
Gore et al. and Meier-Kriesche et al. clearly showed that graft survival in morbid 
obese renal transplant recipients is significantly decreased (10; 11). Data from 
many other studies about morbid obesity are limited due to small numbers (9; 15). 
The data for obesity (BMI 30-35 kg/m2) are less convincing. Some studies did and other 
studies did not find a negative impact on transplant outcome (2-4;10-12). The differences 
between these studies might be caused by the methodology of the studies, time of follow- 
up, study size and the definition of obesity by the BMI. The use of BMI is limited, because 
it measures both fat and fat-free mass and it has not been validated in patients with chronic 
kidney disease (17). Bigaard et al. showed that abdominal fat is a strong predictor ofmortality 
and that waist-circumference correlates highly with abdominal fat (18). In the study from 
Elsayed et al. waist-to-hip ratio, and not BMI, was a significant predictor of cardiac events in 
patients with chronic kidney disease (19). So far, most studies in renal transplant recipients 
defined obesity in terms of BMI. The disadvantage of the use of BMI is that some patients 
with obesity have minimal abdominal fat were others with normal BMI have abdominal 
obesity. Several complications (e.g. cardiovascular risk, wound infections, DGF) are related 
to abdominal fat and the use of BMI is not the best way to identify these patients. For 
future studies it is recommended to include the waist-to-hip ratio next to BMI.
It is further important to refer to the study from Glanton et al. in which it was 
shown that survival of obese patients with ESRD is better after transplantation compared 
to staying on dialysis (2 0 ). Although, the study had several methodological limitations and 
no other study confirmed these findings so far, the results of these study have important 
implications for obese renal transplant recipients.
Cause of decreased graft survival in obese renal transplant 
recipients
Although not all studies found a decreased graft survival in obese patients there is 
circumstantial evidence that obesity is related to renal dysfunction. Kambham described 
an increased incidence of obesity-related glomerulopathy (2 1 ). The pathophysiology of 
obesity-induced glomerulopathy is incompletely understood (2 1 ). The cause of decreased 
allograft survival in (morbid) obese renal transplant recipients is likely to be multifactorial. 
Bosma et al. found an increased GFR and filtration fraction in obese renal transplant 
recipients, suggesting that an increased BMI induces glomerular hyperfiltration (22). In 
healthy subjects obesity and overweight is also associated to glomerular hyperfiltration. 
Glomerular hyperfiltration leads to glomerular injury, eventually leading to proteinuria, 
glomerulosclerosis and chronic allograft nephropathy (11). Obesity is further related 
to several cardiovascular risk factors and cardiovascular disease (e.g. hypertension and 
diabetes). Hypertension and diabetes are strongly related to kidney disease and loss of 
renal function.
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Weight loss before renal transplantation
No studies evaluated the effect of weight loss before transplantation on transplantation 
outcome. Consequently, there is no evidence that weight loss before transplantation 
is beneficial. In dialysis patients low body weight has been related to an increased 
all cause mortality and moderate obesity was related to lower all cause mortality
(23). Increased mortality in patients with BMI < 20 kg/m2 is probably related to 
inflammation and malnutrition. So, there is no evidence that weight loss before 
transplantation is beneficial and some studies suggest that it might be harmful.
On the other hand there is convincing data that obesity is related to an 
increased cardiovascular risk, post-operative complications and probably a decrease 
in graft and patient survival. Besides, most patients gain weight after transplantation 
and weight gain after transplantation in obese patients is higher than in non-obese 
patients. It seems logical to propose weight loss in obese renal transplant candidates, but 
evidence for this recommendation is lacking. Studies that investigate the influence of 
weight loss on patient survival and transplantation outcome are urgently needed.
Based on clinical experience it is well known that it is very difficult for patients 
with ESRD to lose weight. Exercise tolerance is limited by fatigue and (cardiovascular) 
comorbidity. It is therefore very important to collect data about other (surgical and 
medical) options to achieve weight loss in patients with chronic kidney disease.
In the general population bariatric surgery has been shown to be a successful and 
safe method to lose weight and to decrease cardiovascular risk (24). Preliminary data about 
bariatric surgery in ESRD patients are promising, although numbers are still small and 
mortality is not insignificant (25;26). Further research is necessary to find out if bariatric 
surgery is beneficial for renal transplant candidates with morbid obesity.
Conclusions
There is fair evidence that transplantation outcome is decreased in morbid obese (BMI > 
35 kg/m2) renal transplant recipients.
Data about graft and patient survival in moderately obese (BMI 30-35 kg/m2) renal 
transplant recipients are conflicting.
There is fair evidence that obesity and morbid obesity are related to an increased 
incidence of post-operative complications.
Survival of obese patients is better after transplantation compared to staying on dialysis.
There is no evidence that weight reduction before renal transplantation improves 
transplantation outcome in obese renal transplant recipients.
Data about the effect and safety of bariatric surgery in renal transplant candidates is 
necessary.
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Recommendations
Renal transplantation in patients with morbid obesity (BMI> 35 kg/m2) should be 
discouraged (Class II, Level C).
Obesity (30-35 kg/m2) should not be used as absolute contra-indication for renal 
transplantation (Class I, level C).
Obese patients should be informed about the increased risks and should be encouraged 
to lose weight before renal transplantation (Class IIa, level C).
The vascular surgeon should judge whether or not a renal transplantation is technically 
possible in obese renal transplant candidates (Class IIa, Level C).
In chapter 3 we presented a retrospective cohort study in which we analyzed the incidence 
of post-transplant cardiovascular events and risk factors for post-transplant cardiovascular 
events. In our study, the cumulative incidence of post-transplant cardiovascular events was 
40% at 10 years after transplantation, with the highest incidence in the first three months 
after transplantation. The most important predictors for a post-transplant cardiovascular 
event were diabetic nephropathy, cardiovascular disease before transplantation, recipient age 
and time on dialysis. We were not successful in finding a reliable algorithm to predict which 
patients were at the highest risk for an early post-transplant cardiovascular event.
Several other studies analyzed risk factors and predictors for post-transplant 
cardiovascular events (27;28). Most studies found predominantly the same risk factors as 
we found. The fact that we could not find a reliable algorithm to predict the occurrence of 
post-transplant cardiovascular events might be related to the sample size of the study, non- 
traditional risk factors (e.g. cytomegalovirus status and inflammation) and the influence of 
transplantation and donor related riskfactors.Non-traditional riskfactors,and transplantation 
and donor related risk factors were not included in our study. In risk-prediction equations 
defined and validated for the general population, the cardiovascular risk for renal transplant 
recipients is underestimated, probably due to these non-traditional risk factors (29;30). 
Several other studies showed that transplantation related risk factors and disease are 
associated with the incidence of post-transplant cardiovascular disease (27;28).
Recently, the results of the PORT study were published (31). This is a large, multi­
center cohort study that evaluated pre- and post-transplant risk factors for post-transplant 
coronary heart disease in 23,575 patients from 14 transplant centers worldwide. The 
cumulative incidence of coronary heart disease was 3.1%, 5.2%, and 7.6%, respectively at 1,
2, and 5 years after transplantation. The authors succeeded to define reliable risk-prediction 
equations for the occurrence of post-transplant coronary heart disease. Independent 
pre-transplant risk factors were recipient age, BMI, primary cause of ESRD, history 
of diabetes, history of hypertension, history of cardiovascular disease, history of cancer, 
duration of ESRD, hypercholesterolemia, and history of smoking. Several donor related 
risk factors also contributed to post-transplant coronary artery disease risk (e.g. donor 
sex and race, donor type, BMI, history of diabetes, history of hypertension, transplant 
year, number of HLA-mismatches, and cold ischemia time). Only recipient age and sex, 
recipient history of diabetes and history of cancer, the number of cardiovascular comorbid 
conditions, donor type, donor BMI and duration of ESRD contributed to the pre­
transplant equation to predict coronary heart disease in the first year after transplantation.
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Except for the history of cancer, the recipient related risk factors included in the risk- 
equation in the PORT-study were also found in our cohort study. Traditional risk 
factors like hypertension, cholesterol, smoking, and use of anti-hypertensive medication 
were independent predictors for post-transplant cardiac events, but did not significantly 
improve the prediction model. It is important to mention that not all participating centers 
collected these risk factors. Non-traditional risk factors like cytomegalovirus status 
were not significantly related to post-transplant coronary artery disease. Importantly, 
several transplantation related risk factors like acute rejection, post-transplant 
lymphoproliferative disorders, new-onset diabetes mellitus and delayed graft function 
contributed to the long-term risk of post-transplant coronary artery disease.
In conclusion, many pre- and post-transplant, recipient and donor related risk 
factors play a role in the high incidence of post-transplant cardiac events. Recipient age and 
sex, history of diabetes, history of cardiovascular disease and duration of dialysis treatment 
are the most important pre-transplant recipient related risk factors for post-transplant 
cardiovascular disease. In contrast to our study, the authors of the PORT study showed that 
the post-transplant risk of cardiac events can be calculated at the time of transplantation 
based on these and some donor related risk factors. These equations can be used to inform 
patients about their risk, and target the treatment of modifiable risk factors and the evaluation 
ofrenal transplant candidates. It is important to mention that validation studies are necessary 
to confirm the usefulness of the risk-equations found in the PORT-study.
The results show that a multi-factorial approach, aimed at the treatment and/or 
influence of recipient, donor and transplantation related risk factors, will be necessary to 
decrease the incidence of post-transplant cardiovascular events. Randomized, controlled 
trials aimed at the treatment of these risk factors are needed to define whether interventions 
will decrease the high incidence ofpost-transplant cardiovascular disease. Despite the lack of 
these studies, we think it is justified to recommend early treatment of pre- and post-transplant 
cardiovascular risk factors in renal transplant candidates (Class IIa, Level C).
In chapter 4 we showed the results of the study in which we analyzed the effect of our 
cardiac evaluation program on the incidence of perioperative cardiac events. As we 
mentioned in the introduction, there is much discussion in the literature about the benefit 
of pre-transplant cardiac evaluation and intervention in asymptomatic renal transplant 
candidates. We therefore evaluated the effect of our cardiac evaluation program.
Our study showed that the incidence of significant cardiac ischemia in 
asymptomatic, high risk renal transplant candidates is low and that non-invasive cardiac 
stress testing was followed by coronary angiography and intervention in a very low 
percentage of the patients. Furthermore, no significant decrease in perioperative cardiac 
events was found. It is important to mention that there was a significant decrease in the 
incidence of major perioperative cardiac events (cardiac death, STEMI, and non-STEMI 
with peak troponine > 3 |ig/l) after the introduction of the cardiac evaluation program. 
Due to the low incidence of revascularization procedures, this decrease in major cardiac 
events cannot be attributed to the effect of pre-operative cardiac interventions. The 
decrease in major cardiac events might be related to an improvement in medical and 
perioperative treatment in recent years, differences in baseline characteristics between the 
study and historical control group and the exclusion of high risk patients with significant 
cardiac ischemia. In conclusion, our study suggests that non-invasive cardiac stress testing 
in all asymptomatic, high risk renal transplant candidates is unnecessary. Because of the 
small sample size, the relatively low risk profile of our study group and the significant
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difference in major perioperative cardiac events between the screening and control group 
a final conclusion about the necessity of non-invasive cardiac stress testing in all high risk 
renal transplant candidates cannot be drawn solely on our study.
Recently several other studies evaluated the effect of cardiac evaluation and 
intervention in renal transplant recipients (32-34). Unfortunately, no randomized clinical 
trials of sufficient size have been performed so far. Patel et al. evaluated the effect of 
cardiac evaluation and intervention in an observational prospective, single center study 
(n=300) (33). They found that non-invasive testing added little to clinical assessment in 
predicting who needs intervention and that coronary intervention after cardiac testing was 
uncommon (5.6% of the patients underwent PCI). Besides, they found no difference in 
survival between patients who underwent intervention compared to patients who 
underwent angiography without intervention or no angiography. Because the number of 
patients who underwent intervention in this study was small, a final conclusion about the 
effect of intervention cannot be drawn. The authors did show that exercise tolerance 
testing gives important prognostic information. Survival was significantly better in patients 
who could exercise longer than 6 minutes compared to patients who could not exercise for 
6  minutes. Unfortunately, no data about the incidence of perioperatieve cardiac events was 
given. In a study from de Lima et al. 1025 renal transplant candidates underwent non­
invasive cardiac stress testing (32). In 519 patients coronary angiography was done (230 
had significant coronary artery disease) and finally only 30 patients underwent coronary 
intervention. Although significant coronary artery disease was related to a threefold 
increased risk for a cardiac event, only few patients with significant coronary artery disease 
had an indication for intervention following the current American College of Cardiology/ 
American Heart Association (ACC/AHA) guidelines. Patients with significant coronary 
artery disease and no indication for intervention received maximal medical treatment with 
aspirin, -blockers, rennin-angiotensin II system antagonists and statins. Survival in these 
patients was comparable to survival of end-stage renal disease patients in previous studies 
who underwent intervention. These results suggest that revascularization in renal transplant 
candidates can probably be safely restricted to a small group of patients with severe 
coronary artery disease. Importantly, it is unclear how many patients received a renal 
transplant, so no data about the perioperative risk can be obtained from this study. In 
another study from De Lima et al. the authors found no survival difference between 
patients who received medical treatment compared to patients who underwent 
revascularization (34). Importantly, study groups were very small (23 patients versus 11 
patients, respectively) and a final conclusion cannot not be drawn based on this study. 
These studies show that only few asymptomatic renal transplant candidates have an 
indication for (preoperative) revascularization. Furthermore, these studies suggest that 
preoperative revascularization in asymptomatic renal transplant candidates is not superior 
to medical treatment alone. Unfortunately, most studies have methodological limitations 
and study groups are small. No randomized clinical trials in renal transplant recipients of 
sufficient size compared medical treatment with revascularization.
Data from other patient groups are therefore needed to draw a final conclusion. In 
patients undergoing major vascular surgery, two randomized clinical trials compared 
revascularization with medical treatment with medical treatment alone in high risk 
patients (35;36). No difference in outcome was found in both studies. Furthermore, 
Boden et al. found no benefit of PCI with medical treatment compared to medical 
treatment alone in patients with stable coronary artery disease in the general population
(37).
In summary, the incidence of significant cardiac ischemia in asymptomatic, high
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risk renal transplant candidates is low and only few patients have an indication for coronary 
revascularization. Available data in renal transplant candidates suggests that 
revascularization in asymptomatic patients is not better than optimal medical treatment, 
but data is scarce. Importantly, data in patients undergoing non-cardiac surgery supports 
these findings. The question is whether or not we should change our cardiac evaluation 
program based on these data.
The purpose of cardiac evaluation in renal transplant recipients is to identify 
patients with a high risk for a perioperative cardiac event. The results of the evaluation can 
be used to inform patients, help decision making about waitlisting and target pre- and 
perioperative treatment. Another reason for cardiac evaluation and preoperative 
intervention could be to improve long-term survival (and graft survival). There is no 
evidence that preoperative revascularization in asymptomatic renal transplant candidates 
improves long-term survival and there is also no evidence that the risk of revascularization 
before transplantation is lower than after transplantation. Herzog et al. even showed that 
survival after coronary revascularization is better in renal transplant recipients compared 
to patients on dialysis (38). Admittedly, these data may be biased by selection, because 
only the best ESRD-patients receive a renal transplant.
In 2009, the European Society of Cardiology published a guideline for the pre­
operative cardiac risk assessment and perioperative cardiac management in non-cardiac 
surgery (1 ). The question is whether the recommendations in these guidelines can be used 
to guide the evaluation and treatment of renal transplant recipients. In summary, these 
guidelines recommend non-invasive cardiac testing in patients with low functional 
capacity (inability to climb two flights of stairs), 3 or more cardiac risk factors (angina, 
previous myocardial infarction, heart failure, stroke/TIA, renal dysfunction or diabetes 
mellitus requiring insulin therapy) undergoing high risk surgery (perioperative risk for 
cardiac death or myocardial infarction > 5% ). For all other asymptomatic patients non­
invasive cardiac stress testing is not recommended. Medical treatment with beta-blockers, 
statins and continuation of aspirin is recommended for all high risk patients undergoing 
intermediate or high risk surgery. In renal transplantation perioperative risk is between 
1-5% and renal transplantation is considered to be an intermediate risk operation. Based 
on these guidelines, additional non-invasive cardiac stress testing in asymptomatic, high 
risk renal transplant candidates is not recommended. Follow-up of these guidelines will 
introduce a dramatic change in the preoperative assessment of renal transplant candidates. 
The question is whether it is safe to make a major change like this, without evidence from 
randomized clinical trials in renal transplant candidates. Unfortunately, as Patel et al. 
showed in their article, many patients will be needed for a randomized clinical trial (33). 
It is therefore very unlikely that such a trial in renal transplant candidates will be performed 
in the near future. New recommendations for the evaluation of renal transplant candidates 
therefore have to be based on current data. Based on current data there is no hard evidence 
that preoperative management should be different in renal transplant candidates. On the 
other hand there are some differences between renal transplant candidates and patients 
undergoing major non-cardiac surgery that have to be taken in account. First, exercise 
tolerance in end-stage renal disease patients is often limited due to comorbidities. Secondly, 
patients with diabetic nephropathy as cause of primary disease and coronary artery disease 
are often asymptomatic. Thirdly, the loss of a scarce donor organ early after transplantation 
is a dramatic event and every possible effort to prevent this should be undertaken. Fourthly, 
there are no randomized controlled trials in renal transplant recipients that evaluated the 
efficacy and safety of preoperative medical treatment. So, it is not sure whether medical 
treatment in ESRD patients will be as effective as in the general population. Fifthly, for
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the definition of high risk some ESRD specific risk factors have to be taken into account. 
For these reasons, we think that it is reasonable to consider non-invasive cardiac stress 
tests in high risk renal transplant candidates with a decreased exercise tolerance and in 
patients with diabetic nephropathy as cause of ESRD. The results of these tests can be 
used to inform the patient (and donor) about the perioperative risk and prognosis, and can 
be helpful in optimizing perioperative treatment and guidance. W hether or not coronary 
angiography and preoperative revascularization has to be performed in asymptomatic 
patients with significant cardiac ischemia is unclear. A decision about revascularization 
should be taken by the cardiologist in collaboration with the transplant team and should 
be individualized.
Recommendations for cardiac evaluation in asymptomatic 
renal transplant candidates 
1. Define clinical risk:
All patients with one of the following risk factors are considered as high risk patients:
- Prior myocardial infarction
- Prior Stroke/TIA
- Diabetes mellitus
- Peripheral vascular disease
- Time on dialysis > 4 years
- Age >50 years
All patients without one of the abovementioned risk factors are considered as low risk 
patients
2. Check exercise tolerance in all high risk patients:
Definition:
- Poor exercise tolerance: patient is not able to climb two flights of stairs 
without complaints
- Good exercise tolerance: patient is able to climb two flights of stairs 
without complaints*
* It is recommended to walk two flights of stairs together with the patient to check the 
exercise tolerance.
It is recommended to check the exercise tolerance of all high risk renal transplant 
candidates annually.
3. Non-invasive cardiac stress testing:
Low risk patients -  no non-invasive cardiac stress testing (Class III, level B)
High risk patients:
- Good exercise tolerance -  no non-invasive cardiac stress testing 
(Class II, level C)
- Poor exercise tolerance -  perform non-invasive cardiac stress testing 
(Class IIb, level C)
- Diabetic nephropathy as cause of primary kidney disease -  perform non­
invasive cardiac stress testing (Class IIa, level C)
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4. Medical treatment:
Low risk patients -  no additional medical treatment (Class III, level C)
High risk patients:
1. Low dose, titrated beta-blocker treatment (aim: heart rate between 60-70/ 
min) (Class IIa, level C)
2. Continue aspirin in patients with cardiovascular disease or multiple risk 
factors (Class IIa, level C)
3. Consider treatment with statins (optimally start between 30 days and 1 
week before operation (Class IIb, level C)
4. Consider treatment with ACE-inhibitors in patients with known left 
ventricular systolic dysfunction (Class IIb, level C)
5. Pre-operative cardiac revascularization:
There is no evidence that prophylactic pre-operative revascularization improves outcome 
in asymptomatic renal transplant recipients with coronary artery disease (class II, level C)
The decision whether or not to perform preoperative revascularization in asymptomatic 
renal transplant candidates should be taken by cardiologist in collaboration with the 
transplant team and should be individualized.
Chapter 5 describes the results of the multi-center, retrospective study in which we 
evaluated the effect of one pre-transplant blood transfusion (PTF) on sensitization 
and graft survival in unsensitized female renal transplant candidates. Seven Dutch 
renal transplant centers participated in the study. Hypothesis of the study was that pre­
transplant blood transfusions can elucidate historical sensitization and that the avoidance 
of the associated antigens in the kidney donor can improve transplantation outcome. 
Data from all female, non-immunized renal transplant recipients who received a PTF 
(random PTF (rPTF), matched PTF (mPTF) or donor specific blood transfusion 
(DST)) between 1996 and 2006 were collected and analyzed. Anti-HLA-antibodies were 
detected in 20.1% of the patients after the PTF. Sensitization was highest after a DST 
(27%), and lowest after an mPTF (8.1%). No beneficial effect of a PTF on transplantation 
outcome was found. After an rPTF even more acute rejections were found.
Although our retrospective study has several limitations, our study clearly showed 
that there is a high risk of sensitization after a PT F (especially after DST) and that 
there is no positive effect on graft survival in female renal transplant recipients. Based 
on these results, standard pre-transplant blood transfusions in female renal transplant 
candidates have now been abandoned in all Dutch renal transplant centers.
It was suspected that detection of historical immunization by a pre-transplant 
blood transfusion and avoidance of the associated HLA-antigens in the future kidney donor 
would improve transplantation outcome in female renal transplant recipients. The rationale 
behind this theory was that female renal transplant candidates can be sensitized by prior 
pregnancies and miscarriages, but that the antibodies may have disappeared after several
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years and are not detected before transplantation. In previous studies it has been shown that 
a positive historical crossmatch is associated with an increased risk of acute rejection and 
a decreased allograft survival (39-41). Several studies and case-reports found a decreased 
allograft survival or increased acute rejection rate in non-immunized women who received 
a kidney from their offspring or spouse and suggested that undetected sensitization played 
a role (42-44). Furthermore, clinical observations have shown that historical anti-HLA- 
antibodies can become apparent after blood transfusions. Based on these findings it was 
surprising that no beneficial effect of the Dutch pre-transplant blood transfusion policy 
on graft survival was found. In the discussion of the article we gave several possible reasons 
for the fact that we could not find an effect of pre-transplant blood transfusions on graft 
survival. In summary, this could be related to the induction of primary sensitization by pre­
transplant blood transfusions or the increased incidence of acute rejections after a PTF. 
There further are data that suggest that graft survival is not decreased in previously sensitized 
female renal transplant recipients with a negative current and historical crossmatch. In 
several studies no difference in graft survival between female and male renal transplant 
recipients has been found. (45-47). Furthermore, in a large registry study from Fuggle et 
al. there was no difference in death-censored graft survival between female recipients who 
received a kidney from their spouses/partners compared to female recipients who received 
a kidney from non-spousal donors after adjustment for several risk factors (48). In this 
study there also was no difference in graft survival between female recipients who received 
a kidney from their offspring compared to female recipients who received a kidney from 
other related or unrelated living donor transplants. Based on these results it is not to be 
expected that detection of anti-HLA-antibodies by pre-transplant blood transfusions will 
improve renal transplant outcome in female renal transplant recipients. Finally, we cannot 
exclude that a positive effect of pre-transplant blood transfusions was not found due to 
the retrospective character of the study, baseline differences between the transfusion and 
control groups, or the relative small sample size and short follow-up.
Despite the limitations of the study, it is clear that any possible advantage does 
not outweigh the clear disadvantages of pre-transplant blood transfusions in female renal 
transplant recipients. The strongest argument against the use of pre-transplant blood 
transfusions in female renal transplant candidates is the high incidence of sensitization 
(especially after donor specific blood transfusions). All together, there is no place for pre­
transplant blood transfusions in female renal transplant candidates.
Recommendation
Pre-transplant blood transfusions should not be used in female renal transplant 
candidates (level C, Class III)
In chapter 6 we presented the results of a prospective cohort study, in which we analyzed 
the predictive value of a plain X-ray of the pelvis (pelvic X-ray) for vascular calcifications 
in the iliac arteries and the occurrence of complications with the arterial anastomosis. It 
is well known that the incidence of vascular calcifications in renal transplant candidates is 
very high and that the presence of vascular calcifications in the iliac arteries can complicate 
renal transplantation. In many renal transplant centers a pelvic X-ray is performed in the 
pretransplant evaluation process to detect these calcifications, but the predictive value of 
a pelvic X-ray has not been analyzed before. We therefore analyzed the predictive value 
of a pelvic X-ray in a prospective cohort study in 109 renal transplant recipients. Patients 
with evidence of peripheral vascular disease were excluded, because vascular evaluation is
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always done in these patients. Sensitivity and specificity of a pelvic X-ray for the detection 
of vascular calcifications in the iliac arteries was 48% and 82%, respectively. The incidence 
of vascular calcifications was significantly higher in high-risk patients (age > 50 years, 
diabetes mellitus or a history of cardiovascular disease). In all patients it was possible to 
make an arterial anastomosis, but construction of the arterial anastomosis was complicated 
due to vascular calcifications in 5 patients (one kidney was lost due arterial thrombosis after 
endarterectomy). All complications with the arterial anastomosis occurred in high-risk 
patients. The negative and positive predictive value of a pelvic X-ray for complications with 
the arterial anastomosis due to calcifications was 98.8% and 13.8%, respectively.
As we described in our article, we found no other studies that evaluated 
the predictive value of a pelvic X-ray in renal transplant recipients. Comparison with 
the literature is therefore not possible. In the literature it is suggested that high­
resolution helical CT is the best method to detect vascular calcifications. Unfortunately, 
we found no studies that evaluated the predictive value of CT for the detection 
of vascular calcifications in the iliac arteries of renal transplant candidates.
Several factors can explain why there was no strong correlation between the pelvic 
X-ray and calcifications in the iliac arteries. First, detection of vascular calcifications on 
a pelvic X-ray can be difficult due to over-projection of other structures or the quality 
of the X-ray. The quality of the pictures was defined lower in patients with overweight 
and sensitivity was also lower in these patients. The relatively wide inter-observer 
variability also showed that it sometimes difficult to detect vascular calcifications on a 
pelvic X-ray. Secondly, it can be related to our golden standard (detection of vascular 
calcifications by the vascular surgeon during the operation). It is possible that some 
vascular calcifications were missed by the surgeon. We chose this golden standard 
because it gives direct information about the clinical relevance of the calcifications. 
Although a helical CT might be a more sensitive way to detect vascular calcifications, it 
does not give information about the clinical relevance of these calcifications.
In our study the incidence of vascular complications was low (approximately 
5%) and all complications occurred in high-risk patients. This is in agreement with 
the literature (49). Ploussard et al. found no vascular complications in 8 6  patients with 
normal preoperative vascular examination (49). These results show that additional 
investigations can safely be omitted in low risk patients with normal arterial pulses 
and probably also in high-risk patients. Further studies to identify whether or not 
additional investigations are beneficial in high-risk patients are recommended.
Although our study has some limitations and the results have not been confirmed 
in another study, we think it is justified to conclude that a pelvic X-ray is not a reliable 
tool to detect vascular calcifications and does not reliably predict the occurrence of 
technical problems with the arterial anastomosis. Despite the high incidence of vascular 
calcifications, the incidence of technical problems with the anastomosis was low and was 
restricted to high-risk patients. The use of a pelvic X-ray is therefore not recommended 
in renal transplant candidates without evidence for peripheral vascular disease. Based on 
our results, we no longer make a pelvic X-ray in renal transplant candidates with normal 
arterial pulses.
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Recommendations
In renal transplant candidates without evidence for peripheral vascular disease* a pelvic 
X-ray to detect vascular calcifications in the iliac arteries is not recommended (Class III, 
Level C)
Additional investigations (echo-doppler or CT) of the iliac arteries are not recommended 
in patients without clinical evidence of peripheral vascular disease * (Class II, Level C)
* Normal femoral artery pulses, no claudication, no abdominal aortic aneurysm or prior 
major peripheral vascular surgery
Chapter 7 describes a prospective study in renal transplant recipients with secondary 
hyperparathyroidism, who continued cinacalcet directly after renal transplantation. 
Secondary hyperparathyroidism is a frequent problem in renal transplant candidates 
and often persists after renal transplantation. Persisting hyperparathyroidism has 
been related to hypercalcemia, nephrocalcinosis and impaired graft function (50). The 
introduction of cinacalcet provided an alternative to parathyroidectomy and many renal 
transplant candidates are treated with cinacalcet nowadays. It is therefore important to 
find out whether or not it is safe to continue cinacalcet after transplantation.
Twenty-nine patients were included in the study and were followed for six 
months after transplantation. Cinacalcet was restarted after transplantation in a dose of 
30 mg/day as soon as the patient resumed eating. Intact PT H  (iPTH) levels decreased 
significantly after transplantation. In 16 patients one or more episodes with hypercalcemia 
were observed after transplantation. The incidence of hypercalcemia was highest in the 
first two weeks after transplantation. The incidence of severe hypercalcemia (calcium 
> 2.87 mmol/l) was low (n=4; 13%). Hypocalcemia occurred in only 2 patients. Serum 
calcium after transplantation was significantly higher in patients who used a high dose 
of cinacalcet (> 30 mg/day) before transplantation compared to patients on a low dose 
of cinacalcet (< 30 mg/day). No difference in renal function at 3 and 6  months after 
transplantation and in acute rejection rate was observed compared with an age and 
sex matched historical control group. No significant difference in tacrolimus dose and 
tacrolimus through levels was observed between the study and historical control group. 
In several patients mild gastro-intestinal complaints were observed, but none of the 
patients had to stop cinacalcet because of side effects. In conclusion, our study suggests 
that the continuation of cinacalcet after transplantation is safe and feasible.
As we described in the discussion of the article we found no other studies that 
evaluated the continuation of cinacalcet directly after transplantation. Several studies 
evaluated the use of cinacalcet in stable renal transplant recipients (51-53). Most studies 
show that the use of cinacalcet in stable renal transplant recipients is safe and effectively 
decreases iPTH and calcium levels. In 2010 Jadoul et al. published a study in which 
cinacalcet was discontinued in 28 patients who used cinacalcet before transplantation (54). 
The results were compared with 1 0  control patients who were treated with placebo before 
transplantation. No obvious differences in calcium, phosphate and iPTH levels after 
transplantation were observed between the two groups. Unfortunately, laboratory data 
were incomplete and a final conclusion about the safety of discontinuation of cinacalcet 
at the time of transplantation cannot be made on this study. In two other studies the 
effect of cessation of cinacalcet was evaluated in stable renal transplant recipients (51;55). 
In the study from Kruse et al. iPTH and calcium levels remained stable, whereas Leca
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et al. observed that iPTH levels recurred to pretreatment levels directly after stopping 
cinacalcet. Further studies will be necessary to find out whether continuation of 
cinacalcet is better than discontinuation at the time of transplantation.
As we described in the discussion of the article, our study has several limitations. 
First of all the study group was small and quite inhomogeneous (not all patients had severe 
secondary hyperparathyroidism), we did not have a control group with the same degree of 
secondary hyperparathyroidism and follow-up was not long enough to study iftreatmentwith 
cinacalcet reverses hyperparathyroidism or only postpones the need for parathyroidectomy. 
In order to answer this last question, we will follow the patients on cinacalcet 
in our study and attempt to stop cinacalcet one year after transplantation.
Several studies showed that hyperparathyroidism often persists after renal 
transplantation and is related to post-transplant hypercalcemia and hypophosphatemia 
(50;56). In a study from Evenepoel et al. pretransplant iPTH was the strongest predictor for 
post-transplant hyperparathyroidism (56). Persisting hyperparathyroidism has been related 
to renal calcium-phosphate depositions early after transplantation. Controversy exists about 
the influence of these calcium-phosphate depositions on graft survival (50;57).
Based on the current literature it is not known what the best strategy is to 
treat renal transplant candidates with severe secondary hyperparathyroidism. No 
studies compared treatment with cinacalcet with parathyroidectomy in renal transplant 
candidates. In 2001 Kasiske et al. recommended considering parathyroidectomy before 
transplantation in patients who failed medical treatment and have severe, persistent 
complications of hyperparathyroidism (58). In contrast, Gwinner et al. recommended that 
renal transplant candidates should have an iPTH < 50 pmol/l before transplantation to 
prevent early calcification and graft dysfunction and that parathyroidectomy should be 
considered when medical treatment fails (50). No randomized clinical trials compared 
these different treatment strategies in renal transplant candidates with secondary 
hyperparathyroidism. Importantly, low iPTH has been related to low-turnover bone 
disease and post-transplant hypocalcemia and should be prevented (56). Further studies 
are necessary to resolve these questions. Based on the current literature we think it is 
justified to recommend an iPTH  < 50 pmol/l in renal transplant candidates.
In conclusion, our study suggests that the continuation of cinacalcet after 
transplantation is safe and feasible, but many questions do still remain. Firstly, it is not 
exactly known which patients have to be treated with cinacalcet. Secondly, we do not 
know how treatment with cinacalcet compares with pre-transplant parathyroidectomy. 
Thirdly, it is unknown if continuation of cinacalcet is better than early withdrawal. Also, 
the optimum dose of cinacalcet and the long-term effects of cinacalcet after transplantation 
must be defined. Further studies should be initiated to answers these questions.
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Conclusions and recommendations
It is recommended to aim for an iPTH  < 50 pmol/l in renal transplant candidates to 
prevent post-transplant hypercalcemia, nephrocalcinosis and probably graft dysfunction 
(Class IIa, Level C)
In patients with an iPTH  > 50 pmol/l despite maximal conservative treatment (V itamin 
D, phosphate binders, intensive dialyses) treatment with cinacalcet should be initiated 
(Class IIa, Level C)
It is not known how parathyroidectomy compares to treatment with cinacalcet (especially 
long-term data concerning allograft survival/function and bone metabolism are lacking) 
and no recommendation therefore can be given.
Continuation of cinacalcet after renal transplantation is safe and feasible (Class IIa, Level
C)
W hether or not continuation of cinacalcet at the time of transplantation is better than 
withdrawal of cinacalcet at the time of transplantation is not known.
Overall conclusions and future perspectives
The studies presented in this thesis evaluated some important aspects ofthe evaluation of the 
renal transplant candidate. Although most studies were retrospective or prospective, non­
randomized of character, the results are helpful and answers are given to some important 
questions. We now have data about the effect of obesity on transplant outcome in Dutch 
renal transplant recipients. We clearly showed that a pre-transplant blood transfusion does 
not improve transplantation outcome and that a pelvic X-ray is not a reliable tool to detect 
vascular calcifications. Furthermore, we provided data about the use of cinacalcet directly 
after transplantation and showed that non-invasive cardiac stress testing is not necessary 
in all high-risk renal transplant candidates. The results of the studies have already had 
implications for daily practice. Pre-transplant blood transfusions are no longer given in the 
Dutch renal transplant centers, we no longer make a pelvic X-ray before transplantation 
and in the near future we will change our cardiac evaluation program.
On the other hand many questions still remain and some of the studies raised new 
questions. This is also illustrated by the fact that most recommendations have evidence 
level C. More studies are still necessary to answer remaining questions and improve the 
future for renal transplant recipients. In the near future we hope to present a new Dutch 
guideline for the evaluation of the renal transplant candidate.
Chapter 8
116
References
(1) Poldermans D, Bax JJ, Boersma E, De HS, Eeckhout E, Fowkes G et al. Guidelines 
for pre-operative cardiac risk assessment and perioperative cardiac management in 
non-cardiac surgery: The Task Force for Preoperative Cardiac Risk Assessment and 
Perioperative Cardiac Management in Non-cardiac Surgery of the European Society 
of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology 
(ESA). Eur Heart J. 2009 Nov;30(22):2769-812.
(2) Gill IS, Hodge EE, Novick AC, Steinmuller DR, Garred D. Impact of obesity on 
renal transplantation. Transplant Proc 1993 February;25(1 Pt 2):1047-8.
(3) Pirsch JD, Armbrust MJ, Knechtle SJ, D’Alessandro AM, Sollinger HW, Heisey DM 
et al. Obesity as a risk factor following renal transplantation. Transplantation 1995 
February 27;59(4):631-3.
(4) Modlin CS, Flechner SM, Goormastic M, Goldfarb DA, Papajcik D, Mastroianni 
B et al. Should obese patients lose weight before receiving a kidney transplant? 
Transplantation 1997 August 27;64(4):599-604.
(5) Pischon T, Sharma AM. Obesity as a risk factor in renal transplant patients. Nephrol 
Dial Transplant 2001 January;16(1):14-7.
(6 ) Johnson DW, Isbel NM, Brown AM, Kay TD, Franzen K, Hawley CM et al. The 
effect of obesity on renal transplant outcomes. Transplantation 2002 September 
15;74(5):675-81.
(7) Howard RJ, Thai VB, Patton PR, Hemming AW, Reed AI, Van der Werf WJ 
et al. Obesity does not portend a bad outcome for kidney transplant recipients. 
Transplantation 2002 January 15;73(1):53-5.
(8 ) Bennet W, McEvoy K, Henell K, Valente J, Douzdjian V. Morbid obesity does not 
preclude successful renal transplantation. Clin Transplant 2004;18:89-93.
(9) Marks WH, Florence LS, Chapman PH, Precht AF, Perkinson DT. Morbid obesity is 
not a contraindication to kidney transplantation. Am J Surg 2004 May;187(5):635-8.
(10) Meier-Kriesche HU, Arndorfer JA, Kaplan B. The impact of body mass index on renal 
transplant outcomes: a significant independent risk factor for graft failure and patient 
death. Transplantation 2002 January 15;73(1):70-4.
General discussion and recommendations
117
(11) Gore JL, Pham PT, Danovitch GM, Wilkinson AH, Rosenthal JT, Lipshutz GS 
et al. Obesity and outcome following renal transplantation. Am J Transplant 2006 
February;6(2):357-63.
(12) Chang SH, Coates PT, McDonald SP. Effects of body mass index at transplant on 
outcomes of kidney transplantation. Transplantation 2007 October 27;84(8):981-7.
(13) Cacciola RA, Pujar K, Ilham MA, Puliatti C, Asderakis A, Chavez R. Effect 
of degree of obesity on renal transplant outcome. Transplant Proc 2008 
December;40(10):3408-12.
(14) Lynch RJ, Ranney DN, Shijie C, Lee DS, Samala N, Englesbe MJ. Obesity, surgical 
site infection, and outcome following renal transplantation. Clin Transplant. 2 0 1 1  
May;25(3):401-5
(15) Bennett WM, McEvoy KM, Henell KR, Pidikiti S, Douzdjian V, Batiuk T. Kidney 
transplantation in the morbidly obese: complicated but still better than dialysis. Clin 
Transplant 2 0 1 0  October 14.
(16) Lentine KL, Rocca-Rey LA, Bacchi G, Wasi N, Schmitz L, Salvalaggio PR et al. 
Obesity and cardiac risk after kidney transplantation: experience at one center and 
comprehensive literature review. Transplantation 2008 July 27;86(2):303-12.
(17) Potluri K, Hou S. Obesity in kidney transplant recipients and candidates. Am J Kidney 
Dis 2010 July;56(1):143-56.
(18) Bigaard J, Frederiksen K, Tjonneland A, Thomsen BL, Overvad K, Heitmann BL 
et al. Waist circumference and body composition in relation to all-cause mortality in 
middle-aged men and women. Int J Obes (Lond) 2005 July;29(7):778-84.
(19) Elsayed EF, Tighiouart H, Weiner DE, Griffith J, Salem D, Levey AS et al. Waist-to- 
hip ratio and body mass index as risk factors for cardiovascular events in CKD. Am J 
Kidney Dis 2008 July;52(1):49-57.
(2 0 ) Glanton CW, Kao TC, Cruess D, Agodoa LY, Abbott KC. Impact of renal 
transplantation on survival in end-stage renal disease patients with elevated body mass 
index. Kidney Int 2003 February;63(2):647-53.
(21) Kambham N, Markowitz GS, Valeri AM, Lin J, D’Agati VD. Obesity-related 
glomerulopathy: an emerging epidemic. Kidney Int 2001 April;59(4):1498-509.
(22) Bosma RJ, Kwakemaak AJ, van der Heide JJ, de Jong PE, Navis GJ. Body 
mass index and glomerular hyperfiltration in renal transplant recipients: 
cross-sectional analysis and long-term impact. Am J Transplant 2007 
March;7(3):645-52.
Chapter 8
118
(23) Leavey SF, McCullough K, Hecking E, Goodkin D, Port FK, Young EW. Body mass 
index and mortality in ‘healthier’ as compared with ‘sicker’ haemodialysis patients: 
results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol 
Dial Transplant 2001 December;16(12):2386-94.
(24) Maggard MA, Shugarman LR, Suttorp M, Maglione M, Sugerman HJ, Livingston 
EH et al. Meta-analysis: surgical treatment of obesity. Ann Intern Med 2005 April 
5;142(7):547-59.
(25) Modanlou KA, Muthyala U, Xiao H, Schnitzler MA, Salvalaggio PR, Brennan DC 
et al. Bariatric surgery among kidney transplant candidates and recipients: analysis of 
the United States renal data system and literature review. Transplantation 2009 April 
27;87(8):1167-73.
(26) Koshy AN, Coombes JS, W  ilkinson S, Fassett RG. Laparoscopic gastric banding 
surgery performed in obese dialysis patients prior to kidney transplantation. Am J 
Kidney Dis 2008 October;52(4):e15-e17.
(27) Kasiske BL, Maclean JR, Snyder JJ. Acute myocardial infarction and kidney 
transplantation. J Am Soc Nephrol 2006 March;17(3):900-7.
(28) Lentine KL, Brennan DC, Schnitzler MA. Incidence and predictors of 
myocardial infarction after kidney transplantation. J Am Soc Nephrol 2005 
February;16(2):496-506.
(29) Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease 
risk after renal transplantation. J Am Soc Nephrol 2000 September;11(9):1735-43.
(30) Ducloux D, Kazory A, Chalopin JM. Predicting coronary heart disease in renal 
transplant recipients: a prospective study. Kidney Int 2004 July;66(1):441-7.
(31) Israni AK, Snyder JJ, Skeans MA, Peng Y, Maclean JR, Weinhandl ED et al. 
Predicting coronary heart disease after kidney transplantation: Patient Outcomes in 
Renal Transplantation (PORT) Study. Am J Transplant 2010 February;10(2):338-53.
(32) De Lima JJ, Gowdak LH, de Paula FJ, Arantes RL, de Oliveira AL, Ramires JA 
et al. Treatment of coronary artery disease in hemodialysis patients evaluated for 
transplant-a registry study. Transplantation 2 0 1 0  April 15;89(7):845-50.
(33) Patel RK, Mark PB, Johnston N, McGeoch R, Lindsay M, Kingsmore DB 
et al. Prognostic value of cardiovascular screening in potential renal transplant 
recipients: a single-center prospective observational study. Am J Transplant 2008 
August;8(8):1673-83.
(34) De Lima JJ, Gowdak LH, de Paula FJ, Arantes RL, Ianhez LE, Ramires JA 
et al. Influence of coronary artery disease assessment and treatment in the 
incidence of cardiac events in renal transplant recipients. Clin Transplant 2010 
July;24(4):474-80.
General discussion and recommendations
119
(35) Poldermans D, Schouten O, Vidakovic R, Bax JJ, Thomson IR, Hoeks SE et al. A 
clinical randomized trial to evaluate the safety of a noninvasive approach in high-risk 
patients undergoing major vascular surgery: the DECREASE-V Pilot Study. J Am 
Coll Cardiol 2007 May 1;49(17):1763-9.
(36) McFalls EO, Ward HB, Moritz TE, Goldman S, Krupski WC, Littooy F et al. 
Coronary-artery revascularization before elective major vascular surgery. N Engl J Med
2004 December 30;351(27):2795-804.
(37) Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ et al. 
Optimal medical therapy with or without PCI for stable coronary disease. N Engl J 
Med 2007 April 12;356(15):1503-16.
(38) Herzog CA, Ma JZ, Collins AJ. Long-term outcome of renal transplant recipients in 
the United States after coronary revascularization procedures. Circulation 2004 June 
15;109(23):2866-71.
(39) Karpinski M, Rush D, Jeffery J, Exner M, Regele H, Dancea S et al. Flow 
cytometric crossmatching in primary renal transplant recipients with a negative 
anti-human globulin enhanced cytotoxicity crossmatch. J Am Soc Nephrol 2001 
December;12(12):2807-14.
(40) van Kampen CA, Roelen DL, Versteeg-van der Voort Maarschalk MF, Hoitsma 
AJ, Allebes WA, Claas FH. Activated HLA class I-reactive cytotoxic T  lymphocytes 
associated with a positive historical crossmatch predict early graft failure. 
Transplantation 2002 October 27;74(8):1114-9.
(41) Noreen HJ, McKinley DM, Gillingham KJ, Matas AJ, Segall M. Positive remote 
crossmatch: impact on short-term and long-term outcome in cadaver renal 
transplantation. Transplantation 2003 February 27;75(4):501-5.
(42) Mahanty HD, Cherikh WS, Chang GJ, Baxter-Lowe LA, Roberts JP. Influence 
of pretransplant pregnancy on survival of renal allografts from living donors. 
Transplantation 2 0 0 1  July 27;72(2):228-32.
(43) Bohmig GA, Regele H, Saemann MD, Exner M, Druml W, Kovarik J et al. Role of 
humoral immune reactions as target for antirejection therapy in recipients of a spousal- 
donor kidney graft. Am J Kidney Dis 2000 April;35(4):667-73.
(44) Rosenberg JC, Jones B, Oh H. Accelerated rejection following offspring-to-mother 
and husband-to-wife transplants. Clin Transplant 2004 December;18(6):729-33.
(45) Meier-Kriesche HU, Ojo AO, Leavey SF, Hanson JA, Leichtman AB, Magee JC et al. 
Gender differences in the risk for chronic renal allograft failure. Transplantation 2 0 0 1  
February 15;71(3):429-32.
(46) Sola E, Gonzalez-Molina M, Cabello M, Burgos D, Ramos J, Gutierrez C et al. 
Long-term improvement of deceased donor renal allograft survival since 1996: a single 
transplant center study. Transplantation 2 0 1 0  March 27;89(6):714-20.
Chapter 8
120
(47) McGee J, Magnus JH, Zhang R, Florman SS, Hamm LL, Islam TM  et al. Race and 
gender are not independent risk factors of allograft loss after kidney transplantation. 
Am J Surg 2 0 1 1  Apr;201(4):463-7
(48) Fuggle SV, Allen JE, Johnson RJ, Collett D, Mason PD, Dudley C et al. Factors 
affecting graft and patient survival after live donor kidney transplantation in the UK. 
Transplantation 2 0 1 0  March 27;89(6):694-701.
(49) Ploussard G, Mongiat-Artus P, Meria P, Tariel E, Gaudez F, De KE et al. What is 
the relevance of systematic aorto-femoral Doppler ultrasound in the preoperative 
assessment of patients awaiting first kidney transplantation: a monocentric prospective 
study. Nephrol Dial Transplant 2010 January;25(1):270-4.
(50) Gwinner W, Suppa S, Mengel M, Hoy L, Kreipe HH, Haller H et al. Early 
calcification of renal allografts detected by protocol biopsies: causes and clinical 
implications. Am J Transplant 2005 August;5(8):1934-41.
(51) Leca N, Laftavi M, Gundroo A, Kohli R, Min I, Karam J et al. Early and severe 
hyperparathyroidism associated with hypercalcemia after renal transplant treated with 
cinacalcet. Am J Transplant 2006 October;6(10):2391-5.
(52) Kruse AE, Eisenberger U, Frey FJ, Mohaupt MG. The calcimimetic cinacalcet 
normalizes serum calcium in renal transplant patients with persistent 
hyperparathyroidism. Nephrol Dial Transplant 2005 July;20(7):1311-4.
(53) Szwarc I, Argiles A, Garrigue V, Delmas S, Chong G, Deleuze S et al. Cinacalcet 
chloride is efficient and safe in renal transplant recipients with posttransplant 
hyperparathyroidism. Transplantation 2006 September 15;82(5):675-80.
(54) Jadoul M, Banos A, Zani VJ, Hercz G. The effects of discontinuing cinacalcet at the 
time of kidney transplantation. NDT Plus 2010 February;3(1):37-41.
(55) Kruse AE, Eisenberger U, Frey FJ, Mohaupt MG. Effect of cinacalcet cessation 
in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial 
Transplant 2007 August;22(8):2362-5.
(56) Evenepoel P, Van Den BB, Naesens M, De JH, Bammens B, Claes K et al. Calcium 
metabolism in the early posttransplantation period. Clin J Am Soc Nephrol 2009 
March;4(3):665-72.
(57) Evenepoel P, Lerut E, Naesens M, Bammens B, Claes K, Kuypers D et al. 
Localization, etiology and impact of calcium phosphate deposits in renal allografts. 
Am J Transplant 2009 November;9(11):2470-8.
(58) Kasiske BL, Cangro CB, Hariharan S, Hricik DE, Kerman RH, Roth D et al. The 
evaluation of renal transplantation candidates: clinical practice guidelines. Am J 
Transplant 2 0 0 1 ;1  Suppl 2:3-95.
General discussion and recommendations
121
122
Summary
123
Summary
In chapter 1 an introduction to the subject and the rationale behind this thesis is 
given. Furthermore the history and developments of renal transplantation are described. 
Although the results of renal transplantation improved markedly over the last decades, 
patients are still exposed to several risks and complications both on the short- and 
long-term after transplantation. Mortality is still considerably higher than in the 
general population, and is mainly attributable to cardiovascular complications.
In the last decades the end-stage renal disease (ESRD) population has changed. 
Patients are older now and have an increased number of comorbid conditions. Because 
of this and because of the improvement in transplantation outcome, access criteria 
for the transplant candidate list are becoming less strict (e.g. older patients and obese 
patients are often accepted for renal transplantation nowadays). It is therefore important 
that careful evaluation of renal transplant candidates is performed, to decrease the 
incidence of peri- and post-operative complications, and inform renal transplant 
candidates about the risks and benefits of renal transplantation. Although several 
international guidelines for the evaluation of renal transplant candidates exist, many 
recommendations are not based on firm evidence. Further research is therefore necessary 
to improve the evaluation process and ultimately transplantation outcome.
In the study presented in chapter 2 the relation between the body mass index (BMI) and 
transplantation outcome is analyzed. In our study it was shown that both graft and patient 
survival are decreased in patients with overweight and obesity. The risk for graft survival was 
increased for both patients with a low and high BMI, with the highest risk for patients with 
a BMI > 34 kg/m2. Obese patients significantly more often lost their graft because of an 
infectious cause. Next to that, early graft loss (< 3 months after transplantation) was increased 
in obese renal transplant recipients. The risk for patient death was significantly increased 
for all patients with a BMI > 28 kg/m2. There was a trend to an increased mortality due to 
cardiovascular and infectious causes in obese renal transplant recipients. Limitation of our 
study was the lack of information about diabetes and cardiovascular risk factors.
In chapter 3 we presented a retrospective cohort study in which we analyzed the incidence 
of post-transplant cardiovascular events and risk factors for post-transplant cardiovascular 
events. In our study, the cumulative incidence of post-transplant cardiovascular events was 
40% at 10 years after transplantation, with the highest incidence in the first three months 
after transplantation. The most important predictors for a post-transplant cardiovascular 
event were diabetic nephropathy, cardiovascular disease before transplantation, recipient age 
and time on dialysis. We were not successful in finding a reliable algorithm to predict which 
patients were at the highest risk for an early post-transplant cardiovascular event.
In chapter 4 we showed the results ofthe study in which we analyzed the effect ofour cardiac 
evaluation program on the incidence ofperioperative cardiac events. As we mentioned in the 
introduction, there is much discussion in the literature about the benefit of pre-transplant 
cardiac evaluation and intervention in asymptomatic renal transplant candidates.
Since 2004 all asymptomatic, high risk renal transplant candidates had to undergo 
non-invasive cardiac stress testing followed by coronary angiography and intervention 
when significant cardiac ischemia was found. To evaluate the effect of our screening 
program, the incidence of perioperative cardiac events was analyzed and compared with 
a historical control group. Our study showed that the incidence of significant cardiac
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ischemia in asymptomatic, high risk renal transplant candidates is low. Non-invasive 
cardiac stress testing was followed by coronary angiography and intervention in a very 
low percentage of the patients. After the introduction of the cardiac evaluation program, 
there was only a minor, non-significant increase in the number of coronary angiographies 
and interventions, compared to the control group. Furthermore, no significant decrease in 
perioperative cardiac events was found. In conclusion, our study shows that non-invasive 
cardiac stress testing in all asymptomatic, high risk renal transplant candidates is unnecessary.
Chapter 5 describes the results of a multi-center, retrospective study in which the effect 
of one pre-transplant blood transfusion (PTF) on sensitization and graft survival in 
unsensitized female renal transplant candidates was evaluated. Seven Dutch renal transplant 
centers participated in the study. Hypothesis of the study was that pre-transplant blood 
transfusions can elucidate historical sensitization and that the avoidance of the associated 
antigens in the kidney donor can improve transplantation outcome. Data from all female, 
non-immunized renal transplant candidates who received a PT F (random PTF (rPTF), 
matched PTF (mPTF) or donor specific blood transfusion (DST)) between 1996 and 2006 
were collected and analyzed. Anti-HLA-antibodies were detected in 2 0 .1% of the patients 
after the PTF. Differentiation between historical and primary sensitization was hampered 
by the fact that many patients had anti-HLA-antibodies against both the transfusion donor 
and their partner or children. Sensitization was highest after a DST (27%), and lowest after 
an mPTF (8.1%). No beneficial effect of a PT F on transplantation outcome was found in 
any of the groups. After an rPTF even more acute rejections were found. Based on our study 
pre-transplant blood transfusions are no longer given in the Dutch renal transplant centers.
In chapter 6 we presented the results of a prospective cohort study, in which we analyzed 
the predictive value of a plain X-ray of the pelvis (pelvic X-ray) for vascular calcifications 
in the iliac arteries and the occurrence of complications with the arterial anastomosis. It 
is well known that the incidence of vascular calcifications in renal transplant candidates is 
very high and that the presence of vascular calcifications in the iliac arteries can complicate 
renal transplantation. In many renal transplant centers a pelvic X-ray is performed in the 
pretransplant evaluation process to detect these calcifications, but the predictive value of 
a pelvic X-ray has not been analyzed before. We therefore analyzed the predictive value 
of a pelvic X-ray in a prospective cohort study in 109 renal transplant recipients. Patients 
with evidence of peripheral vascular disease were excluded, because vascular evaluation is 
always done in these patients. Vascular calcifications were found on the pelvic X-ray in 
33 (30.2%) of the 109 renal transplant candidates. In 35 patients the surgeon detected 
vascular calcifications in the iliac arteries during the operation. Sensitivity and specificity 
of a pelvic X-ray for the detection of vascular calcifications in the iliac arteries was 48% and 
82%, respectively. The incidence of vascular calcifications was significantly higher in high­
risk patients (age > 50 years, diabetes mellitus or a history of cardiovascular disease). In all 
patients it was possible to make an arterial anastomosis, but construction of the arterial 
anastomosis was complicated due to vascular calcifications in 5 patients (one kidney was 
lost due to arterial thrombosis after endarterectomy). All complications with the arterial 
anastomosis occurred in high-risk patients. The negative and positive predictive value of 
a pelvic X-ray for complications with the arterial anastomosis due to calcifications was 
98.8% and 13.8%, respectively. In conclusion a pelvic X-ray is not a reliable tool to detect 
vascular calcifications in the iliac arteries and is therefore not recommended.
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Chapter 7 describes a prospective study in renal transplant recipients with secondary 
hyperparathyroidism, who continued cinacalcet directly after renal transplantation. 
Secondary hyperparathyroidism is a frequent problem in renal transplant candidates 
and often persists after renal transplantation. Persisting hyperparathyroidism has 
been related to hypercalcemia, nephrocalcinosis and impaired graft function. The 
introduction of cinacalcet provided an alternative to parathyroidectomy and many renal 
transplant candidates are treated with cinacalcet nowadays. It is therefore important to 
find out whether or not it is safe to continue cinacalcet after transplantation.
Twenty-nine patients were included in the study and were followed for six months 
after transplantation. Cinacalcet was restarted after transplantation in a dose of 30 mg/day 
as soon as the patient resumed eating. Intact PTH  (iPTH) levels decreased significantly 
after transplantation. In 16 patients one or more episodes with hypercalcemia were 
observed after transplantation. The incidence of hypercalcemia was highest in the first two 
weeks after transplantation. The incidence of severe hypercalcemia (calcium > 2.87 mmol/l) 
was low (n=4; 13%). Hypocalcemia occurred in only 2 patients. No difference in renal 
function at 3 and 6 months after transplantation and in acute rejection rate was observed 
compared with an age and sex matched historical control group. No significant difference 
in tacrolimus dose and tacrolimus through levels was observed between the study and 
historical control group. In several patients mild gastro-intestinal complaints were observed, 
but none of the patients had to stop cinacalcet because of side effects. In conclusion, our 
study suggests that the continuation of cinacalcet after transplantation is safe and feasible.
In Chapter 8 the results of the six studies are discussed and recommendations for the 
evaluation of the renal transplant candidate are given for the six subjects.
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In hoofdstuk 1 wordt een introductie van het onderwerp gegeven en wordt de 
achterliggende gedachte achter de onderzoeken in dit proefschrift beschreven. Verder 
worden de historie en ontwikkelingen op het gebied van niertransplantatie beschreven. In 
de afgelopen jaren zijn de resultaten na niertransplantatie aanmerkelijk verbeterd, maar 
niertransplantatiepatiënten worden nog steeds blootgesteld aan verschillende risico’s en 
complicaties op de korte en lange termijn. De overleving van niertransplantatiepatiënten 
is nog steeds duidelijk korter dan van de algemene populatie. Dit wordt grotendeels 
veroorzaakt door een verhoogde cardiovasculaire sterfte.
In de afgelopen jaren is de patiëntengroep met eindstadium nierfalen duidelijk 
veranderd. Patiënten zijn ouder en hebben meer bijkomende ziektes. Mede hierdoor en 
door de verbeteringen in de uitkomst na een niertransplantatie zijn de toelatingscriteria 
voor de transplantatielijst versoepeld en worden oudere patiënten en patiënten met 
bijkomende aandoeningen vaker geaccepteerd voor een niertransplantatie. Het is daarom 
belangrijk dat er een grondige evaluatie van niertransplantatiekandidaten plaatsvindt. Het 
doel hiervan is om het aantal peri- en postoperatieve complicaties te verminderen en 
niertransplantatiekandidaten goed te kunnen informeren over de risico’s en de voor- en 
nadelen van een niertransplantatie. In de afgelopen jaren zijn er al verschillende 
internationale richtlijnen voor de evaluatie en voorbereiding van de 
niertransplantatiekandidaat gepubliceerd. Helaas kunnen veel aanbevelingen nog niet met 
hard wetenschappelijk bewijs worden onderbouwd. Verder onderzoek is dan ook nodig 
om het evaluatieproces en uiteindelijk de uitkomst na niertransplantatie te verbeteren.
In hoofdstuk 2 worden de resultaten gepresenteerd van een retrospectief onderzoek naar 
de relatie tussen de body mass index (BMI) en de resultaten van niertransplantatie. Onze 
studie laat zien dat zowel de transplantaat- als patiëntenoverleving verlaagd is bij patiënten 
met obesitas (BMI > 30 kg/m2). Het risico op transplantaatfalen was zowel verhoogd voor 
patiënten met ondergewicht als met overgewicht, met het hoogste risico voor patiënten 
met een BMI > 34 kg/m2. Falen van de transplantaatnier was bij obesitas significant vaker 
het gevolg van een infectieuze oorzaak. Bovendien kwam vroeg transplantaatfalen (< 3 
maanden na transplantatie) vaker voor bij patiënten met obesitas. Dit zou kunnen wijzen 
op transplantaatfalen door operatie gerelateerde aandoeningen. Het risico op overlijden 
was groter voor alle patiënten met een BMI > 28 kg/m2. Er was een trend naar een 
verhoogde mortaliteit door cardiovasculaire en infectieuze oorzaken bij patiënten met 
obesitas. Beperking van de studie was het ontbreken van gegevens over diabetes en 
cardiovasculaire risicofactoren.
In hoofdstuk 3 wordt een retrospectieve studie gepresenteerd waarin de incidentie van 
en risicofactoren voor een cardiovasculaire gebeurtenis (myocard infarct, percutane 
coronaire interventie (PCI) of coronary artery bypass grafting (CABG), cerebrovasculair 
accident (CVA) of dood door een cardiale oorzaak) na niertransplantatie werden 
onderzocht. In deze studie was de cumulatieve incidentie van cardiovasculaire 
gebeurtenissen 10 jaar na transplantatie 40%. De incidentie van cardiovasculaire 
gebeurtenissen was het hoogste in de eerste 3 maanden na transplantatie. De belangrijkste 
voorspellers voor een cardiovasculaire gebeurtenis na transplantatie waren diabetische 
nefropathie, eerdere cardiovasculaire ziekte, leeftijd van de patiënt en de duur van de 
behandeling met dialyse. Helaas kon er op grond van onze studie geen betrouwbaar model 
worden gevonden om het risico op een cardiovasculaire gebeurtenis na transplantatie
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betrouwbaar te voorspellen.
In hoofdstuk 4 wordt de studie beschreven waarin het effect van het huidige cardiale 
evaluatie proces bij niertransplantatiekandidaten in het UMC St. Radboud is onderzocht. 
In de literatuur is er veel discussie over het nut van cardiale evaluatie van asymptomatische 
niertransplantatiekandidaten.
Sinds 2004 moesten alle hoog risico niertransplantatiekandidaten zonder 
hartklachten een niet-invasief stressonderzoek ondergaan (myocardscintigrafie of 
dobutamine stress-echocardiografie). Als er bij het onderzoek significante ischemie van 
het hart gevonden werd, moesten patiënten verwezen worden naar de cardioloog voor een 
coronair angiogram (indien nodig gevolgd door een interventie (PCI of CABG)). Om het 
effect van dit beleid te analyseren werd de incidentie van peri-operatieve cardiale 
gebeurtenissen (< 30 dagen na transplantatie) na introductie van het evaluatieproces 
vergeleken met een historische controle groep. De studie laat zien dat de incidentie van 
significante ischemie bij asymptomatische, hoog risico niertransplantatiekandidaten laag 
is. Verder was het percentage patiënten dat na een niet-invasief onderzoek van het hart 
een coronair angiogram of interventie onderging erg laag. Na de introductie van het 
cardiale evaluatie programma was er geen significante toename van het aantal coronair 
angiogrammen of interventies waarneembaar. Ook werd er geen significante daling van 
het aantal peri-operatieve cardiale gebeurtenissen gevonden. Conclusie van ons onderzoek 
is dat het niet zinvol is om bij alle asymptomatische, hoog risico niertransplantatiekandidaten 
een niet-invasief cardiaal onderzoek te doen.
Hoofdstuk 5 beschrijft de resultaten van een multi-center, retrospectief onderzoek naar 
het effect van een protocollaire bloedtransfusie (PTF) bij vrouwelijke niertransplantatie- 
kandidaten op immunisatie en transplantaatoverleving. De bloedtransfusie werd alleen 
gegeven aan niet geïmmuniseerde vrouwen (negatieve complement dependent cytotoxicity 
test). Zeven Nederlandse transplantatie centra namen deel aan het onderzoek. De 
hypothese van het onderzoek was dat een PTF voor transplantatie historische immunisatie 
aan het licht kan brengen en dat het vermijden van de gerelateerde HLA-antigenen bij de 
toekomstige nierdonor de transplantatie-uitkomst zou kunnen verbeteren. Gegevens van 
alle vrouwelijke, niet geïmmuniseerde niertransplantatie kandidaten die een PTF (random 
PTF (rPTF), gematchte PTF (mPTF) of een donor specifieke bloedtransfusie (DST)) 
ontvingen tussen 1996 en 2006 werden verzameld en geanalyseerd. Na de toediening van 
een PT F werden bij 20,1% van de patiënten anti-HLA-antistoffen gevonden. Het 
onderscheid tussen primaire en historische immunisatie was niet altijd te maken omdat 
veel patiënten zowel antistoffen tegen de HLA-kenmerken van de bloeddonor als tegen 
die van de kinderen of de partner hadden. Immunisatie kwam het meeste voor na een 
donorspecifieke transfusie en het minste na een mPTF. Voor geen van de transfusies kon 
een positief effect op de transplantatie uitkomst worden gevonden. Na een rPTF kwamen 
zelfs meer acute rejecties voor. Op grond van deze resultaten worden er in de Nederlandse 
niertransplantatie centra geen protocollaire bloedtransfusies meer gegeven.
In hoofdstuk 6 worden de resultaten beschreven van een prospectieve studie naar de 
voorspellende waarde van een bekkenfoto (X-bekken) voor het opsporen van 
vaatverkalkingen in de iliacale arteriën en het optreden van complicaties met de arteriële 
anastomose bij niertransplantatiekandidaten. Het is bekend dat vasculaire calcificaties bij 
niertransplantatiekandidaten veel voorkomen en dat deze kunnen leiden tot complicaties 
met de arteriële anastomose. In veel transplantatiecentra wordt een X-bekken verricht om
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deze calcificaties op te sporen, maar de voorspellende waarde van een dergelijke foto is 
nooit onderzocht. Daarom hebben we de voorspellende waarde van een X-bekken 
onderzocht bij 109 niertransplantatiekandidaten. Patiënten met perifeer vaatlijden werden 
uitgesloten van het onderzoek, omdat bij deze groep altijd aanvullend onderzoek wordt 
gedaan. Bij 33 patiënten (30,2%) werden vaatverkalkingen op de X-bekken gevonden. De 
vaatchirurg vond bij 35 patiënten vaatverkalkingen in de iliacale vaten. De sensitiviteit en 
specificiteit van een X-bekken was respectievelijk 48% en 82%. De incidentie van 
vaatverkalkingen was het hoogste bij hoog risico patiënten (leeftijd > 50 jaar, diabetes 
mellitus en eerdere cardiovasculaire ziekte). Bij alle patiënten kon een arteriële anastomose 
worden aangelegd, maar bij 5 patiënten werd de constructie van de arteriële anastomose 
bemoeilijkt door de aanwezigheid van verkalkingen (één van deze nieren ging verloren 
door een arteriële trombose na een endarterectomie). De negatief en positief voorspellende 
waarde van een X-bekken voor het optreden van complicaties met de arteriële anastomose 
door verkalkingen was respectievelijk 98,8% en 13,8%. De conclusie van het onderzoek is 
dat een X-bekken geen betrouwbaar onderzoek is om vaatverkalkingen in de iliacale vaten 
op te sporen en dat het onderzoek niet aanbevolen kan worden.
Hoofdstuk 7 beschrijft een prospectieve studie waarin niertransplantatiekandidaten 
met secundaire hyperparathyreoïdie, die behandeld werden met cinacalcet, na transplantatie 
zijn vervolgd. Secundaire hyperparathyreoïdie is een frequent voorkomend probleem bij 
niertransplantatiekandidaten en persisteert vaak na de transplantatie. Persisterende 
hyperparathyreoïdie is gerelateerd aan hypercalciëmie, nefrocalcinose en verminderde 
transplantaatfunctie. De introductie van cinacalcet biedt dan ook een alternatief voor 
parathyreoïdectomie en veel niertransplantatiekandidaten worden behandeld met 
cinacalcet. H et is daarom belangrijk om te onderzoeken of cinacalcet na transplantatie 
veilig doorgegeven kan worden.
In onze studie werden 29 patiënten geïncludeerd en zij werden tot 6 maanden na 
de transplantatie vervolgd. Bij alle patiënten werd de cinacalcet na de transplantatie hervat 
in een dosering van 30 mg/dag zodra zij weer konden eten. Na transplantatie was er bij 
alle patiënten een significante daling van het PTH. Bij 16 patiënten kwam er een episode 
met hypercalciëmie voor. De incidentie van hypercalciëmie was het hoogste in de eerste 2 
weken na transplantatie. Ernstige hypercalciëmie (calcium > 2,87 mmol/l) kwam weinig 
voor (n=4). Hypocalciëmie werd bij slechts 2 patiënten geconstateerd. Er was geen verschil 
in nierfunctie en het aantal acute rejecties op 3 en 6 maanden na transplantatie vergeleken 
met een voor leeftijd en geslacht gematchte controlegroep. Ook waren er geen verschillen 
in tacrolimus- dosering en -spiegels tussen beide groepen. Bij meerdere patiënten traden 
gastrointestinale bijwerkingen op, maar bij geen van de patiënten was staken van de 
cinacalcet in verband met bijwerkingen noodzakelijk. Conclusie van het onderzoek is dat 
cinacalcet na transplantatie veilig gecontinueerd kan worden.
In hoofdstuk 8 worden de resultaten van de 6  studies besproken en worden aanbevelingen 
voor de evaluatie van de niertransplantatiekandidaat voor de 6  onderwerpen gegeven.
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Vele mensen hebben bijgedragen aan de verschillende onderzoeken in dit proefschrift. Het 
is niet mogelijk om in dit dankwoord iedereen persoonlijk te bedanken. Het zal duidelijk 
zijn dat het voltooien van dit proefschrift niet mogelijk zou zijn geweest zonder de hulp 
van al die mensen. Ik wil dan ook iedereen bedanken die een bijdrage heeft geleverd aan 
de onderzoeken in dit proefschrift.
Zonder iemand te kort te willen doen, zijn er toch een aantal mensen die ik in het bijzonder 
willen bedanken. Allereerst wil ik mijn promotor bedanken. Andries, je vroeg me om het 
kort te houden en dat zal ik dan ook doen. Zonder jouw optimisme, relativeringsvermogen, 
scherpe analyses en soms de benodigde peptalk was dit boekje er nooit gekomen. Bedankt 
voor de fijne samenwerking!
Drie van de onderzoeken in dit proefschrift zijn verricht in samenwerking met 
verschillende transplantatiecentra uit Nederland. M et name het verzamelen van de data 
voor de bloedtransfusiestudie is een hele grote klus geweest. Vanuit alle transplantatiecentra 
is er heel veel werk verzet om deze data bij elkaar te krijgen. Zeer veel dank ben ik 
verschuldigd aan de transplantatienefrologen, immunologen, medewerkers van de 
bloedtransfusielaboratoria en anderen uit de transplantatiecentra die hebben meegewerkt 
aan het verzamelen van alle data.
W il Allebes wil ik graag speciaal bedanken voor zijn grote bijdrage aan het 
bloedtransfusieonderzoek. De vele inspanningen en overlegmomenten hebben 
uiteindelijk geleid tot een belangrijke beleidswijziging bij de voorbereiding van 
niertransplantatiekandidaten.
Ook het verzamelen van de data voor het onderzoek naar cardiale risicofactoren voor 
cardiale events na transplantatie (hoofdstuk 3) is veel werk geweest. Iedereen die hier een 
bijdrage aan heeft geleverd, wil ik hartelijk bedanken. Speciale dank gaat uit naar Ellen 
Hoogeveen en Joke Roodnat. De medewerkers van de afdeling statistiek van het UMC St. 
Radboud wil ik bedanken voor de hulp bij het maken van de database en de vele analyses 
die zij hebben verricht.
Aline Hemke en Cynthia Konijn van de Nederlandse Orgaan Transplantatie Registratie 
(NOTR), bedankt voor jullie hulp bij het aanleveren van de gegevens uit de database. 
Nooit was het jullie te veel als er weer een verzoek voor een aanvulling op de database 
kwam.
Stijn Peeters wil ik bedanken voor zijn werk aan het onderzoek naar het effect van cardiale 
screening voor niertransplantatie. Vele uren heb je doorgebracht in het archief om alle data 
bij elkaar te sprokkelen. Ook Maureen van der Vlugt wil ik bedanken voor haar hulp bij 
dit onderzoek. Vele overlegmomenten en revisies hebben uiteindelijk geleid tot een mooie 
publicatie.
Daan van der Vliet en Heleen Dekker, bedankt voor jullie belangrijke bijdrage aan het 
onderzoek naar vaatverkalkingen in de bekkenvaten. Ook de overige vaatchirurgen van 
UMC St. Raboud wil ik bedanken voor hun medewerking aan dit onderzoek.
De Nierstichting wil ik bedanken voor hun subsidie voor het project Ketenkwaliteit 
Niertransplantatie. Dit project was het startpunt van dit promotieonderzoek, zonder deze 
subsidie was dit promotietraject niet van de grond gekomen.
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De collega’s van de afdeling Nefrologie wil ik bedanken voor de fijne samenwerking en 
gezelligheid tijdens de opleiding en de onderzoeksperiode. Ook wil ik jullie bedanken voor 
de hulp bij het uitvoeren van de onderzoeken, de inclusie van de patiënten en jullie vaak 
nuttige commentaar. Ook de medewerkers van het secretariaat en de verpleegafdeling 
van de afdeling Nefrologie en de transplantatieverpleegkundigen wil ik bedanken voor 
hun hulp.
Mijn ouders wil ik bedanken voor hun steun. Bedankt dat jullie altijd voor ons klaar staan! 
Mijn verdere familie en vrienden wil ik bedanken voor hun hulp en steun in moeilijke 
tijden, maar ook voor de vele mooie momenten samen. Hopelijk volgen er nog velen!
Mijn neven Rob en Martin Loman wil ik bedanken voor het ontwerpen van de cover en 
de lay-out van dit boekje. Het was erg leuk om dit met jullie samen te doen.
Lieve Trudy, het onderzoek zit er op! Het onderzoek doen ging met pieken en dalen. 
Bedankt voor jouw hulp, liefde en geduld. Het afgelopen jaar heeft ons geleerd dat er veel 
belangrijkere dingen zijn dan werk en onderzoek. Ik hoop dat we samen met onze dochter 
Sofie nog heel veel mooie, gezonde jaren te gaan hebben.
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Jeroen Aalten werd geboren op 2 december 1973 te ’s-Graveland. In 1992 behaalde hij 
zijn VWO-diploma aan het Willem de Zwijger college te Bussum. In hetzelfde jaar 
begon hij zijn studie Geneeskunde aan de Vrije Universiteit te Amsterdam. Eind 1998 
behaalde hij zijn artsexamen. Begin 1999 begon hij als arts-assistent interne geneeskunde 
in het Spaarne Ziekenhuis te Heemstede. In 2001 begon hij zijn opleiding tot internist 
in het St. Joseph Ziekenhuis (tegenwoordig Maxima Medisch Centrum) te Veldhoven 
(opleider dr. A.W.L. van den Wall Bake). In 2003 vervolgde hij zijn opleiding in het 
UMC St. Radboud te Nijmegen (opleider Prof. dr. J.W.M. van der Meer). In 2004 startte 
het project ketenkwaliteit niertransplantatie, waarbij hij werkte aan een protocol voor de 
voorbereiding van niertransplantatiekandidaten op een niertransplantatie. Uiteindelijk 
heeft dit geleid tot dit proefschrift.
Op 15 juni 2007 werd de opleiding tot internist afgerond. Hierna volgde hij de opleiding 
in het aandachtsgebied Nefrologie. Het eerste deel van deze opleiding werd verricht in 
het Canisius Wilhelmina Ziekenhuis te Nijmegen (opleider dr. M.A.G.J. ten Dam ) en 
het laatste deel in het UMC St. Radboud (opleider Prof. dr. J.H.M. Berden). Hierna 
werkte hij een jaar als internist-nefroloog in het UMC St. Radboud. Vanaf 1 juli 2010 
tot en met 31 juli 2011 was hij werkzaam als waarnemend internist-nefroloog in het 
Deventer Ziekenhuis. Vanaf 1 augustus 2011 is hij werkzaam als internist-nefroloog in 
de maatschap interne geneeskunde van het Sint Jansdal Ziekenhuis te Harderwijk (deels 
Meander Medisch Centrum Amersfoort).
Hij is getrouwd met Trudy Loman. Samen hebben zij een dochter, Sofie (2008).
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